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Perhaps the most valuable result o f  all education is the ability to make yourself do the 
thing you have to do, when it ought to be done, whether you like it or not; it is the first 
lesson that ought to be learned; and however early a man's training begins, it is 
probably the last lesson that he learns thoroughly.
Thomas Henry Huxley (1825-1895)
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Abstract
Z-band Alternately Spliced PDZ-containing protein (ZASP) is a sarcomeric Z- 
disk protein expressed in human cardiac and skeletal muscle that is involved in a 
dominant familial dilated cardiomyopathy. ZASP interacts with the last 150 amino acids 
of a-actinin-2, the major component of the Z-disk, via an N-terminal PDZ domain. 
ZASP and a-actinin-2 are thought to play an important structural role, probably by 
forming a ternary complex with titin Z-repeats. We have determined the structure of 
ZASP PDZ and characterised its interaction with a-actinin-2. We show that ZASP PDZ 
is a classical class 1 PDZ domain that recognises with micromolar affinity the carboxy- 
terminal sequence of an a-actinin-2 calmodulin-like domain. We also characterised the 
ternary complex ZASP/a-actinin-2/titin and the role of each component, showing that 
the a-actinin-2/ZASP PDZ interaction involves a binding surface distinct from that 
involved in the recognition of the titin Z repeats. Finally, we used the ZASP PDZ 
structure to model other members of the enigma family by homology and to predict 
their abilities to bind a-actinin-2.
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1.1 Muscle
Movement plays a vital role for all living systems, whether it is the transport of 
single molecules, to the entire movement of an organism. In mammalian systems, 
skeletal muscle contraction is essential for walking, running, swimming, and flying, or 
even involuntary movements such as the beating heart (cardiac) and peristalsis (smooth 
muscle). Striated muscle (i.e. cardiac and skeletal muscle) is composed from many 
muscle fibres, which are huge single cells formed during development by the fusion of 
many separate cells. These form cylindrical structures known as myofibrils, which are 
the contractile elements of the muscle cell. Myofibrils in turn are made up of a 
microscopic contractile element known as the sarcomere, a complex network of proteins 
and membranes (Figure 1.1). Depending on the organism and tissue type, the sarcomere 
is approximately 2 pm in length and can shorten to 70% of its original length during 
contraction.
Transmission Electron Microscopy (TEM) gives an overview of muscle 
ultrastructure (Figure 1.2), giving rise to the description of the sarcomere in terms of 
thick and thin filaments, I and A bands, and Z and M lines (Huxley and Niedergerke, 
1954; Huxley and Hanson, 1954). The thin filament is primarily composed of actin, 
tethered to the Z-disk. The thin filaments then interdigitate with the thick filaments - the 
main constituent being myosin. The thick filament terminates at the M-line. Studies by 
electron microscopy of the A band cross-section reveal that six thin filaments encircle the 
thick filament in a hexagonal arrangement. This also shows that cross-bridges, formed 
by the globular head of myosin, extend to interact with actin.
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Figure 1.1: a) Schematic representation of the sarcomere. The position of the Z-disk and 
M-line is indicated. A single molecule titin filament (indicated in green) connects the Z- 
disk to the M-line. In the Z-disk a-actinin-2 (in yellow) forms transversal connections 
between actin filaments (in red) and is bound to ZASP (in blue). Myosin and F-actin are 
coloured purple and red respectively, b) Domain architecture of the titin region localised 
in the Z-disk, a-actinin-2 and ZASP (variant 3).
Figure 1.2: Transmission Electron Microscope picture of striated mammalian muscle 
(http://www.udel.edu/BiologyAVags/), labelled to indicate the position of the sarcomere, 
I and A bands, Z and M lines, and the sarcoplasmic reticulum.
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Globular actin (G-actin) polymerises to form fibres (F-actin), with a double 
helical ultrastructure in the thin filament. The helix has thirteen molecules of actin per 
six turns. F-actin has a structurally polarised orientation, and its monomers are in a 
constant state of association and dissociation, with the fast growing positive (+ve) 
‘barbed’ end in the Z-disk, and the slow growing negative (-ve) ‘pointed’ end pointing 
towards the M-line. The protein CapZ is responsible for capping the barbed end, acting 
to prevent the addition and loss of actin, whilst tropomodulin is able to carry out the 
same function at the pointed end. The thin filament also contains two molecules of 
nebulin, which is thought to act as a ‘molecular ruler’, regulating the length of the thin- 
filament. Also associated with the thin filaments are tropomyosin and the troponin 
complex, which regulates the binding of myosin to actin in a calcium dependent manner.
Myosin forms a bundle of approximately 200-400 molecules per thick filament, 
the number of which is regulated by C-protein. The length of the thick filament is 
regulated by titin (see 1.3). There is also a polarity of the thick filaments, with the 
myosin heads orientating in one direction to face the Z-disk. Each myosin molecule is a 
complex of six polypeptide chains (Figure 1.3): two ‘heavy chains’ and two pairs of 
different light chain -  the essential and the regulatory light chains (ELC and RLC). The 
N-terminal half of the one of the heavy chains form a globular head, to which ELC and 
RLC associate, while the C-terminal half forms a fibrous alpha-helical tail, which in turn 
forms a coiled-coil with the second heavy chain (rod-like domain). In 1953, Andrew 
Szent-Gyorgi used limited trypsin digestion on myosin to produce ‘light’ (LMM) and 
‘heavy’ meromyosin (HMM), which contained the rod-like domain and the two globular 
heads of myosin (Szent-Gyorgyi, 1953) with a section of rod-like domain, respectively. 
HMM could be further proteolytically cleaved using papain to just the globular head of 
myosin, termed subffagment 1 (SI), and the remaining section of rod-like domain (S2) 
(Margossian and Lowey, 1973a; Margossian and Lowey, 1973b).
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The Myosin II molecule
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Coiled coil tail
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Figure 1.3: The myosin II molecule, indicating the production of different sub fragments 
by two types proteolytic cleavage: trypsin cleavage resulting in HMM and LMM, and 
papain cleavage, producing SI and S2.
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The original sliding filament model (or swinging cross-bridge hypothesis) 
(Huxley and Hanson, 1954) states that muscle contraction occurs when the myosin 
filaments slide past the actin filaments, with no shortening of either filament, thus 
shortening the entire sarcomere. This model for muscle contraction developed to include 
the role of ATP hydrolysis in ‘The Lymn-Taylor cycle’ (Lymn and Taylor, 1971). 
Further refinement of the model was made by the observations in structural and 
spectroscopic data (Reviewed in (Cooke, 1986)), which defined that the movement 
between actin and myosin arose from the C-terminal end of SI acting as a lever (‘The 
Lever-Arm Hypothesis’). (For a review on the mechanism of muscle contraction see 
(Holmes and Geeves, 2000))
Muscle contraction is a multi-step cycle involving the globular heads of myosin, 
actin, and adenosine triphosphate (ATP) hydrolysis. The myosin head undergoes a series 
of ordered conformational changes depending on the presence of ATP, adenosine 
diphosphate ADP, and inorganic phosphate (Pi) (Figure 1.4). The start of the cycle 
begins with myosin bound to actin in the rigor conformation. The binding of ATP to 
myosin reduces the affinity of myosin for actin, and the two proteins separate. Myosin 
then hydrolyses ATP causing it to adopt a cocked conformational change, priming the 
‘power stroke’. The weak association of the myosin-ADP-Pi complex with actin results 
in the concomitant release of Pi, increasing the affinity of myosin for actin. This is 
immediately followed by a large conformational change in myosin (the power stroke), 
and ADP is simultaneously released, hence, the initial rigor position is established. This 
series of reactions results in the force-generation required for filament movement, 
therefore for the sarcomere to shorten, and ultimately for muscle to contract.
24
Chapter 1: Introduction
Thin filament
w
Myosin Rigor complex
S1 ^
6. ADP release 1 . ATP binds to S1
Thick filament v releasing actin
ADP ATP
| 5 Power stroke
2. ATP hydrolysis 
causing cocking of 
S1 head
»
________________   3. W eak binding
4. Pi release resulting^ heac* t0
in strong binding of t
S1 head to actin
Figure 1.4: The lever arm hypothesis of muscle contraction, adapted from (Rayment et 
ah, 1993a). The diagram shows the process between myosin, actin, and ATP. The cycle 
begins from actin and myosin bound together in the ‘rigor complex’, after which ATP 
hydrolysis leads to a series of step-wise conformational changes. The sequence of events 
ends with the power-stroke, hence, re-starting the cycle.
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A major advance in understanding these concerted changes in protein structure 
came with the structural elucidation of the components involved. The atomic model of 
the actin filament (Lorenz et al., 1993) was derived from the crystal structure of g-actin 
solved in complex with DNase I (Kabsch et al., 1990), used in conjunction with x-ray 
fibre diagrams (Holmes et al., 1990). The structure of rigor state scallop myosin SI 
fragment was determined (Rayment et al., 1993b), leading to the atomic model of the 
rigor conformation of ‘decorated actin’ (i.e. actin fibres with many bound SI) to be 
established (Rayment et al., 1993a). Different conformational states of myosin were also 
critical for confirming details in the hypothesis of muscle contraction, such as myosin in 
the ‘cocked’ position (pre-power stroke -  myosin bound to ADP) (Dominguez et al.,
1998).
Although interactions between actin and myosin have been well-characterised, 
structural information of other proteins with a structural and regulatory role within the 
sarcomere have yet to be determined; this would give us a richer understanding about 
muscle contraction. An essential component of the sarcomere is a multi-protein complex 
known as the Z-disk, whose functions are to keep the structure of the sarcomere in 
register and to transmit tension during muscle contraction. The major component of the 
Z-disk is the muscle specific a-actinin-2, a multi-domain protein that tethers major 
proteins such as actin and titin within the sarcomere (Faulkner et al., 1999; Ohtsuka et 
al., 1997b). In the next sections I will review what is known about the three structural 
components of the sarcomere that are the object of this thesis: a-actinin, titin, and ZASP.
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1.2 g-Actinin-2
a-Actinin belongs to the spectrin super-family, defined by the presence of a 
specific number of spectrin repeats (first identified in spectrin) and their ability to bind 
actin, of which a-spectrin, P-spectrin, Pheavy spectrin, and dystrophin are members (Baron 
et al., 1987; Beggs et al., 1992; Dubreuil, 1991). There are four variants of a-actinin 
which are expressed depending on the cell and muscle type: a-actinin 1 and 4 are non­
muscle proteins involved in cytoskeletal interactions, while a-actinin 2 and 3 are muscle 
specific. a-Actinin-2 and 3 are both present in striated muscle, but only a-actinin-2 is 
expressed in cardiac muscle. a-Actinin-3 may be functionally redundant, as its 
deficiency carries no obvious phenotype; a-actinin-2 may compensate for its function 
(Mills et al., 2001). However, the presence o f different variants of a-actinin-3 may be 
used as an indicator of elite athletic ability (Yang et al., 2003) (Figure 1.5). 
Chromosomal mapping of a-actinin-2 shows that the gene's locus is lq43 (Beggs et al., 
1992; Tiso et al., 1999).
a-Actinin-2’s exists as a rod shaped anti-parallel homodimer (Blanchard et al., 
1989), comprising of two calponin-homology (CH) domains, four spectrin-like repeats 
and a calmodulin-like domain (Figure 1.6). a-Actinin-2’s main function appears to be to 
act as a scaffold for the assembly of the Z-disk. It is able to do this by forming crucial 
interactions between components of the sarcomere at locations along its sequence 
(Luther, 2000a). The calmodulin-like domain contains four potential EF-hands, which
^  I
have divergently evolved to not require Ca to bind its target protein (Nakayama and 
Kretsinger, 1994).
Currently, the structure of full-length a-actinin-2 has not been elucidated. 
However, sections of a-actinin solved using NMR or x-ray crystallography shows that it 
is mostly composed of a-helical domains. These structures include two of the central 
spectrin-like repeats (R3-R4) (Djinovic-Carugo et al., 1999), subsequently super-ceded 
by the structure of all four spectrin-like repeats (R1-R2-R3-R4) (Ylanne et al., 2001), and 
the structure of a-actinin-2’s last two EF-hands in complex with titin’s seventh Z-repeat 
(Atkinson et al., 2001) (Figure 1.7). Spectrin-like motifs are 100-120 residue domains 
forming an a-helical triple coiled-coil elongated structure. Each spectrin motif is joined 
together by a helical segment between the C-terminal helix of the first spectrin domain, 
and the N-terminal helix of the preceding domain. Both structures of the spectrin 
domains are anti-parallel in-register homodimers, with a self-association Kd of 2 pM and 
10 pm respectively (Djinovic-Carugo et al., 1999; Flood et al., 1995; Flood et al., 1997).
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Both structures show a similar degree of surface burial of 9.2% and 11% of the 
accessible surface of the monomer, for the two and four spectrin structures respectively. 
These structures act as models for the dimerisation of a-actinin-2 in vivo; the R1-R4 
structure shows a rigid-rod configuration, possibly caused by an end-to-end 90 ° twist.
a-Actinin-2’s last two EF-hands (Act-EF34) in complex with titin’s seventh Z- 
repeat (ZR7) was solved by NMR (Atkinson et al., 2001). This complex shows an 
unconventional binding mechanism, compared to calmodulin, as these EF-hands do not 
require the presence of Ca2+ for target binding. Act-EF34 has four a-helices -  two helix- 
loop-helix motifs joined by a flexible linker. These EF-hands saddle titin-Zr7 in a ‘semi­
open’ conformation, with an EF-hand either side of the target; titin-Zr7 is made to adopt 
an a-helical configuration from a previously unstructured conformation (Atkinson et al., 
2000a; Joseph et al., 2001). Titin’s Z-repeats have been shown to be bound by Act-EF34 
at nanomolar affinities with ZR7 being the tightest at 100-250 nm (Joseph et al., 2001).
Although there is no structure of either of a-actinin’s calponin homology 
domains, the structure of a CH domain derived from P-spectrin (Carugo et al., 1997) has 
a 57% sequence identity with a-actinin-2’s second CH domain (CH2), so should 
therefore adopt a similar fold. a-Actinin-2’s first CH (CHI) domain only has a 15% 
sequence identity with the P-spectrin’s CH domain, so may have significant structural 
differences. The calponin-homology domains are thought to work in tandem to bind 
actin, as the affinity for both domains with actin is tighter than that of a single CH 
domain (Way et al., 1992). Actin is thought to bind between the last helix of CHI and 
the first helix of CH2. The CH domain is a globular a-helical protein, which has an 
unique fold. These structures of a-actinin-2 mean that only the first CHI domain and the 
first two EF-hands of the calmodulin like domain are yet to be structurally described.
At time of writing, there are at least eight proteins found to interact directly with 
a-actinin-2 (Figure 1.6), at different regions (Faulkner et al., 2001). Among these, titin 
and ZASP has been identified to interact with a-actinin-2 (Faulkner et al., 1999; Ohtsuka 
et al., 1997a).
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Running in the genes
A SINGLE gene may mark a 
person out as an elite sprinter 
or marathon runner, it was 
claimed yesterday.
The gene comes in two 
forms that gear an athlete up 
either for short bursts of 
speed or long endurance.
The discovery raises the 
prospect of identifying poten­
tial top athletes at birth, using 
a DNA test.
Australian researchers, who
examined the genetic profiles 
of more than 300 athletes, 
identified two versions of a 
gene called alpha-actinin-3, 
or ACTN3, New Scientist mag­
azine reported.
The exact role of actinin-3 
is unclear, but researchers 
believe it may “ confer a 
greater capacity for the  
absorption or transmission of 
force during rapid, forceful 
contraction” of the muscles.
Figure 1.5: The Telegraph 28 August 2003
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Figure 1.6: Diagram of the domain organisation of a-actinin-2 and its binding partners. 
The arrows indicate the region of a-actinin-2 that the binding partners have been found to 
interact with - CapZ has only been localised to all of the spectrin-like motifs. The 
program SMART (Schultz et al., 2000) was used to predict the different domains: 
calponin-homology domain (CH); spectrin-like domains (SPEC), and EF-hand domains 
(EFh). Interacting proteins include actin (Panasenko and Gusev, 2001), titin/connectin 
(Ohtsuka et al., 1997b) ZASP (Faulkner et al., 1999), ALP (Xia et al., 1997), CapZ (Papa 
et al., 1999), Myotilin (Salmikangas et al., 1999), Myopalladin (Bang et al., 2001), 
FATZ/Calsarcin-2/Myozenin (Faulkner et al., 2000; Frey et al., 2000; Takada et al., 
2001)
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Figure 1.7: Solved structures from regions of a-actinin-2; a) the second calponin 
homology domain of P-spectrin (1AA2), 57% sequence identity with a-actinin-2’s CH2 
domain, coloured by secondary structure succession (from blue to red); b) the last two 
EF-hands in complex with titin’s seventh Z-repeat (1H8B), coloured yellow and green 
respectively; c) four spectrin-like repeats in an anti-parallel homodimer (1HCI), coloured 
green and orange to demarcate each monomer. B and C have blue and red spheres to 
distinguish the N and C termini respectively.
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1.3 Titin
Titin (also known as connectin) is a giant elastic filamentous protein (for review, 
see (Maruyama, 1997) and (Trinick, 1996)). As well as being the largest protein 
described to date (3 MDa), it is the third most abundant protein in vertebrate striated 
muscle (Maruyama et al., 1981). Single titin molecules are ~1 pM in length and span 
half of the sarcomere, with its N-terminus bound in the Z-disk and C-terminus localising 
in the M-line (Figure 1.1), unambiguously orientating the titin molecule. Its main 
functions are to help the sarcomere keep alignment during muscle contraction 
(Maruyama et al., 1981; Trinick et al., 1984), and also to act as a molecular ruler to 
regulate the assembly and length of the thick filament (Whiting et al., 1989). Therefore, 
titin is an essential component of the sarcomere’s scaffold. Its string-like appearance has 
been noted by EM, also revealing that it appears to have a globular head consisting of 
bound M-line proteins.
To achieve its functions, various sections of titin appear to have specific 
functions: the I band is believed to act as an elastic connection between the thick 
filaments and the Z-disk; in the A band it is associated with myosin and other 
constituents of the thick filament; and in the M-line it forms an integral part of an 
extensive protein meshwork. Sequencing human cardiac titin (Labeit and Kolmerer,
1995) revealed that it is a modular protein, composed of 26,926 residues, of which 90% 
is made up from -100 (fibronectin type III domain-like (Fn3)) and -100 
(immunoglobulin domain-like (Ig)) repeated sequences (Figure 1.8). These repeats make 
up a complex modular architecture.
Although the structure of full-length titin has not been solved, different sections 
of titin have been solved independently, including a Fn3-like module by NMR (Goll et 
al., 1998), several Ig-like repeats by NMR (Improta et al., 1996; Pfuhl et al., 1997; Pfuhl 
and Pastore, 1995) and x-ray crystallography (Mayans et al., 2001), and the serine kinase 
domain by x-ray (Mayans et al., 1998). Only a-actinin-2’s last 73 residues are required 
to bind an N-terminal region of titin referred to as the ‘Z-repeats (Ohtsuka et al., 1997a; 
Ohtsuka et al., 1997b), between Ig repeats 3 and 4. Z-repeats are 45 residue motifs that 
vary depending on muscle type, which have been shown to be responsible for 
determining Z-disk thickness (Gautel et al., 1996). The structure of a-actinin-2’s last 
two EF-hands (Act-EF34) has been solved by NMR in complex with a region of titin 
called Z-repeat 7 (ZR7) (Atkinson et al., 2001) -  here the EF-hands bind to the target in a 
‘semi-open’ conformation, which may be a general solution for calcium-independent 
recognition of the target sequence.
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Figure 1.8: Predicted domain representation of the primary sequence of the cardiac titin 
filament cDNA (From (Labeit and Kolmerer, 1995)). The immunoglobulin-like domains 
are represented in red, while the fibronectin type 3-like domains are in white. Irregular 
areas of sequences are shown in blue, PEVK region in yellow, and titin kinase in black. 
Titin domains have been labelled according to the main sarcomeric region (Z-line, A- 
band, I-band, and M-line). Note that the Z-repeats are found between Ig domains 3 and 4 
in the Z-disk region of titin.
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1.4 ZASP
A protein named ZASP, identified relatively recently, is only found in the Z-disk 
of skeletal and cardiac muscles (Faulkner et al., 1999). ZASP belongs to the enigma 
family of cytoskeletal proteins, defined by the presence of a combination of PDZ and 
LIM domains. The enigma family includes enigma/LMP (Guy et al., 1999), ENH 
(Nakagawa et al., 2000), ALP (Xia et al., 1997), RIL (Cuppen et al., 1998), and elfin 
(Kotaka et al., 2001), Most enigma proteins appear to have a relation to cytoskeletal 
function: ZASP, ALP, and ENH have been found to interact with a-actinin-2, and whilst 
enigma has been found to bind p-tropomyosin. Depending on the isoform, ZASP and 
cypher comprise either one or two known sequence motifs: a N-terminal PDZ alone or in 
conjunction with three carboxy-terminal LIM domains (Table 1.1).
The interaction between ZASP and a-actinin-2 has been mapped to ZASP’s PDZ 
domain (ZASP-PDZ) and to the C-terminus of a-actinin-2 (Faulkner et al., 1999; Zhou et 
al., 2001). PDZs are protein modules of 80-120 residues involved in targeting and 
clustering of membrane proteins or directing cellular proteins to multi-protein 
complexes, named after the first three proteins identified to contain the motif (post- 
synaptic protein of density 95 kDa, disks-large, and zonula occludens-1) (for a review 
see (Hung and Sheng, 2002)). Three types of interaction involving PDZ motifs have been 
described in detail (Hung and Sheng, 2002). The first two types, class 1 and 2, involve 
binding of carboxy-terminal protein sequences through either an -(S/T)-x-(V/I/L) or a - 
(F/Y)-x-(F/V/A) sequence motif. The third type of recognition involves internal - (S/T)- 
x-V- sequences motifs. Over fifty PDZ domains have been solved by either NMR or X- 
ray crystallography (from the Protein Data Bank -  http://www.rcsb.org). A structural 
alignment of these PDZ domains calculated by DALI (Holm and Sander, 1996a) show 
that approximately twenty of these structures can be represented by three solved 
structures: DlgA (lpdr), CASK (lkwa), and syntrophin (lqav) (Doyle et al., 1996; 
Hillier et al., 1999; Morais Cabral et al., 1996). This suggests that most PDZ domains 
have a fairly consistent architecture (N.B. not all of the PDZ domains have yet been 
characterised by the DALI server, hence more may be in these three groups). The PDZ 
domain is a P-sandwich, composed of six strands, flanked at either side by two alpha- 
helices. The second P-strand and the second a-helix form a groove, which has been 
observed to be the binding groove for most of the PDZ domains solved in complex with 
its target protein (PDB Accession Codes: 1B8Q (Tochio et al., 2000), 1BE9 (Doyle et al.,
1996), 1MFG (Birrane et al., 2003), 1MFL (Birrane et al., 2003), 1N7T (Skelton et al.,
33
Chapter 1: Introduction
2003), lOBX (Kang et al., 2003), lOBY (Kang et al., 2003), 1QAV (Hillier et al., 
1999)). These structures of PDZ complexes have all been found solved in the presence 
of a peptide deriving from their target protein, with the exception of 1QAV; this is a 
heterodimer between two PDZ domains derived from neuronal nitric oxide synthase 
(nNOS) and syntrophin (Hillier et al., 1999). In general, PDZ domains show no major 
change in tertiary structure upon complex formation, for example, as observed between 
the third PDZ domain from PSD-95 in complex with a C-terminal peptide derived from 
Cript (Doyle et al., 1996).
The LIM domains are a cysteine rich motif of approximately 50-60 residues, 
which derived its name from Lin-11, Isl 1, and Mec-3 from Caenorhabditis elegans, rat, 
and C. elegans respectively (for a review, see (Bach, 2000)). LIM proteins have been 
found to either be involved in cell line determination or cytoskeletal structure and 
organogenesis. Cypher’s LIM domains have been found to bind various isoforms of 
Protein Kinase C (PKC), suggesting a putative function of coupling a-actinin-2 to PKC 
function. The non-LIM containing isoforms of cypher may function to inhibit LIM 
containing cypher’s activity.
Mutations in ZASP have been linked to dilated cardiomyopathy (DCM), a 
primary cardiac muscle disease characterised by ventricular dilatation and systolic 
dysfunction (Dec and Fuster, 1994; Goodwin, 1982; Johnson and Palacios, 1982; Sugrue 
et al., 1992). DCM is a major cause of morbidity and mortality, affecting 40 people in 
every 100,000 of the population (Codd et al., 1989). The underlying cause of DCM is 
heterogeneous, with approximately 30% of genetic origin (Grunig et al., 1998; Keeling et 
al., 1995; Michels et al., 1992). Autosomal dominant inheritance of DCM is the most 
common (Towbin, 1999). Multiple genetic loci have been identified for autosomal 
dominant DCM, while mutations have been identified in actin, desmin, lamin A/C, 8 - 
sarcoglycan, p-sarcoglycan, P-myosin heavy chain, cardiac troponin T, a-tropomyosin, 
titin, a-dystrobrevin, and vinculin (Arbustini et al., 2002; Brodsky et al., 2000; Gerull et 
al., 2002; Ichida et al., 2001; Towbin, 1998; Towbin and Bowles, 2002). These genes 
contribute to structural support of the myocyte and link the sarcomere to the sarcolemma 
and extracellular matrix (ECM), as well as to the nuclear lamina (Towbin, 1998). From 
samples of patients with DCM (Arimura et al., 2003; Vatta et al., 2003), single 
polymorphisms were identified within in ZASP which were specific to ~l-4% of DCM 
cases. These mutations include single mutations localised to ZASP4 (T213I, S196L, and 
I352M), outside the PDZ domain in ZASP 1-3 (N115K), and within the 3rd LIM domain 
in ZASP2-4 (D626N). So far the only characterisation of these mutations has been for
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D626N found to have a higher affinity for PKC, which may disrupt downstream PKC 
pathways important for the correct cardiac muscle function (Johnson et al., 1996; Liu et 
al., 1999). Cypher (the murine ZASP orthologue (aka oracle (Passier et al., 2000)) 
knockout mice display a severe form of congenital myopathy and die from failure of 
multiple striated muscles (Zhou et al., 2001), again suggesting that ZASP is an important 
muscle protein required for maintaining the cytoskeletal ultrastructure during contraction. 
Structural information about ZASP would be a great aid to understanding its functional 
relationship with a-actinin-2 , and this may in turn be useful for identifying why 
mutations in ZASP lead to cases of DCM.
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Table 1.1: SMART domain predictions and information regarding their residue number 
and molecular weight of the different splice variants of ZASP, cypher (aka oracle). Red 
hexagons represent PDZ domains, yellow triangles represent LIM domains, and purple 
and grey sections represent complex and non-domain containing regions respectively. 
ZASP1, cypher2c and cypher2s do not contain the LIM domains. Note that cypher’s 
isoforms have been characterised in terms of expression in skeletal (s) and cardiac 
muscle (c), hence the s/c suffix.
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There are currently two main methods routinely used for structure determination 
at atomic resolution: x-ray crystallography and Nuclear Magnetic Resonance (NMR). 
NMR is an indirect technique, meaning that structures are modelled using data deriving 
from several variables (such as chemical composition and structure), whereas structures 
solved by x-ray crystallography originate directly from the electron density of the 
structure. X-ray crystallography has its limitations such as the ability to crystallise the 
molecule and artefacts due to crystal packing. However, NMR is also not without its 
limitations; NMR structure calculation is limited by the size of the macromolecule. Also, 
the duration of the whole procedure of NMR structure calculation is usually lengthy. 
Despite these limitations, NMR structures make up a significant percentage of the 
Protein Data Bank (15% on Jan 2004).
The input data for NMR protein structure calculation derive from geometric 
measurements such as distances, angles, and relative orientations between the atoms in 
the molecule. Data from NMR experiments arise from a pattern of peaks related to the 
atoms chemical environment (i.e. the chemical shift), so before measurement of 
structural restraints, the peaks need to be assigned to the atoms. This is achieved by 
acquiring spectra that correlate atoms depending on how they are covalently bonded to 
each other (through-bond), such as COSY, TOCSY, or ‘back-bone’ experiments. As 
mentioned previously, the size of the studied macromolecule limits the NMR structure 
determination, this is mainly because the number peaks increase with the protein’s size 
leading to peak overlap, which is difficult to deconvolute. Although running two- 
dimensional NMR experiments improve the overlap problem, a common strategy is to 
isotopically label the protein with 15N and 13C. It is then possible to run spectra to
15 13separate the proton signals on whether they are connected to spin active N or C.
After the atoms of the molecule has been assigned to their chemical shift, the 
through-space Nuclear Overhauser Effect spectroscopy (NOESY) data can be interpreted 
to measure distances between the atoms; the presence of a NOE signal between atoms 
can be detected up to a distance of 6  A. Other experiments can be run to obtain 
additional distance information, such as hydrogen bonds (Cordier and Grzesiek, 1999). 
The dihedral angles can be measured using NMR three-bond J-coupling experiments 
(e.g. the HNHA for <p angles), or by using TALOS (Comilescu et al., 1999), which 
operates by comparing the chemical shift assignment with a database of known protein 
assignments with known secondary structure elements. Also, the ‘dipolar-coupling’ can
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be measured, which is a measurement of the angle of a bond vector (e.g. the amide bond) 
with respect to the external magnetic field; this is a ‘long-range’ restraint that can 
orientate structural features of the protein, or align interacting molecules.
All of these restraints are then inputted into a structure calculation program, of 
which two of the most commonly used are CYANA (Guntert et al., 1997) and XPLOR 
(Schwieters et al., 2003). Both can calculate structures using torsion angle dynamics 
with simulated annealing, but XPLOR can also using a simulated annealing protocol in 
Cartesian coordinate space (for review see (Guntert, 1998)).
Modem computational methods shorten the duration of structure determination by 
automating the assignment of distance constraints derived from NOESY spectra. 
Programs such as Ambiguous Restraints for Iterative Assignment (ARIA) (Linge et al., 
2003a) and ‘Combined Automated NOE assignment and structure Determination’ 
(CANDID) (Herrmann et al., 2002) can substantially accelerate the process and may 
reduce the human bias during a manual structure calculation. Another advance in NMR 
structure calculation is the use of ‘water-refinement’ protocols (Linge et al., 2003b; 
Spronk et al., 2002), which are designed to tackle problems in NMR structure quality. 
The problems occur as a result of simplification of the force field for rapid structure 
calculation. This means electrostatics and van der Waals terms are usually neglected, 
leading to non-optimal packing, and unsatisfied hydrogen bond acceptors and donors. 
Refining the NMR calculated structures in a full molecular dynamics force field 
including electrostatic and Lennard-Jones non-bonded potentials and the interaction with 
solvent is one way to improve the structures.
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1.6 Aims
Structural information helps us to understand how muscle proteins interact to 
produce the process of muscle contraction -  demonstrated by the studies of actin and 
myosin. However, structural information regarding the scaffolding features of the 
sarcomere, such as the Z-disk, is still in its infancy. Cryo-EM reconstructions of the Z- 
line have been studied (Luther, 1991; Luther, 2000b; Luther et al., 2002; Luther et al., 
2003; Luther and Squire, 2002). However, finding an atomic resolution model of the 
sarcomere based on these models has yet to be accomplished, due to the lack of 
structures defining interactions between components in this region. Hence, the 
elucidation of high-resolution structures in this region must be established. The 
interactions between these components should also be studied at sufficient resolution, so 
the structural details and orientations between these proteins can be clarified.
Despite the crucial structural role that the a-actinin-2/ZASP interaction may play 
in the sarcomere, no description of the interaction at atomic resolution is currently 
available. An important question is whether or not a-actinin-2/ZASP recognition 
competes with other a-actinin-2 interactions, such as those with titin Z-repeats, thus 
requiring a major rearrangement of the a-actinin- 2  structure to accommodate multiple 
complexes. It is also interesting to understand if  and how other members of the enigma 
family could compete the a-actinin-2 interaction. Several point mutations within ZASP 
have been identified in a form of dilated cardiomyopathy, so structural information 
regarding its function would further the understanding of its role in this disease.
To address these questions, the structure of ZASP-PDZ was solved by NMR. 
NMR and fluorescence spectroscopy was applied to study the interaction between a- 
actinin-2 and ZASP-PDZ. The possibility of the mutual coexistence of both a-actinin- 
2/ZASP and titin/a-actinin-2 interactions were explored by characterising the binary and 
ternary complexes. The ZASP-PDZ coordinates were also used as a template to build 
homology models of other PDZ domains of the enigma family and to map conserved 
residues that could be functionally important.
39
Chapter 2: Materials and Methods
Chapter 2
Materials and Methods
2.1 Bioinformatics
Protein primary sequences were analysed by different computational services to 
derive various properties. General protein properties were calculated by ProtParam 
(http://us.expasy.org/tools/protparam.html). Protein sequence similarity searches were 
performed by the BLASTP program (Altschul et al., 1997) on the non-redundant proteins 
database nrdb95 running on the EMBL server (http://www.embl- 
ebi.ac.uk/~holm/nrdb90/) (Holm and Sander, 1998); subsequent sequence alignment was 
done by ClustalX (Thompson et al., 1997). Selected proteins were analysed for domain 
identification using the Simple Modular Architecture Research Tool (SMART - EMBL 
Server) (Schultz et al., 2000). Secondary structure prediction was forecast by the 
PredictProtein PHDsec server (http://cubic.bioc.columbia.edu/predictprotein/) (Rost and 
Sander, 1993). Information regarding tertiary protein properties was also 
computationally assessed, including the usage of the DALI server to find similar protein 
structures (Holm and Sander, 1996a). Also, homology modelling was calculated by 
SWISS-MODEL in combination with Swiss PDB Viewer (Guex and Peitsch, 1997).
2.2 Plasmid Production
The constructs were available from previous studies (Faulkner et al., 1999; 
Joseph et al., 2001). The sequence for human skeletal muscle ZASP-PDZ was derived 
from GenBank (http://www.ncbi.nlm.nih.gov/Genbank) AJ133766 (1-85) with a Serine-2 
to Alanine mutation, which was supplied from the group of Georgine Faulkner (ICGEB, 
Padua, Italy). Human skeletal muscle a-actinin-2 last four and last two EF-hands, Act- 
EF1234 and Act-EF34, derived from GenBank M86406 (745-894 and 822-894 
respectively). A pET9d plasmid that conferred kanamycin resistance, for transformant 
selection, was utilised for protein expression. These constructs were designed to be 
produced as fusion proteins to aid protein purification; this included a N-terminal six-
40
Chapter 2: Materials and Methods 
histidine-tag (6 HIS) and S. Japonicum glutathion transferase (GST) tag. A sequence 
encoding a seven-residue Tobacco Etch Virus (TEV) protease recognition site separated 
the tags from the target protein allowing cleavage between them.
Plasmid purification was achieved using the QIAprep Spin Miniprep Kit (Qiagen) 
as described in the provided protocol. Single transformed colonies were grown overnight 
in 5 ml of Luria-Bertani (LB) medium (Maniatis et al., 1989) at 37 °C at 200 rpm. The 
cells were centrifuged (4000 rpm, 9mins) and re-suspended in re-suspension buffer (PI). 
The cells were then lysed by addition of alkaline lysis buffer (P2), followed by acid 
neutralisation by addition of buffer N3. Bacterial debris was pelleted by centrifugation 
( 1 2 0 0 0  rpm/ 1 0  mins) using a bench micro-centrifuge, and the supernatant was transferred 
to a QIAprep spin column placed in a 2 ml collection tube. The column was then 
centrifuged for 13,000 rpm for 1 min. The bound plasmid DNA on the column was then 
washed with buffer PE, which contains 80 % ethanol, allowing the removal of water 
insoluble cell debris. Buffer PE was removed by centrifugation and the column was left 
to rest for 5 mins to allow residual ethanol to evaporate. The plasmid DNA was eluted 
with 50 pi of nuclease free H2 O, pre-heated to 70 °C.
2.3 Protein Expression
2.3.1 Transformation of Competent Cells
The constructs were transformed using standard protocols using E. Coli 
BL21(DE3) or BL21(DE3)pLysS competent cells (Novagen). The plasmid DNA (1 pi of 
between 1 0 0 - 2 0 0  ng/pl) was added to 2 0 0  pi of competent cells, followed by ice 
incubation for 30 mins. The cells were heat-shocked for 60 seconds at 42 °C in a water 
bath followed by incubation on ice for 1-2 mins. 200 pi of SOC medium was added to 
the sample and left for 1 hour at 37 °C, after which they were spread on LB agar plates 
containing ampicillin (100 pl/ml) or kanamycin (30 pg/ml), depending on the construct, 
and left to incubate at 37 °C for 16 hrs.
2.3.2 Fermentation
Unlabelled protein was obtained from cells grown in LB broth (Maniatis et al., 
1989) containing kanamycin (30 pg/ml) to select and grow the transformed cells. 
Typically, a single colony was used to inoculate 25 ml of media per litre of intended
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broth fermentation, incubating for approximately 16 hours at 37 °C. The 25 ml growth 
was then used inoculate one litre of media and the cells grown at 37 °C. The cells were 
induced to express the fusion protein by the addition of isopropyl 0-D- 
thiogalactopyranoside IPTG (0.5 mM final concentration) at E. ColV s period of 
exponential growth (O.D59 5  nm ~ 0.5-0.6); specifically BL21(DE3) contains a T7 
polymerase under a lacZ promoter, which transcribes the target that is under a T7 
promoter. The cells were then incubated at 37 °C for an additional three hours to allow 
for protein expression.
Uniformly labelled 15N or 13C labelled protein was produced by using isotopically 
enriched reagents as a source of the desired isotope, as opposed to using LB broth. 15N- 
ammonium sulphate was the only nitrogen source to produce 15N-labelled protein, while 
15N/13C-labelled protein was produced by substituting 12C-glucose with 13C6 -D-glucose 
as the only source of carbon. The protocols for expression and purification were 
otherwise identical. See Appendix 10.2.1 and 10.2.2 for media compositions.
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Here is a general schematic of the steps for protein purification:
Protein Expression  
^  Lysis
Cell Lysate
Nickel Agarose Column
Target ProteinGST6H
TEV Protease
Target ProteinGST6H
Size Exclusion/Nickel Agarose Column
Figure 2.1: Schematic of the steps of protein purification for 6HIS (6H), GST, and 
‘TEV cleavage site’ (red circles) tagged proteins. Cells are lysed after protein 
expression, and the cell lysate is passed down a nickel-agarose column. The fusion 
protein is recovered and subsequently cleaved using the TEV protease. The target 
protein is then purified from the 6HIS-GST by size exclusion or another nickel-agarose 
purification.
2.4.1 Cell Lysis
Protein purification was carried out as described in a previous study (Joseph et 
al., 2001). The fusion protein is expressed in the cytoplasm, so the cells need to be lysed 
- breaking the bacterial cell wall and plasma membrane. Cells were pelleted after cell 
growth by centrifugation and re-suspended in lysis buffer (20 mM Tris.HCl pH8, 200 
mM NaCl, 5 mM imidazole, 0.2% v/v IPEGAL CA-630), using 25 ml per litre growth of 
cells. IPEGAL CA-630 prevents hydrophobic membrane proteins aggregating, lysozyme 
was added as an aid to cell lysis, as it catabolises polysaccharide components of bacterial
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cell walls, and DNase I was added to reduce the lysate viscosity. A single tablet of 
‘Protease Inhibitor Cocktail’ (Roche) was also added to prevent protein degradation. The 
cells were left to incubate for 2 0  minutes on ice, to allow lysis to occur, followed by 
homogenisation by sonication (MODEL 250, Branson) using a 50% duty cycle with a 
50-watt output for 5 minutes on ice. The supernatant was collected after centrifugation 
(20,000 rpm for 30 minutes at 4 °C). See Appendix 10.2.3 for solution compositions.
2.4.2 Nickel NT A Agarose Protein Purification From Lysate
The 6 HIS-tagged protein was affinity purified from the cell extract by nickel- 
nitrilotriacetic acid (Ni-NTA) agarose column (QLAGEN). A column was packed with 
Ni-NTA (1 ml per litre of growth medium), and equilibrated with five column volumes 
(CV) of ‘Lysis Buffer’ (See Appendix 10.2.3 for buffer composition). The cell lysate 
was passed through the column followed by 5 CV of Wash Buffer, 5 CV of ‘1M NaCl 
Wash Buffer’, and 5 CV of ‘30 mM Imidazole Wash Buffer’. These washes are intended 
to remove any non-specifically bound protein contaminants from the column. The 6 HIS- 
tagged protein was eluted with 5 CV of ‘300 mM Imidazole Wash Buffer’. All the 
fractions were checked on 15% acrylamide gel electrophoresis to track the outcome of 
the purification.
2.4.3 Tobacco-Etch Virus Cleavage
Cleavage of the 6 HIS-GST from protein of interest was achieved by using TEV 
protease (Gibco BRL®). The TEV protease is specific to a seven-residue tag (GLU-X- 
X-TYR-X-GLN-SER, cleavage between GLN and SER) between the GST and the 
desired protein. Approximately 2-3 pM TEV protease was used for the elution from the 
Ni-NTA column, and this was incubated for approximately 16 hours at room 
temperature.
2.4.4 Gel Filtration (FPLC) Protein Purification
The target protein was purified from 6 HIS-GST (approx 25 kDa) by gel filtration 
using a Superdex 75 16/60 column (Pharmacia). The sample was concentrated to 
approximately 5 ml by using a filter concentrator (Amicon) to improve the separation on 
the column. The column was typically equilibrated with 20 mM Tris.HCl pH 8 , 200 mM
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NaCl, 0.2% NaN3 , which was 0.2 pm filtered and de-gassed -  this buffer was also used 
for the elution. The elution profile was then analysed and the fractions of interest were 
run 15% acrylamide gel electrophoresis for assessment.
2.4.5 Nickel NT A Protein Purification After TEV Cleavage
Act-EF1234 was purified using the Ni-NTA column, as there was a problem with 
aggregation if  FPLC was used. Following the TEV cleavage, the product was buffer 
exchanged to ‘1M NaCl Wash Buffer’ using a PD-10 column (Sephadex G25-M 
Pharmacia) to remove the imidazole. The sample was then applied to a Ni-NTA column 
containing the same quantity of Ni-NTA agarose from the purification from cell lysate, 
this time equilibrated with 5 CV ‘1M NaCl Wash Buffer. The flow-through and a further 
2 CV of 1M NaCl Wash Buffer was collected. 5 CV of ‘300 mM Imidazole Wash 
Buffer’ was passed though the column to remove the 6 HIS-GST from the column. The 
sample was then checked by 15% acrylamide gel electrophoresis.
2.4.6 Buffer Exchange Using PD-10 Columns
Protein samples were then buffer exchanged using a Sephadex G-25M PD-10 
column (Pharmacia) using the standard protocol supplied. After equilibration of the PD- 
10 column with 25 ml of the desired buffer, 2.5 ml of protein solution were passed 
through. The protein was eluted with 3.5 ml of the desired buffer. All protein samples 
were buffer exchanged into 20 mM Na2 PC>4 , 0.02% NaN3 , and pH 6 .6 . All NMR 
samples were prepared with the addition of 1 0 % v/v deuterium oxide (D2 O) added after 
buffer exchange.
2.4.7 Concentration Determination Using Absorption Spectroscopy
Protein concentration was determined using the Beer-Lambert equation (Equation 
2.1) using a double beam HELIOS a spectrophotometer (UNICAM). An accurate 
measurement of the extinction coefficient at 280 nm was determined for each protein by 
the Edelhoch method (Pace et al., 1995) (Equation 2.2). The absorbance was measured 
for the protein in the experimental buffer and also in 6 M-guanidinium hydrochloride 
(GuHCl), subtracting the buffer baseline reading. The extinction coefficient is calculated 
from the amino acid composition using Equation 2.2, and then the extinction coefficient
45
Chapter 2: Materials and Methods 
in the buffer is calculated from Equation 2.3. Typical NMR sample protein 
concentrations were approximately 0.5 mM, adjusted by utilising a filter concentrator 
(Amicon).
Absorbance — e c - l
Equation 2.1: Beer-Lambert equation. Absorbance is equal to the product of the 
extinction coefficient (e), concentration (c) and path length (1).
£280, GuHCl = (HTrp) • (5685) + (#Tyr) • (1285) + (# Cys) • (125)
Equation 2.2: The Edelhoch Method of extinction coefficient (e) calculation from amino
acid composition.
e2SQ,buffer = (A^ buffer){e2S0’GuHCl)
A280, GuHCl
Equation 2.3: Calculation of extinction coefficient for protein in experimental buffer, 
from the extinction coefficient calculated by amino acid composition.
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2.5 NMR
2.5.1 Spectroscopy
NMR data were recorded on Varian spectrometers: Unity-500, Unity 600, Inova- 
600, and Inova-800 MHz (*H frequency), all equipped for ^ /^ C /^ N  triple-resonance 
experiments. The spectrometers were controlled by the VNMR software 
(http://www.varian.com/) installed on SPARC workstations running Sun OS v5.7 
(http://www.sun.com/).
Details for each spectrum, including the number of points, spectral width, 
spectrometer *H frequency, and carrier frequency, for each dimension can be found in the 
Appendix 10.3, while many of the details for the pulse sequences can be found in 
(Cavanagh et al., 1996). Water suppression was achieved using WATERGATE (Piotto 
et al., 1992) in all experiments and experiments were run at a temperature of 300 K 
unless otherwise stated.
Two-dimensional COSY, NOESY, and TOCSY spectra were run on 
unlabelled protein. Different combinations of mixing times (40-150 milliseconds) and 
temperatures (283-300 K) were tested to determine optimal conditions for TOCSY and 
NOESY spectra. ZASP-PDZ, Act-EF1234, and Act-EF34 were found to behave well at 
300 K, and therefore set for all spectral acquisition.
15N Hetronuclear Single Quantum Correlation spectra (HSQC) were run on 15N 
single or 15N/13C doubly isotopically labelled protein. The 15N-HSQC was used for 
various purposes, such as sample quality evaluation, titrations, assignment purposes, etc, 
so acquisition parameters varied between (1024 x 64) to (2048 x 1024) data points. 13C- 
HSQC was run on 1 3C-labelled protein for assignment purposes. 15N-TOCSY-HSQC 
spectra were run on 15N-labelled ZASP-PDZ and Act-EF34, using mixing times of 100 
and 80 ms respectively. 15N-NOESY-HSQC spectra were run on ZASP-PDZ, using 
mixing times of 50 and 100 ms, and 80 ms for Act-EF34. HNHA and HNHB 
experiments were run on both samples of 15N-ZASP-PDZ and 15N-Act-EF34. Only 15N- 
TOCSY-HSQC and 15N-NOESY-HSQC spectra were acquired for the assignment of the 
15N-ZASP-PDZ/Act-EF1234 complex, which was present at a 1:2 ratio (see Binding 
Chapter 6  and Appendix 10.8)
15N/1 3C-labelled protein was used for detecting CBCACONH and CBCANH 
spectra for both ZASP-PDZ and Act-EF34’s backbone atoms assignment, and a HNCO 
spectrum was run for ZASP-PDZ. Side-chain assignments were completed using an
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HCCH-TOCSY for ZASP-PDZ. Additional spectra were acquired for the structure of 
ZASP-PDZ, including a 13C-NOESY HSQC. T l, T2, and NOE relaxation data spectra 
were also acquired for ZASP-PDZ and Act-EF34 (see Appendix 10.3.1.1.20 and 
10.3.1.2.9 for relaxation delays used).
2.5.2 Spectral Processing
NMR spectra processed using nmrPipe (Delaglio et al., 1995). Typically, the 
acquisition dimension was multiplied by a Gaussian window function and a 90° shifted 
sine-bell function in the indirect dimensions to enhance the resolution of the spectra. 
Polynomial solvent subtraction was used on the acquisition dimension if required, and 
linear prediction was used on indirect dimension appropriately to improve and increase 
the resolution of the spectrum respectively. All dimensions were zero-filled to the next 
appropriate power of two. SPSCAN (http://www.molebio.uni-jena.de/~rwg/spscan)) was 
used to convert the nmrPipe data to XEASY (Bartels et al., 1995) for analysis.
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2.6 NMR Structure Determination
Here is a schematic for NMR structure determination:
Calculate Structure
Assign sidechain atom s 
1 H-15N-T OCSY-HSQ C 
HCCH-TOCSY
Calculate Additional Structural Restraints 
Phi/Psi Angle 
Hydrogen bonds 
Dipolar Couplings
A ssign short/long range distance restraints 
1H-15N-NOESY  
1H-13C-NOESY
Assign backbone atoms 
1 5N-HSQC, 1 3C-HSQC  
e  g HN(CO )CA/HNCA 
HNCO
Figure 2.2: NMR structure determination pipeline. First, the backbone atoms of the 
protein ‘chemical shift’ are assigned, allowing for sidechain atoms assignment. 
Structural restraints are then analysed (distance, angular, and orientational), which are 
then used for structure calculation.
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All NOESY spectra were acquired and processed as outlined in Materials and 
Methods 2.5. Spectral analysis was performed using XEASY (Bartels et al., 1995). A 
combination of two and three-dimensional NOESY spectra were analysed for distance 
constraint assignment. The NOESY spectra included a ^^H -N O ESY  with a 100 ms 
mixing time, ^-^N-NOESY-HSQC at 50 ms, and ^-^C-NOESY-HSQC at 100 ms. 
The 'H-^N-NOESY-HSQC was analysed by using an assigned !H-15N-HSQC-TOCSY 
peak list followed by picking all other observable NOESY peaks. The same procedure 
was implemented for analysing the ^-^C-NOESY-HSQC, by using HCCH-TOCSY 
peak list. The ^^H -N O ESY  was analysed by utilising the assignments made in the 15N 
and 13C NOESY-HSQC and analysing the remaining peaks.
Peak assignment began with assigning short and medium-range NOEs, while 
initial long-range NOEs assignment was achieved by finding peaks with unique 
assignment possibility. A homology model of ZASP-PDZ assisted initial long-range 
NOE assignment, and secondary structure prediction was useful for assigning medium- 
range NOEs. Peaks with multiple assignments were assigned by observing restraints on 
preliminary calculated structures. This procedure was then semi-automated by 
employing MOLMOL (Koradi et al., 1996) to calculate distances less than 7 A between 
all atoms in 10 from the best 30 of 100 CYANA generated structures. This distance 
information was then combined with the possible assignments observed in XEASY, and 
a Perl script (‘dist_search.pl’, Appendix 10.9.5) was used for the quick evaluation of the 
constraint.
2.6.2 Distance Calibration
The distance calibration involves converting peak intensities or volumes into 
upper-distance limits between atoms (Equation 2.4), both are directly proportional to 
each other (Equation 2.5), assuming that the line-width for all peaks is identical, so either 
can be used for peak calibration. Peak integration for the NOESY spectra was 
calculated using SPSCAN (http://www.molebio.uni-jena.de/~rwg/spscan) with five 
iterations of integration, while peak intensities were directly measured in XEASY. 
CALIBA (Guntert et al., 1997) was utilised for distance calibration, or alternatively the 
Perl script ‘calibrate.pl’ (Appendix 10.9.7) categorised the volumes/intensities into
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strong/medium/weak/very weak. Known distances in secondary structure elements 
(Wuthrich, 1986) verified the calibration.
Equation 2.4: Peak volume is inversely proportional to distance.
V = I •( 7T.r2^
Equation 2.5: Relationship between volume and intensity.
Peak overlap was resolved on an individual restraint basis by looking at 
alternative instances where the overlap was not present; for example, the ^^H-N O ESY , 
in some cases, had less overlap than the three-dimensional spectra due to its higher 
resolution. If the peak overlap was not resolved by this substitution, the restraint was set 
to the maximum observable NOE distance of 6 A. Pseudoatom correction was added to 
all cases where there was chemical shift redundancy for stereo-pairs that were not stereo- 
specifically assigned. Stereo-specific assignment was calculated by GLOMSA (Guntert 
et al., 1991) -  this makes stereo-specific assignments of diastereotopic substituents of 
prochiral centres from calculated structures and distance restraints.
2.6.3 Hydrogen Bonds, Dihedral Angles, and Residual Dipolar Couplings
Directly observed hydrogen bonds were used as structural restraints by acquiring 
and analysing a modified HNCO (Cordier and Grzesiek, 1999). Dihedral angle (cp and \|/) 
restraints were calculated using the program TALOS (Comilescu et al., 1999), which 
operates by comparing the chemical shift assignment with a database of known protein 
assignments with known secondary structure elements. Additional and confirmatory <p 
dihedral angles were calculated using HNHA spectra. The ZASP-PDZ NMR sample was 
partially aligned by using a poly(ethylene glycol) liquid crystalline phase (Ruckert and 
Otting, 2000): n-dodecyl-penta(ethylene glycol) (C12E5) was added to the NMR sample 
at a 5% w/v ratio, and n-hexanol was added at a 0.96 molar ratio against the C12E5 to 
form the lyotropic liquid crystalline phase. Dipolar coupling values for the backbone 
amide protons were measured by running a J-modulated HSQC experiment (Tjandra et 
al., 1996).
51
Chapter 2: Materials and Methods
2.6.4 CYANA
The structure of ZASP-PDZ was calculated with CYANA (Guntert et al., 1997): a 
program that uses simulated annealing combined with molecular dynamics in torsion 
angle space. Distance restraints from the 'H-'H-NOESY, 13C-NOESY-HSQC, and 15N- 
NOESY-HSQC were included for the structure calculation. Restraints from the 
hydrogen bond experiment, and also the dihedral angles calculated from TALOS and 
HNHA spectra were inputted only after the NOE data had converged. The simulated 
annealing protocol involved a high temperature conformational search stage of 2000 
steps, followed by slow cooling over 8000 steps with conjugate gradient minimisation at 
the end. The redundant dihedral angle (REDAC (Guntert and Wuthrich, 1991)) strategy 
was used to help the convergence of the structures, typically using 5 cycles of 100 
structures. Tolerated violations included upper, lower, and van der Waals distance limits
o
of 0.5 A, and angle violations of 5 degrees.
2.6.5 CANDID
The assignment of ZASP-PDZ and the peak list (both in XEASY format) from 
the !H-13C, and *H-15N NOESY spectra were used for the CANDID module
(Herrmann et al., 2002) within CYANA. The chemical shift tolerances used in both 
dimensions of the ^-'H-NOESY were 0.02 ppm, and 0.03 and 0.05 ppm for the proton 
and 13C/15N nuclei in the three-dimensional NOESY spectra respectively. Non-NOE 
restraints included hydrogen bonds, and the TALOS and HNHA dihedral angles. The 
default run of seven cycles was used for CANDID structure calculation.
2.6.6 XPLOR
The NIH version of XPLOR (Schwieters et al., 2003) was utilised for the 
structure calculation of ZASP-PDZ, again using torsion angle dynamics with simulated 
annealing (Stein et al., 1997). Structural data from CYANA calculations were directly 
converted for use in the XPLOR calculation: NOE upper-limit boundaries were
converted from the CYANA calculation using the Perl script d2x.pl (Appendix 10.9.1). 
The pseudoatom correction which was automatically added to the distance constraints 
from the CYANA calculation were subtracted (as XPLOR can add its own pseudoatom
o
correction), and all distances were defined as straight upper-limit boundaries with a 1.8 A
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lower-limit. The stereo-specific assignments were implicit from the converted NOE 
restraints. Hydrogen bond definitions were inputted with standard XPLOR definitions. 
Dihedral angles (<p and \|/) were converted using aco2tbl.pl (Appendix 10.9.3), and all 
angles were inputted with and error of ± 30 degrees. 78 RDCs were derived from the 
HSQC-IPAP spectra, but 15 were unused, as they were deemed intrinsically mobile. 
Mobility was gauged by looking at the relaxation analysis (Appendix 10.3.1.1.20) - if  the 
backbone amide T1/T2 relaxation was outside one standard deviation from the mean, or 
if  the backbone amide had an NOE value of less than 0.7. Tolerated violations included
o
upper, lower, and van der Waals distance limits of 0.5 A, and angle violations of 5 
degrees.
2.6.7 CHARM22 Water Refinement
Twenty of the best structures from both XMANUAL and XCANDID calculations 
were water-refined using the ‘CHARMM22 water-refinement protocol’. The protocol 
was carried out as detailed in (Spronk et al., 2002), in combination with distance and 
dihedral angle constraints.
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Unlabelled and 15N-lablelled protein was expressed and purified as detailed in 
Materials and Methods 2.3 and 2.4. 15N-HSQC spectra acquisition was carried out as 
shown in Materials and Methods 2.5, typically acquired using (2048 x 64) points in the 
direct and indirect dimensions respectively. Titration schemes varied depending on the 
titration; a typical pair-wise NMR titration involved the incremental addition of 
unlabelled protein to an amount of 15N-lablelled protein and acquiring l5N-HSQC spectra 
for each addition of unlabelled protein. Molar ratios of 15N-labelled to unlabelled protein 
ranged between 10:1 to 1:2, or until no further spectral changes were observed 
(Appendix 10.8).
NMR spectra were converted and processed in nmrPipe (Delaglio et al., 1995) as 
described in Materials and Methods 2.5, and analysis of the changes in lH and 15N 
chemical shift in the 15N-HSQC was monitored using XEASY (Bartels et al., 1995). The 
A8weighted change was calculated for each peak using Equation 2.6 to simplify the 
analysis, instead of using !H and 15N chemical shift data. The final concentration point 
of the titration was used to plot the binding charts (A8weighted vs. residue number).
^weighted ~
AS,1 5 N
10
Equation 2.6: Calculation of A 5 weighted, which combines !H and 15N changes in chemical 
shift. The 15N dimension is divided by ten to account for the difference in gyro-magnetic 
ratio between !H and 15N.
Dissociation constant (Kd) calculations were performed to assess the affinity 
between proteins. Peaks in the spectra were visually inspected to check their suitability 
for Kd calculation; to simplify the analysis, only peaks in fast exchange (with respect to 
the NMR time-scale) were used. For each calculation, a 1:1 binding model was assumed 
(Equation 2.7), from which the Kd is determined (Equation 2.8). Equation 2.9 (Roberts, 
1993) shows that the Kd can be solved from the observed chemical shift (80bs), the initial 
chemical shift of the ligand (8l), the total amount of enzyme ( E t) ,  and the total amount of 
ligand Lt -  the 8el and Kd is then solved using non-linear regressional analysis (using the 
computer program Prism (Graphpad). 80bs is a weighted average of the chemical shifts of 
the protein free in solution (8l) and in complex (8el) (Equation 2.10); the weighting
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being the fractional population of each state (pL and pel respectively, defined in Equation 
2.11: A and B).
k + i
E + L EL 
k - i
Equation 2.7: Simple binding model of and enzyme (E) binding to a ligand (L) forming 
the complex (EL). The equilibrium constants for association and dissociation dictate 
where the equilibrium lies.
[E][L]
“ Kx IEL\
Equation 2.8: The dissociation constant (Kd) is calculated from the concentration of the 
enzyme [E], ligand [L], and the resultant complex [EL].
* * (8el - S l ) \e t +Lt + K d) - ^ { E r +Lt + K df  + 4  E TLT }
= --------------------------------------IL r--------------------------------------
Equation 2.9: This indicates that the Kd can be determined from 8 0bs (see above for a 
definition of the parameters). By plotting 8 0bs against Lj, non-linear regression analysis 
can be used to determine 8el and Kd.
&obs ~  &l P l  +  & EL P el
Equation 2.10: Observed chemical shift is the weighted average of the chemical shift 
values from the bound and free states.
A) Pt [L] + [EL]
B ) P e l = _ L E ^
HEL [L\ + [EL]
Equation 2.11: A) The mole fraction of the ligand (pl) is calculated from concentration 
of the free ligand [L], divided by the total amount of ligand -  the free ligand and the 
ligand in complex [EL]. B) The mole fraction of the complex is calculated in an 
analogous fashion.
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The fluorometric titrations were carried out by Dr. Steve Martin (NIMR, 
London). Dissociation constants for the interaction of ZASP-PDZ or ZASP-PDZ/tZR7 
with Act-EF34 were determined at 20 °C in 20 mM phosphate (pH 6.6) by direct 
fluorometric titration at 322 nm using a SPEX FluoroMax fluorimeter with Xex = 295 
nm. Only one tryptophan in ZASP-PDZ is present, so the titrations of ZASP or ZASP- 
tZR7 with Act-EF34 (A) were fit to the following equation: Fluorescence = F(Z)[Z] + 
F(AZ)[AZ], where the F values are the molar fluorescence intensities and Z denotes tZR7 
and the ZASP-tZR7 complex. A value for the dissociation constant (Kd) was obtained 
from a non-linear least squares fit to this equation (Marquardt method) with 
concentrations calculated by solving the equation:
[AZ]2 - [AZ](Kd + A t o t  +  Z t o t )  +  A t o t Z t o t  =  0
Equation 2.8: A t o t  and Z j o t  are the initial concentrations of unbound Act-EF34 and 
ZASP-PDZ respectively. [AZ] is the concentration of the complex.
Derived by the following proof; where Act-EF34 (A) binds to ZASP-PDZ (Z) according 
to the following scheme:
A + Z <-» AZ with Kd = [A] [Z] / [AZ]
Total concentrations of A and Z ( A t o t  and Z t o t )  are given by:
A To t = [ A ]  +  [A Z ]
Z To t = [ Z ]  +  [A Z ]
Then:
Kd = ( A TOt  - [AZ]) (Z TOt  - [AZ]) / [AZ]
and:
Kd.[AZ] — A t o t - Z t o t  -  [AZ]( A t o t  +  Z t o t )  +  [AZ]2
and:
[AZ]2 -  [AZ](Kd +  A t o t  +  Z t o t )  +  A t o t - Z t o t  =  0
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2.9 Peptide synthesis and purification of the Minimal Titin ZR7 peptide
Peptide synthesis was carried out by Dr. Remo Guerrini (University of Ferrara, 
Italy). The peptide was designed by observing the residues present in the NMR structure 
of Act-EF34 in complex with ZR7 (Atkinson et al., 2001), plus an addition one further 
residue of the ZR7 sequence to aid the peptide synthesis. The tZR7 peptide 
(GKKAEAVATWAAVDQARVREPR) was synthesized using standard solid-phase 
synthesis techniques (Atherton and Sheppard, 1989) with a Milligen 9050 synthesizer. 
Protected amino acids and chemicals were purchased from Bachem, Novabiochem or 
Fluka (Switzerland). The resin loaded with glutamic acid (Fmoc-Glu(OBut)-PEG-PS) 
from Millipore (Waltham, MA, U.S.A.) (0.5 g) was treated with piperidine (20%) in
DMF. The Na -Fmoc amino acid derivatives were sequentially coupled to the growing 
peptide chain by using a four-fold excess of [0-(7-azabenzotriazol-l-yl)-l,l,3,3- 
tetramethyluronium hexafluorophosphate] (HATU (Carpino, 1993)) in DMF. Piperidine 
(20%) in DMF was used to remove the Fmoc group at all steps. The protected peptide- 
PEG-PS-Resin was cleaved from the resin by treatment with 
TFA/H20/phenol/ethanedithiol/thioanisole (reagent K) (82.5 : 5 : 5: 2.5: 5; v/v) (King et 
al., 1990).
Crude peptide was purified by preparative reversed-phase HPLC using a Water 
Delta Prep 4000 system with a Waters PrepLC 40 mm Assembly column Cl 8 (30 x 4 
cm, 300 A, 15 mm spherical particle size column) using a linear gradient from 10 to 40% 
of acetonitrile in 0.1% TFA. The molecular weight of the compound was confirmed by a 
Matrix Assisted Laser Desorption Ionisation Time of Flight (MALDI-TOF) analysis 
using a Hewlett Packard G2025A LD-TOF system mass spectrometer.
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Chapter 3
Protein Expression and Purification
3.1 Protein Purification of ZASP-PDZ
All expression and purification was carried out as stated in the Materials and 
Methods (2.3 and 2.4). Expression of ZASP-PDZ was carried in LB, 15N minimal media, 
and 15N/13C minimal media. Protein purification after cell lysis was performed by nickel 
agarose affinity purification to recover the fusion protein: ZASP-PDZ gave a predictable 
elution profile for each of the purification steps; the gel (Figure 3.1) showed that the first 
three washes removed the other proteins contained in the cell lysate. The first wash 
showed an excess of the 6HIS-GST-ZASP-PDZ fusion protein, as some is present in the 
unbound fraction. The ‘30 mM Imidazole Wash’ showed no detectable impurities, 
whilst the ‘300 mM Imidazole Wash’ successfully recovered the fusion protein from the 
column.
The fusion protein was then subsequently cleaved with TEV protease (Figure 
3.1), which is apparent from the gel: it appears that >95% of the fusion protein was 
cleaved, giving the 6HIS-GST, and ZASP-PDZ. ZASP-PDZ was then recovered from 
TEV protease and 6HIS-GST by size exclusion. The FPLC profile (Figure 3.2) shows 
well-resolved peaks with GST, TEV, and ZASP-PDZ eluting at 55, 70 and 95 ml 
respectively. A polyacrylamide SDS gel (Figure 3.3) showed that the ZASP-PDZ 
contained a single species. The sample was buffer exchanged and concentrated between 
0.5 -  1.0 mM, depending on the usage. The UV/VIS spectrum (Figure 3.4) gave a 
profile from which the concentration of the protein could be determined at 280 nm using 
the extinction coefficient (8250 M-l cm-1) derived from the Edelhoch method (Materials 
and Methods 2.4.7 and Appendix 10.1). The yield for the unlabelled ZASP-PDZ protein 
was approximately 9 mg/L of LB media, whilst either single 15N or double 15N/13C 
labelled expressions were around 5-6 mg/L of minimal media.
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Figure 3.1: Polyacrylamide SDS gel of the purification of ZASP-PDZ; from cell lysis up 
till TEV protease cleavage. 1) Broad molecular weight marker (Appendix 10.2.6), 2) cell 
lysate supernatant, 3 to 7) nickel agarose purification (in order, unbound fraction, column 
buffer wash, ‘1M NaCP wash, 30 mM imidazole wash, and 300 mM imidazole wash, 8) 
TEV protease cleavage product containing 6HIS-GST and ZASP-PDZ.
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Figure 3.2: FPLC elution profile of ZASP-PDZ monitoring fluorescence at 260 and 280 
nm.
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I 2 3 4 5 6
Figure 3.3: Polyacrylamide SDS gel of a ZASP-PDZ FPLC result. 1) Marker, 2) un­
cleaved 6HIS/GST/ZASP-PDZ, 3) GST (eluent at 55 ml from Figure 3.2), 4-7) Pure 
ZASP-PDZ elution (elution volume of 95 ml).
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Figure 3.4: UV/Visible light absorbance spectra of ZASP-PDZ (at 0.57 mM), used to 
measure protein concentration at 280 nm.
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3.2 Protein Purification of Act-EF34
Identical protocols as for ZASP-PDZ were used to express and purify Act-EF34, 
expressing in LB, 15N, and 15N/13C minimal media. Nickel agarose and TEV protease 
cleavage was performed to recover the fusion protein, and cleave Act-EF34 from the 
6HIS-GST, respectively (Figure 3.5). Initial attempts to express and purify Act-EF34 
resulted in co-purification with GST after FPLC purification. However, alterations to the 
protocol of cell lysis by sonication improved the purification -  the heat caused by 
sonication may have aggregated the protein, so steps were made to limit the sonication 
time and improve heat dissipation. After these changes were made the construct was 
well behaved, with the fusion protein being correctly expressed, purified, and cleaved.
Act-EF34 was purified by size exclusion (Figure 3.7), giving an elution profile 
showing three distinct peaks for GST, TEV, and Act-EF34, eluting at 55, 70 and 90 ml 
respectively, which appeared to give a single species (Figure 3.8). The sample was 
buffer exchanged to NMR buffer and concentrated between 0.5 -  1.0 mM. The 
concentration of Act-EF34 was deduced from a UV/VIS spectrum at 280 nm (Figure 3.6) 
using the extinction coefficient (6400 M-l cm-1). The yield of Act-EF34 was 
approximately 4 mg/L of LB media, while only approximately 2 mg/L of 15N minimal 
media.
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Figure 3.5: Polyacrylamide SDS gel of Act-EF34 purification, from cell lysis until TEV 
protease cleavage. 1) Molecular weight marker, 2) cell lysate, 3 to 7) nickel agarose 
purification (in order of, unbound fraction, column buffer wash, ‘1M NaCl’ wash, 30 
mM imidazole wash, and 300 mM imidazole wash, 8) TEV protease cleavage product.
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Figure 3.6: UV/Visible light absorbance spectra of Act-EF34 (at 0.27 mM), used to 
measure protein concentration at 280 nm.
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Figure 3.7: FPLC elution profile of Act-EF34 monitoring fluorescence at 260 and 280 
nm. Act-EF34 is shown here to elute at a volume of 90 ml.
Figure 3.8: Polyacrylamide SDS Gel of an Act-EF34 FPLC result. 1) Marker, 2) 6HIS- 
GST-Act-EF34 fusion protein (elution volume of 55 ml) 3) GST (elution volume of 70 
ml), 4-7) Pure Act-EF34 elution (elution volume of 90 ml).
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3.3 Purification of Act-EF1234
Act-EF1234 was expressed in LB and singularly labelled (15N) minimal media. 
After cell lysis Act-EF1234 fusion protein was purified by nickel agarose column, 
followed by TEV protease cleavage, again giving a well-behaved and predictable profile 
(Figure 3.9). However, Act-EF1234 aggregated on FPLC purification, so imidazole was 
removed via buffer exchange allowing nickel agarose column purification (Figure 3.10). 
The sample was buffer exchanged and concentrated, and the concentration was deduced 
from a UV/VIS spectrum at 280 nm (Figure 3.11), using the extinction coefficient (7800 
M-l cm-1). The yield for Act-EF1234 was quite variable, possibly due to the 
aggregation problems, varying between approximately 2-3 mg/L of LB, and roughly 2 
mg/L for 15N minimal media.
Figure 3.9: Polyacrylamide SDS gel of the purification of Act-EF1234 from cell lysis 
until TEV protease cleavage. 1) Broad molecular weight marker, 2) cell lysate, 3 to 7) 
nickel agarose purification (in order, unbound fraction, column buffer wash, ‘1M NaCl’ 
wash, 30 mM imidazole wash, and 300 mM imidazole wash).
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Figure 3.10: Polyacrylamide SDS gel of the nickel agarose column purification for Act- 
EF1234. 1) Molecular weight marker, 4) Elution from first nickel agarose column, 5) 
TEV cleavage product, 6) Second nickel agarose column elution 7) Third nickel agarose 
column elution containing pure Act-EF1234.
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Figure 3.11: UV/Visible light absorbance spectra of Act-EF1234 (at 0.51 mM), used to 
measure protein concentration at 280 nm.
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All three constructs of ZASP-PDZ, Act-EF1234, and Act-EF34 were successfully 
expressed and purified. A serious complication was that 6HIS-GST-Act-EF1234 TEV 
cleavage product precipitated upon concentration, thus making purification by size 
exclusion problematic. Opting for a second nickel-agarose affinity purification to 
remove the 6HIS-GST, resulting in a pure Act-EF1234 product, circumvented this. After 
the constructs were purified, buffer exchange into ‘NMR buffer’ and protein 
concentration was trivial, allowing for the production of NMR amenable samples. 
ZASP-PDZ was the best behaved, as protein expression and purification was not 
problematic, and the yield was the highest -  up to 9 mg/L in LB media. ZASP-PDZ was 
also very stable, as it did not appear to degrade, even left for months at 4 °C. Act-EF34 
was the next best behaved, giving fairly predictable expression and purification profiles, 
and respectable yields. However, there was a problem with the uniformity of the sample, 
as a second species appeared to form after a few days at 4 °C or room temperature. This 
problem was later resolved (see Resonance Assignment 4.3). Act-EF1234 was the 
hardest to handle, as the purification appeared elusive before modification of the 
purification protocol. Also the yields were not high at 2-3 mg/L - compared to ZASP- 
PDZ at 9 mg/L from rich media. However, Act-EF1234 was well behaved enough to 
work with for the given applications.
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Resonance Assignment: ZASP-PDZ 
with and without Act-EF1234
Here, the complete ^  15N and 13C resonance assignments of ZASP-PDZ and the 
]H and 15N assignment of ZASP-PDZ domain in complex with Act-EF1234 (forming a 
26.3-kDa complex) is reported. Also presented here are the backbone assignments of the 
75-residue Act-EF34. The assignment of ZASP-PDZ and Act-EF34 allows the surface 
of interaction between them to be identified. Also, the ZASP-PDZ assignment is crucial 
for its structure calculation. Previous assignment of Act-EF34 in complex with titin-ZR7 
was available at the beginning of the study (Atkinson et al., 2000b); however, assignment 
of unbound Act-EF34 was necessary as there is a major conformational rearrangement 
upon complex formation. By initially assigning the individual components of ZASP- 
PDZ and Act-EF34, as opposed to the complex, alternative interactions that could arise 
can be studied in a modular fashion -  for example, alternative constructs of a-actinin-2 
(e.g. Act-EF1234) or the binding properties of mutants of either component.
4.1 Assignment of ZASP-PDZ
The 15N-HSQC spectra of the 87-residue ZASP-PDZ displayed 104 peaks, given 
by the backbone amides from 83 non-proline residues, 10 pairs of glutamine and 
asparagine side chain amides and one tryptophan indole NH (Figure 4.1). In addition, 
nine low intensity peaks were observed, derived from a possible minor form of the 
protein. The 15N-HSQC spectrum was well dispersed, and the ID spectrum shows up- 
field shifted methyl chemical shifts, indicative of a folded protein. Analysis of HNCA, 
HN(CO)CA, CBCA(CO)NH, and CBCANH (Figure 4.2) spectra allowed the sequential 
assignment of the ZASP-PDZ, while HNHA and HNCO spectra were used to complete 
the backbone assignment. A combination of 13C-HSQC, HCCH-TOCSY, HNHB, 15N- 
edited TOCSY, and regular 2D TOCSY spectra were used to assign side-chain *H and 
13C resonances.
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Figure 4.1: 15N-HSQC spectrum of ZASP-PDZ at pH 6.6 and 27 °C, showing a well- 
resolved spectrum. The spectrum is labelled with amide backbone resonance 
assignments, and the solid horizontal lines indicate side-chain amide protons of 
asparagine and glutamine residues.
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Figure 4.2: Sample of the CBCANH spectra of ZASP-PDZ -  red and blue peaks is Ca 
and Cp resonances respectively, and the residue type and number is indicated at the 
bottom. The black lines highlight backbone connectivity.
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4.2 Assignment of lsN-ZASP-PDZ bound to Act-EF1234
15N-HSQC spectra were acquired for each point in the titration of 15N-ZASP-PDZ 
with unlabelled Act-EF1234 (Section 6.1.2), and 15N-edited TOCSY and NOESY spectra 
were subsequently acquired for the complex. The final point of the ZASP-PDZ/Act- 
EF1234 titration contained 94 peaks, of which 74 were backbone amides resonances and 
20 were side-chain peaks. Five of the backbone amides undergo severe exchange 
broadening during the titration, while others became overlapped (Figure 6.4). Many of 
the amide !H and 15N chemical shifts could be assigned by following the titration by 15N- 
HSQC spectra, and further resonances were assigned by comparing 15N-edited 
TOCSY and NOESY spectra of the complex with those of unbound ZASP-PDZ (Figure
4.3).
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Figure 4.3: Sample of the 15N-NOESY-HSQC comparison of the unbound and Act- 
EF1234 bound forms of 15N-ZASP-PDZ - the residue type and number is indicated at the 
bottom. * Denotes the bound form of ZASP, while red and green peaks denote assigned 
and unassigned peaks respectively.
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The backbone Act-EF34 atoms were assigned in the same manner as ZASP-PDZ, 
using a combination of 15N-HSQC, CBCACONH, CBCANH, HNHA, and HNHB 
spectra (Figure 4.10). The N-HSQC revealed that a second species appears after a few 
hours at room temperature, resulting in approximately 32 additional peaks to the 77 
expected (from 69 non-proline amides, plus 4 pairs of glutamine side chain amide 
protons) (Figure 4.7). The secondary species appear to derive from homo-dimer 
formation from the lone Act-EF34 cysteine residue (C41) forming an intermolecular 
disulphide bond. Although 2 mM P-mercaptoethanol was present in the buffer to prevent 
disulphide bond formation, this only appeared to be only partially effective. The 
CBCACONH/CBCANH spectra revealed ‘doubled’ backbone amides - these were T4, 
T6, G56, A66, L67, Y68, and G69. The second species was not observed once Act-EF34 
was in complex with ZR7, which could be due to burial of the Act-EF34’s cysteine 
residue (Figure 4.5). A non-reducing gel revealed a peak around 16 kDa, double Act- 
EF34 alone (Figure 4.6), so triakylphosphine (TCEP, Figure 4.4) added to the sample to 
reduce the disulphide bond, returning the dimer to a monomeric species. The 
effectiveness of the treatment is apparent by the improvement of the relative intensities of 
the monomeric species peaks in the 15N-HSQC (Figure 4.8 and Figure 4.9).
?H 
?H
H00C-H X-H oC-P +  R-S-S-R +  H20
2 CH2-COOH
2-c h 2-c o o h  h o o c -h2c -h2c -p = o
2 2 i T  ' * c h 2-c h 2-c o o h
c h 2-c h 2-c o o h
+
2RSH
Figure 4.4: Schematic of the mechanism of TCEP reduction of disulphide bonds. TCEP 
reacts with water to reduce the disulphide bonds, resulting in an oxidised phosphorus 
atom
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Figure 4.5: Ribbon representation of Act-EF34 (yellow) in complex with titin-ZR7 
(green), indicating the position of cysteine 41 (van der Waals representation). Titin-ZR7 
may prevent Act-EF34 homodimer formation, as it buries the thiol group between the 
surface of interaction.
1 2  3 4 A B C D E
Figure 4.6: Polyacrylamide SDS gel electrophoresis of A: Sample of freshly prepared 
Act-EF34 revealing a trace of the dimeric second species (4) using the Broad Molecular 
Marker (1) for size estimation. B: Non-reducing polyacrylamide SDS gel of an old 
sample of Act-EF34 (B) in the presence of 3:1 (C) and 10:1 TCEP (D) to protein ratios.
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Figure 4.7: 15N-HSQC of ‘fresh’ Act-EF34 without TCEP. The protein appears 
unfolded or aggregated, as the peaks are ‘clumped’ in the centre of the spectrum.
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Figure 4.8: 15N-HSQC of Act-EF34 with 1:3 ratio of TCEP. The relative intensities of 
the peaks have increased, and some of the peaks from the second species have 
disappeared.
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Figure 4.9: Graph showing the change in relative intensity (to the C-terminal residue) 
on addition of a molar ratio of 3:1 TCEP to Act-EF34. This indicates the formation of 
the monomeric species from the disulphide-bonded homodimer: line-widths are narrower 
for smaller molecular species, hence, an increase in intensity indicates a reduction in size.
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Figure 4.10: 15N-HSQC spectrum of Act-EF34 at pH 6.6 and 27 °C, showing amide 
backbone resonance assignments. Solid horizontal lines indicate side-chain amide 
protons of asparagine and glutamine residues, and the arrows indicate assignment of 
‘second species’ peaks.
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The assignment of Act-EF1234 alone is unavailable, so an attempt to transfer 
Act-EF34’s assignment by superimposing Act-EF1234 and Act-EF34 15N-HSQC spectra 
was made (Figure 4.11). This revealed a conformational difference between them, as 
many peaks could not be superimposed -  one would expect the additional residues 
between Act-EF1234 to have a simple additive contribution if they were congruous. 
However, the peaks from Act-EF 1234 and Act-EF34 C-terminal residues (specifically 
G69, S71, D72, and L73 -  Act-EF34 nomenclature) were similar enough to be assigned 
by superimposition, possibly reflecting the lack of structure observed in this region 
(Atkinson et al., 2001). Although the superimposition revealed this conformational 
difference, a previous study (Joseph et al., 2001) showed that both constructs converge to 
the same conformation upon binding to a peptide derived from titin seventh Z-repeat 
(ZR7), therefore, the two constructs of a-actinin-2 appear to have the same functional 
properties.
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Figure 4.11: 15N-HSQC superimposition of ZASP-PDZ bound to I5N-Act-EF34 (black 
peaks) and 15N-Act-EF1234 (red peaks). While some peaks are super-imposable, most 
are not. See (Joseph et al., 2001) for both Act-EF34 and Act-EF1234 converging upon 
binding titin-ZR7.
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The assignment of the ]H, 15N and 13C resonances were obtained for the unbound 
ZASP-PDZ domain. The backbone atoms were fully assigned, with the exception of the 
backbone carbonyl resonances that are followed by a proline. All side chain resonances 
were assigned, except for the lH resonances of the N-terminal methionine, 13C
resonances of the aromatic side-chains past their Cp 13C resonances for Leu-7 and His-62
1 1
past their CP C and H resonances for Pro-12, and most exchangeable side-chain 
protons.
The 15N-HSQC titration of the ZASP-PDZ/Act-EF1234 complex facilitated the 
transfer of 94% of the backbone amide assignments. This allowed further assignment of 
!H resonances by comparing the 15N-edited TOCSY and NOESY spectra with those of 
unbound ZASP-PDZ. Residues 13-18 appear to be in chemical exchange upon complex 
formation; although it was possible to follow their amide resonances in the titration, their 
side-chain !H resonances could not be observed. Proline residues 10, 12, 26 and 34 and 
other side-chain assignments could not be completed, leading to the *H and 15N 
assignment to be 76% of that of unbound ZASP-PDZ. The assignments have been 
deposited with the BioMagResBank (http://www.bmrc.wisc.edu) with the accession 
codes BMRB-5696 (unbound ZASP-PDZ) and BMRB-5697 (ZASP-PDZ/Act-EF1234).
The backbone assignment of all of the backbone atoms of Act-EF34 was 
completed with the exception of the carbonyls, the first two N-terminal residues, and 
G52. Also, some backbone amide atoms from Act-EF1234 were assigned by comparing 
the 15N-HSQC spectra of assigned Act-EF34.
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Both manual and automatic procedures have been performed for the structure 
determination of ZASP-PDZ. Manual structure calculation was carried out using NOE 
constraints derived from !H-13C, and 'H-^N NOESY spectra, directly observed
hydrogen bonds (Cordier and Grzesiek, 1999), TALOS (Comilescu et al., 1999) and 
HNHA dihedral angles, and residual dipolar couplings (RDCs). A homology model and 
secondary structure prediction of ZASP-PDZ were utilised as an initial guide for manual 
structure determination. CANDID was employed for automated structure calculation, 
using unassigned peak lists, the chemical shift assignment (Appendix 10.4.1), and 
dihedral angle and hydrogen bond information defined in the manual calculation. The 
structure calculation was also undertaken in both CYAN A and XPLOR -  allowing us to 
benefit from the speed and accessibility of CYAN A, and also the extra functionality of 
XPLOR (such as the ability to use RDCs). Structural restraints deriving from both 
manual and automatic structure calculations were exported to XPLOR after convergence 
within CYANA for re-calculation and subsequent improvement using the ‘CHARMM22 
water-refmement’. The quality of the calculated structures was checked using WHATIF 
(Hooft et al., 1996) and PROCHECK-NMR (Laskowski et al., 1996), while checking 
them against known PDZ domains assessed the accuracy of the structures. The bundles 
deriving from different structure calculation protocols were compared and assessed to 
determine the most effective calculation procedure.
5.1 Secondary Structure Prediction of ZASP-PDZ
The secondary structure prediction of ZASP-PDZ reveals six P-strands and two a- 
helices, typical of the PDZ domain (Figure 5.1). Although the prediction shows five 
areas of P-strand, the PDZ domain actually contains six, as the forth predicted P-strand is 
actually a continuous P-hairpin.
80
Chapter 5: NMR Structure o f ZASP-PDZ
1 .....................1 1 ....................2 1 ................... 3 1 ...................4 1 ................... 5 1 ................... 6 1 ....................7 1 ....................  8 1 ___
E E E E E E E  E E E E E  E E E E E E  H H H  E E E E E E  H H H H H H H H H H H H  E E E E E E E
GAMAYSVTLTGPGPWGFRLQGGKDFNMPLTISRITPGSKAAQSQLSQGDLWAIDGVNTDTMTHLEAQNKIKSASYNLSLTLQKSKR 
pl P2 p3 al p3/4 a2 p6
Figure 5.1: Secondary structure prediction of ZASP-PDZ domain. H represents a- 
helices, and E represents P-strands.
5.2 Manual Structure Determination
The manual structure determination of ZASP-PDZ was calculated using CYAN A 
(CMANUAL -  Appendix 10.5). The NOESY spectrum had excellent dispersion and 
resolution (Figure 5.2), allowing for the near to complete assignment (Table 5.1). A total 
of 1403 unique distances were manually assigned (Table 5.2). These were subsequently 
modified by CYAN A to remove fixed intra-residue distances, and short/medium-range 
distances above the maximum possible distance. Further alterations of the distance 
restraints were made by CYAN A, by the stereo-specific assignments made by 
GLOMSA. Additional restraints from the hydrogen bond experiment, and the 
TALOS/HNHA dihedral angles were also used for the structure calculation. Fifty 
percent (out of 100 structures) of the CMANUAL structures converged with no upper,
o o  o
lower, van der Waals, or torsion angle violations (0.5 A, 0.5 A, 0.5 A, 5 degrees, 
respectively). The restraints were subsequently converted to XPLOR format and the 
structures were recalculated (XMANUAL), after which, twenty of the best of these 
structures were selected for ‘CHARMM22 water-refinement’ (RXMANUAL).
Spectra Assigned Peaks Unassigned
Peaks
Total Peaks % Assigned
15n -n o e s y -h s q c 705 57 762 92.5
i3C-NOESY-HSQC 1402 167 1569 89.4
'h - 'h -n o e s y 2180 476 2656 82.1
Table 5.1: Summary of the analysis of the ’H^H-NOESY, and 13C and 15N NOESY- 
HSQC spectra: i.e. number of peaks picked, number of assignments made, and 
percentage assigned.
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Figure 5.2: Extract of the lsN-NOESY HSQC of l5N-ZASP-PDZ. The lsN-HSQC 
(Figure 4.1 -  l5N-HSQC) showed good dispersion of the peaks, therefore the lsN- 
NOESY HSQC was also well resolved. The residue type and number is indicated at the 
bottom of each strip.
82
Chapter 5: NMR Structure o f ZASP-PDZ
Distance Type Intra Short Med Long Total
Unique Distances 722 320 134 227 1403
Modified Distances 216 285 136 246 883
Final Restraints 219 292 143 241 895
Table 5.2: Summary of the final distance restraints used for the CMANUAL structure 
calculation. Unique distances are those present after combining the restraints from all of 
the NOESY spectra, while modified distances are superfluous restraints. The final 
restraints are the modified restraints after taking into account stereo-specific assignment.
A homology model of ZASP-PDZ was built as a guide for the NMR structure 
calculation. The PDB (http://www.rcsb.org) was searched for PDZ domains and their 
protein sequences were subsequently aligned against the ZASP-PDZ domain (Appendix 
10.7). A CLUSTALX (Thompson et al., 1997) sequence alignment of the PDZ domain 
sequences shows that interleukin 16 (Muhlhahn et al., 1998) (PDB accession code IL16) 
is the closest PDZ domain (Figure 5.3). However, after taking into consideration gaps 
and insertions, the third PDZ domain from PSD95 (Doyle et al., 1996) (PSD95-PDZ3, 
PDB accession code 1BFE) was chosen as ZASP-PDZ’s template for the homology 
model. Pair-wise comparisons of the sequences of PSD95-PDZ3 and ZASP-PDZ (Figure
5.4) shows no gaps or insertions after the sixth residue on the ZASP-PDZ construct, and 
a 22.5% sequence identity and 47.5% sequence homology in the remaining 80 residues 
of the two proteins. The homology model was generated using SWISS-MODEL (Guex 
and Peitsch, 1997; Peitsch, 1995; Schwede et al., 2003) (Figure 5.5). PSD95-PDZ3 was 
also a useful choice as it had been solved in complex with its target peptide derived from 
Cript (PDB Accession code: 1BE9), which was useful as a guide to study the ZASP/a- 
actinin-2 interaction.
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Figure 5.3: Phylogenetic tree derived from a CLUSTALX alignment of all solved PDZ 
domains in the PDB, generated using NJplot (Perriere and Gouy, 1996). Although IL16 
was the closest relation to ZASP-PDZ, after taking into consideration gaps and 
insertions, 1BFE/1BE9 was a better template for ZASP-PDZ’s homology model.
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Figure 5.4: Pair-wise CLUSTALX alignment of ZASP-PDZ and 1BE9/1BFE, showing 
a 22.5% sequence identity and 47.5% sequence homology.
84
Chapter 5: NMR Structure o f  ZASP-PDZ
Figure 5.5: Homology model of ZASP-PDZ, generated by SWISS-MODEL, based on 
the alignment with 1BFE -  residues coloured in red, orange, and blue represent identical, 
chemically similar, and no similarity respectively.
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5.3 Automatic Structure Determination
The ^^H -N O ESY  spectra was utilised for the automatic structure determination 
using CANDID as it has the most self-consistent peak and chemical shift lists; CANDID 
makes possible assignments based on chemical shift tolerances, therefore it operates best 
when there is no deviation between chemical shift and peak lists. The three-dimensional 
NOESY spectra had lower resolution than the two-dimensional NOESY, leading to less 
precision in chemical shift: peaks in the manually assigned ^^H -N O ESY  could be 
picked within an error of ±0.01 ppm, but only ±0.02 ppm for the three-dimensional 
NOESY. This allowed a lower chemical shift tolerance to be used for the CANDID 
calculation for the homonuclear peak list: tolerances of 0.03, 0.03, 0.04 ppm (!H (direct), 
lH (indirect), 13C/15N (indirect)) was used for the 3D NOESY peak lists, while 0.02 in 
both direct and indirect dimensions could be used for the 2D NOESY peak list: an 
additional 0.01 ppm was used to take into account errors in NOESY peak picking. One 
notable limitation in CANDID was that for correct calculation of ZASP-PDZ, the 
dihedral angles and hydrogen bonds were needed; to circumvent the problem we added 
to the hydrogen bonds observed in the HNCO and those inferred from the MANUAL 
bundle. If these restraints were excluded from the calculation, the algorithm would 
incorrectly calculate the structure (Figure 5.6) -  p i, P2, and P3 have an inconsistent 
orientation compared with the standard PDZ fold, and the first alpha helix was not 
correctly formed.
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Figure 5.6: Stereogram of the bundle of the best 20 structures from the ZASP-PDZ 
CANDID automatic structure determination using just NOE distance constraints. The 
structure is incorrectly folded and parts of the secondary structure have not been formed .
5.4 Structure Description
The structure of ZASP-PDZ adopts a conventional PDZ fold: it is a mixed a/p 
protein that folds into a six-stranded P-sandwich flanked by and two a-helices on 
opposite sides (Figure 5.7). The topology of the anti-parallel P strands is clearly visible 
(Figure 5.8). The first and last p strands (pi and p6) form an anti-parallel P-sheet, on the 
opposite side of the p2-p3 anti-parallel P-sheet and a2, with P4 going across these 
structural elements. The groove between P2 and a2 which starts from the ‘GLGF’ loop 
(residues P9, W10, G11 and FI2 in ZASP-PDZ) and ends at the C-terminal portion of P2 
is the conventional site of interaction for class 1 PDZ binding partners (Figure 7.2). In 
ZASP-PDZ, this pocket is delimited by the unique tryptophan at the N-terminal end of
P2.
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Figure 5.7: A backbone ensemble stereogram of the structure of ZASP-PDZ 
(CCANDID).
Figure 5.8: Ribbon diagram depicting secondary structure elements of ZASP-PDZ (red 
= a helices, yellow = p strands) (CCANDID). ZASP-PDZ has 6 P-strands and 2 a- 
helices forming a P-sandwich.
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5.5 Restraint Comparison: Manual vs. Automatic
A comparison between the NOE assignments used in the structure calculation 
between the manual and automatic procedure was conducted. Table 5.3 (also Figure 
5.9) shows that there were more manual NOE assignments made than the automatic 
CANDID assignment. The differences in the restraints used in the manual and CANDID 
calculations were compared on a ‘residue-by-residue connectivity’ basis: this revealed 
that CANDID made 52 additional peak assignments -  for example, if  there were five 
connectivities between residues ‘a’ and ‘b ’ made in the automatic assignment, this would 
be five additional peak assignments more than the manual assignment. Analysis of these 
peaks in the manually assigned peak list showed that 33 were unassigned, 6 were 
discarded during the structure calculation but previously assigned the same, and 13 were 
assigned differently. Of the 13 differently assigned peaks, 8 were short-range, and 5 
were long-range: one appeared to be miss-assigned in the manual structure calculation 
and the four were as good in either structure calculation. Conversely, there were 84 
restraints present in the manual restraint list additional to CANDID’s, of which 33 were 
short-range, 22 were additional from 13C/15N-NOESY spectra, 18 were unassigned in 
CANDID, and 11 were assigned differently. Of the 11 differently assigned, all were 
structurally possible, comprising of short-range and 6 long-range restraints.
There were 290 peaks that CANDID did not assign: 88% were not assigned in the 
manual assignment and 12% had assignments in the manual assignment. Also, the 
general distribution of the type of restraint reveals that although CANDID makes more 
intra-residue assignments (+6.6%) than the manual calculation, but less short-range 
assignments (-6.0%), there is no significant difference between the distribution of either 
the medium (-1.2%) or long-range constraints (+0.62). CANDID’s method of dealing 
with stereo-pairs and distance violations appears to result in the average distance being 
smaller than the manual calculation: 3.91 ± 0.57 A, compared with 5.4 ± 1.64 A. This 
will lead to more precise structures, even though CANDID has 5% fewer restraints 
compared to the manually assigned structure.
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Sequence
Sequence
Figure 5.9: Distance constraint plot of the A) manual and the B) CANDID structure 
calculation. White, light grey, dark grey, and black colours represent intra-residue, short- 
range, medium-range, and long-range distance connectivities respectively.
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CANDID MANUAL
Peak Assignment
Total Peaks 2655 2655
Without assignment 290 475
With assignment 2365 2180
Restraints not included in opposite restraint file 
(residue by residue comparison)
52 84
NOESY Distance Restraints
Intra residue 265 (31.1%) 219 (24.5%)
Short range 227 (26.6%) 292 (32.6%)
Medium range 126 (14.8%) 143 (16.0%)
Long range 235 (27.5%) 241 (26.9%)
Angular restraints
♦ 51 51
V 46 46
H bonds 30 7
Total No of restraints 980 998
RDCs* 63 63
Stereo specific assignments 25 25
a|e
Table 5.3: Comparison of the manual and automatic assignment of ZASP-PDZ. Only 
added to the XCANDID and XMANUAL refinements.
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5.6 Physical Comparison of ZASP-PDZ structure calculations
After having setup the conditions with several exploratory runs, we decided to 
analyse six bundles obtained by different protocols (Figure 5.10): primary manual and 
automatic structure calculations in CYANA (CMANUAL & CCANDID), which were 
subsequently recalculated in XPLOR (XMANUAL & XCANDID), and further refined 
using the ‘CHARMM22 water refinement’ (RXMANUAL & RXCANDID). Although 
the fold was the same for all of the calculated structures, the structure details diverged 
depending on the protocol used. Therefore, a comparison of the structures was 
undertaken to observe the effect of the CYANA -> XPLOR -> Water refinement, and 
also the differences between the manual and automatic calculations. The structure with 
the lowest RMSD to the mean from the best 20 structures for each bundle was compared 
for each calculation procedure. RMSD calculations were calculated per residue, using 
the backbone atoms of residues that did not have a flexible profile from the relaxation 
analysis (Appendix 10.3.1.1.20): these were residues: 3-7,9-10,12,15-30,32-37,39-
58,60-72, and 76-82. Only significant changes in these regions were considered for 
further investigation, as flexible regions of the protein are likely to have a high RMSD. 
RMSD changes over 2 A were considered as a significant change.
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B
Figure 5.10: Structure of ZASP-PDZ. NMR bundles corresponding to the manually (top 
row) and automatically (bottom row) assigned structure families. From left to right are 
displayed the bundles without refinement (A and D), with RDC (B and E) and water 
refinement (C and F) respectively. All structures have no distance violations greater than 
0.5 A and no dihedral angle violations greater than 5 ° from the experimental data.
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A series of pair-wise RMSD calculations using WHATIF revealed significant 
differences in the manual CYANA to XPLOR conversion (Figure 5.11 and Figure 5.12), 
having significant changes at 10-12, 20, 22-24, 26-27, 35-37, 41-45, 69-71, 73-74, 83-85. 
Many of these residues are in loops or areas of random coil, and will therefore have few 
structural restraints. The inclusion of the RDCs appeared to re-orientate the loop after 
a l,  bringing it closer to the core of the molecule, and also a2 appears to shift around 5 ° 
from the base of the helix. The proceeding water refinement produced few changes, with 
only significant variations observed in residues 35, 74, and 83-85. The CCANDID to 
XCANDID conversion (Figure 5.11 and Figure 5.12) only had significant changes in 
residues 9-11 (loop) and 82-84 (C-termini), again, both flexible regions. The RDCs 
appeared to show no notable effects on the structure. The water refinement showed even 
less of a change than the conversion from CYANA to XPLOR (Figure 5.11 and Figure 
5.12), only giving a change in residue 10. Many of the differences between CYANA and 
XPLOR are probably due to the addition of RDC restraints on conversion to XPLOR and 
also the difference in the force field used to calculate the structures. Also, since the 
average distance restraint is looser for the manual calculation (Section 5.5), these 
differences will have a larger effect on the calculated structures as it is less constrained.
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Figure 5.11: Comparison of ZASP-PDZ structure calculations (lowest RMSD to the 
mean) for both manual (top) and CANDID (bottom), after conversion from CYANA to 
XPLOR (left) and water-refinement (right). The structures of the comparison (labelled) 
have been superimposed, and colour coded from blue to red to denote the change in 
RMSD (low to high respectively).
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Figure 5.12: Comparison of ZASP-PDZ structure calculations (lowest RMSD to the 
mean) for both manual (A) and CANDID (B). The result for the CANDID/XPLOR 
comparison is in black, whilst the result for the XPLOR/water-refinement is in red.
96
Chapter 5: NMR Structure o f  ZASP-PDZ
Differences between the manual and the CANDID structure calculation in 
CYANA (Figure 5.14) show changes in several different places: the general appearance 
shows that the CANDID result is more compact than the manual. This is mainly due to 
the orientation of the GLGF loop (13-16), beginning of P3 (27), 34-38, the loop at 40-47, 
and between a2 and p6 at 69-77. The differences in the manual and automatic structures 
after exporting the data into XPLOR appear to show even more variations, the most 
notable being the start of the helix at 60-63. However, there is improvement of 
convergence of the loop at 42-45 as it has a lower RMSD value. The water refinement 
shows even better convergence between 41-46.
Comparing the overall pair-wise RMSD of the structure calculations show that 
the water refinement improved the convergence between the structures within the manual 
and automatic calculations (i.e. the difference in the structures between from CYANA to 
XPLOR is more than the difference between XPLOR and water-refined structures) 
(Figure 5.13). The water-refinement also appeared to improve convergence between the 
manual and CANDID structures (i.e. CMANUAL vs. CCANDID, XMANUAL vs. 
XCANDID, and RXMANUAL vs. RXCANDID).
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Figure 5.13: Summary of the average pair-wise RMSD between the structure 
calculations. The first four values show less difference between the manual and 
CANDID structures between the conversions, while the last 3 values signify the 
difference between the manual and CANDID procedures.
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Figure 5.14: A) Comparison of ZASP-PDZ manual and CANDID structure calculations 
(lowest RMSD to the mean). The result for the CMANUAL/CCANDID comparison is 
in black, XMANUAL/XCANDID is in red, whilst the result for the 
RXMANUAL/RXCANDID is in blue. B) The residue-by-residue comparison of the 
manual and CANDID calculation, in both XPLOR and CYANA and after water 
refinement. The structures of the comparison (labelled) have been superimposed, and 
colour coded from blue to red to denote the change in RMSD (low to high respectively).
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5.7 Precision. Quality, and Accuracy Comparison
The calculated structures were compared for precision, quality, and accuracy. 
Here, an important distinction between precision and accuracy is made. If you have a 
target, for example -  a darts board, then the accuracy is how close your dart is to the 
bull’s-eye, (i.e. the target or ‘true’ result). The precision is how close your darts are 
bunched together (i.e. the difference between your results). Therefore, these are two 
mutually exclusive variables.
5.7.1 Precision: RMSD Calculations
An analysis of the RMSD for each structure was performed with and without 
residues that were identified as flexible from the relaxation analysis (Table 5.4 and 
Figure 5.15, Appendix 10.3.1.1.20). The CANDID structures had lower RMSD values 
than the manual structures for each RMSD category. Therefore, the CANDID structures 
have a higher precision compared to the manual calculation, with the CCANDID 
structures having the best overall precision (although RXCANDID structures had a 
slightly better ordered heavy atom RMSD).
RMSD From Mean
Ordered Heavy Atom
Ordered Backbone
Overall Heavy Atom
Overall Backbone
■  CMANUAL
□ XMANUAL
□ RXMANUAL
■ CCANDID
■ XCANDID
■ RXCANDID
0.2 0.4 0.6 0.8 1
RMSD
1.2 1.4 1.6 1.8
Figure 5.15: Comparison of the backbone and heavy atom RMSD for the best 20 
structures from all structure calculations. RMSD calculations include the overall result, 
and an ordered selection of residues (3-7,9-10,12,15-30,32-37,39-58,60-72, and 76-82). 
The CANDID group of structures consistently have better precision to their manual 
calculation counterpart.
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CMANUAL XMANUAL RXMANUAL CCANDID XCANDID RXCANDID
RMSD from mean
Overall Backbone 1.11 1.10 1.10 0.63 1.05 0.91
Overall Heavy Atom 1.73 1.65 1.66 1.23 1.54 1.47
Ordered Backbone 0.88 0.92 0.93 0.49 0.65 0.54
Ordered Heavy Atom 1.41 1.35 1.37 0.95 0.97 0.90
Structure Z-scores:
1 st generation packing quality -3.987 -3.903 -4.786 -1.853 -3.151 -2.872
2nd generation packing quality -4.228 -5.854 -5.787 -2.948 -4.028 -2.941
Ramachandran plot -4.173 -5.636 -4.82 -3.342 -5.499 -3.217
Chi-1/chi-2 rotamer normality -4.433 -4. 851 -3.09 -4.509 -4.981 -2.943
Backbone conformation -5.106 -2.316 -3.382 -3.579 -3.446 -2.003
RMS Z-scores:
Bond lengths 0.444 0.944 1.023 0.443 0.950 1.024
Bond angles 0.955 1.388 1.307 0.954 1.375 1.283
Omega angle restraints 0.022 0.135 1.689 0.000 0.177 1.401
Side chain planarity 0.023 0.046 1.173 0.025 0.039 1.284
Improper dihedral distribution 0.615 0.966 0.994 0.614 0.963 0.993
Inside/Outside distribution 1.082 1.063 1.045 1.066 1.040 1.034
Ramachandran plot (%)
Most favored regions 70.9 72.5 76.3 73.8 65.1 81.6
Additional allowed regions 25.7 22.9 19.8 24.3 31.6 16.8
Generously allowed regions 2.8 3.7 2.5 1.1 2.5 1.3
Disallowed regions 0.6 0.8 1.3 0.8 0.8 0.3
Table 5.4: Values from the RMSD calculation, WHATIF scores, and Ramachandran plot 
statistics for each structure calculation. RMSD has been calculated overall and with only 
the selection of residues 3-7,9-10,12,15-30,32-37,39-58,60-72, and 76-82 (ordered). 
Backbone atoms are defined by the backbone Ca, N, and CO, while C, N, O, and S 
define the heavy atoms.
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WHATIF (Hooft et al., 1996) was used to check the quality of various structural 
parameters such as packing, dihedral angles (i.e. Ramachandran plot (\\f & <p), chi (x) 
angle analysis, and cd angle restraints), backbone conformation, and allowed bond 
lengths, etc (Table 5.4). The graph for the WHATIF ‘structure Z scores’ (Figure 5.16A) 
give a result where an average result is 0, a better than average result is positive, and a 
worse than average result is negative. The WHATIF ‘RMS Z-scores’ (Figure 5.16B) 
should be as close to 1 as possible. From the six structure calculations, RXCANDID 
consistently gave the best ‘structure Z-scores’. Both the RXMANUAL and RXCANDID 
structures give a comparably good ‘RMS Z-score’, showing definite improvement from 
their CYANA and XPLOR counterparts. From this analysis, the best quality structure 
calculation is RXCANDID.
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WHATIF Structure Z-Scores
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Figure 5.16: Comparison of the WHATIF structure (A) and RMS (B) Z-scores for all 
structure calculations. The RXCANDID structures give consistently the best structure Z- 
scores, with the exception of ‘1st generation packing quality’, while RXMANUAL and 
RXCANDID structures give a comparably good ‘RMS Z-score’
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5.7.3 Quality: Ramachandran plots
PROCHECK-NMR (Laskowski et al., 1996) was used to conduct the detailed 
Ramachandran plot analysis of each structure calculation for the best twenty structures, 
giving an accurate distribution of the residues in the favoured, additional allowed, 
generously allowed, and disallowed regions (Table 5.4 and Figure 5.18). All structure 
calculations have over 98% of their residues in the allowed regions and over 95% in the 
favoured and additionally allowed regions (both excluding glycine and proline residues). 
Again, the water-refinement appeared to improve the quality of the structures, increasing 
the percentage distribution of residues in the ‘most favoured regions’ compared to the 
CYAN A and XPLOR counterparts. However, the RXCANDID again had the best 
quality, with the highest percentage of residues in the ‘most favoured regions’ and the 
least number of residues in the ‘disallowed regions’ (Figure 5.17).
waterrefine_zasp_all (20 models)
180-r-,
90-
45-
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-135-
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Figure 5.17: Ramachandran plot of RXCANDID generated in PROCHECK-NMR.
Squares and triangles represent non-glycine residues and glycine residues respectively.
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Figure 5.18: A) Ramachandran plot comparison of all of the structure calculations, 
giving the distribution of residues in the most favoured (red), additionally allowed 
(yellow), generously allowed (light blue), and disallowed regions (white). Graph B has 
been zoomed to highlight the differences in the additionally, generously, and disallowed 
regions. RXCANDID has the best overall Ramachandran scores.
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5.7.4 Accuracy: Comparison O f Known PDZ Domains
To estimate the structure accuracy of our results, we compared them with the 
known structures of PDZ domains as suggested in (Walma et al., 2002). Here, they 
compared their NMR structure of mouse PTP-BL PDZ domain (lgml)  with the NMR 
structure of human PTP-Bas PDZ2 (3pdz) (Kozlov et al., 2000), to which it shared a 94% 
sequence identity. The comparison also included the crystal structures DlgA (lpdr - 34% 
identity), CASK (lkwa - 28% identity), and syntrophin (lqav - 39% identity) (Doyle et 
al., 1996; Hillier et al., 1999; Morais Cabral et al., 1996). They found that although 3pdz 
had the highest sequence identity to lgml, it ironically had the highest RMSD compared 
with the crystal structures; hence the 3pdz was not deemed as accurate.
A DALI structural similarity search (Holm and Sander, 1996b) of ZASP-PDZ 
resulted in six ‘hits’ with RMSD values between 2.5-3.0 A and sequence identities 
ranging between 21-30%, all corresponding to PDZ domains (Table 5.5). The highest 
similarity is with the crystal structure of the 3rd PDZ domain from human disks large 
protein (DlgA, entry code lpdr (Morais Cabral et al., 1996), which superposes ZASP- 
PDZ with an RMSD of 2.5 A (Z score of 11.1, 23% sequence identity). Pair-wise 
comparison of lpdr with the high resolution crystallographic structures of two 
representatives of the major interaction classes (lkwa and lqav (Doyle et al., 1996; 
Hillier et al., 1999)) shows that the structural variability between the ZASP-PDZ final 
bundles is in regions with the largest variability for the crystal structures (Figure 5.19). 
This would suggest that the two bundles have a comparable accuracy.
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PDB/Chain Rep Z RMSD LALI LSEQ2 %Ide Protein Name
1PDR 12 8.7 2.5 81 96 27 3rd PDZ from DLG
2PDZ-A 1PDR 8.1 2.7 80 86 30 Syntrophin PDZ domain
1QAV 5 7.8 3.0 83 112 22 Neuronal nitric oxide sythase
1192 1PDR 7.8 2.7 79 91 28 Na+/H+ exch. regulatory factor
1KWA-A 1KWA 6.9 2.7 78 88 21 Human cask/lin-2 PDZ domain
1KEF-A 1PDR 6.9 3.0 81 93 28 Synapse associated protein-90
Field
Rep
RMSD
LALI
LSEQ2
%Ide
Definition
A number denotes the number of structures in the PDB the fold represents, or a 
PDB accession code denotes the structure in the PDB that represents it in the 
FSSP.
Z-score: strength of structural similarity in standard deviations above expected. 
Only scores >2 are reported.
Positional root mean square deviation of superimposed CA atoms in Angstroms. 
Total number of equivalent residues.
Length of the entire chain of the equivalent structure.
Percentage Identity
Table 5.5: Results from the DALI search of ZASP-PDZ.
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Figure 5.19: Pair-wise comparison of the manually and automatically assigned bundles, 
lkwa and lqav structures with lpdr, taken as a reference. The pair-wise Z scores as 
obtained by WHATIF MOTIF option are plotted versus the sequence of lpdr. The 
secondary structure elements of lpdr are indicated underneath with yellow (p-strands) 
and red (a-helices) boxes.
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The solution structure of ZASP-PDZ was solved using manual and automatic 
procedures, different structure calculation programs, and different protocols giving a total 
of six separate results. The structures were compared in terms of precision, accuracy, 
and quality. The automatic NOESY assignment and structure calculation (CANDID) 
was faster than the manual procedure, taking hours rather than weeks. RMSD 
calculations showed that the CANDID structures had higher precision than manually 
calculated structures. The WHATIF scores also showed that the CANDID structures had 
higher quality than the manual structures, although the Ramachandran plot showed 
relatively minor differences between the two methods. Comparing the manual and 
automatic calculated structures against known PDZ structures, using pair-wise RMSD 
calculations as a guide, gave an indication of accuracy. Again, the CANDID structures 
appeared to be more accurate than the manually calculated structures. The RDC 
constraints had less effect on the CANDID calculation than the manual calculation, 
meaning they had better agreement with the automatically calculated NOE distance 
restraints. On these criteria, the CANDID structures are better than those of the manual 
run. These differences between the automatic and manual calculated structure could be 
explained by looking at the way the NOESY spectra were analysed. CANDID was able 
to keep the average distance length lower in comparison to the manual run, which lead to 
a more compact and therefore more precise, structure. However, there were less NOESY 
peak assignments made by CANDID in the final structure calculation, which could be 
down to the elimination of restraint that did not agree with the structure. A limitation 
with CANDID was that it could only correctly calculate the PDZ fold with restraints 
additional to the NOE distances -  without dihedral angles and hydrogen bonds, the 
program did not come to the correct solution. Also another limitation of CANDID is the 
high percentage of proton assignment (typically 90%) needed for it to come to a correct 
calculation, and within that, a good agreement between the peak list and the assignment 
list.
The structural restraints were converted from CYAN A to XPLOR for structure 
calculation; hence a comparison was made between the structures calculated by each 
program. This conversion caused significant differences in the structure, which can be 
attributed to the difference in force field between CYANA and XPLOR: CYANA uses a 
ECEPP/2 force field (Momany et al., 1975; Nemethy et al., 1983), whereas XPLOR uses 
a adapted CHARMM force field (Brooks et al., 1983). The force field defines geometric
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parameters, partial atomic charges, non-bonded interactions, hydrogen bond interactions, 
and intrinsic torsional potentials for the amino acids, hence the differences in the results. 
The comparison of ZASP-PDZ against the known PDZ domains was close between 
CYANA and XPLOR structures, meaning there was no significant improvement in 
accuracy on conversion to XPLOR. The ‘lowest RMSD to the mean structures’ pair­
wise residue comparison of the CYANA and XPLOR calculations showed no important 
differences. However, analysis at backbone and heavy atom RMSD calculations over 
their best twenty structures show that the precision of the CYANA calculated structures 
are better than XPLOR. This is probably due to the REDAC strategy that reduces the 
conformations the CYANA calculated structures are allowed to occupy. The REDAC 
strategy is also a feature in CYANA that improved the convergence of the calculated 
structures. The WHATIF scores for the XPLOR structures appear to be better than that 
of CYANA, as it gave better scores in the WHATIF RMS comparison; this could also be 
attributed to the difference in force field between the two programs.
The CHARMM22 water refinement appears to have improved the precision and 
quality of the XCANDID structures. All of the RMSD calculations show a small 
improvement (backbone, and heavy atom, both with and without the selected residues). 
The PROCHECK-NMR results show a marked improvement after water refinement, as 
there is a increase in the percentage of residues in the most favoured regions of the 
Ramachandran plot with the concomitant decrease of residues in the additionally, 
generously and disallowed regions. WHATIF analysis also shows improvement in every 
assessment parameter in both the ‘Structure Z-score’ and ‘RMS Z-score’ categories. 
However, the XMANUAL structures did not appear to benefit as much as the XCANDID 
structures -  the precision decreased in categories except for the overall backbone RMSD. 
The quality of the water refined XMANUAL structures did not improve significantly, as 
the Ramachandran plot only saw minor variations in the distribution of the residues in the 
favoured regions. Also, the WHATIF analysis did not show significant improvement in 
the ‘Structure Z-scores’, but there were some minor improvements in the ‘RMS Z- 
scores’.
From this analysis, the water refined RXCANDID structures were chosen to 
represent the solution structure of ZASP-PDZ, as the CANDID structures were better 
than the manually derived structures in terms of precision, accuracy, and quality, 
especially after water refinement.
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Chapter 6
Interaction of a-Actinin-2 with ZASP 
and Titin
The interaction between a-actinin-2 with ZASP and titin was characterised by 
both NMR and fluorometric titration. Two a-actinin-2 constructs were used: Act- 
EF1234 and Act-EF34, which contains all four and last two EF-hands of its calmodulin­
like domain respectively, as well as the ZASP-PDZ construct. The tertiary complex was 
formed by first saturating Act-EF34 with tZR7 - a synthetic peptide that spans 24 
•residues of the seventh Z-repeat of titin: tZR7 was designed to comprise of the region of 
interaction observed in the structure of Act-EF34/ZR7 complex (See Appendix 10.1.5 
and (Atkinson et al., 2001)) -  N.B. ZR7 was chosen from seven Z-repeats studied as it 
had the highest Kd to Act-EF 1234/34 (Joseph et al., 2001). ZASP-PDZ was 
subsequently titrated against the Act-EF34/tZR7 complex to form the tertiary complex.
The affinity of the interaction between ZASP-PDZ and a-actinin-2 was measured 
using fluorescence spectroscopy, by following the signal of the unique tryptophan 
residue (W13) present in ZASP-PDZ and titrating Act-EF34. The fluorometric titration 
was then repeated using the Act-EF34/tZR7 complex to check whether the presence of 
tZR7 would modulate the interaction affinity.
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6.1 NMR Titrations
6.1.11SN-Act-EF1234 and 1SN-Act-EF34 with ZASP-PDZ
The residues involved in the interaction between Act-EF34 and Act-EF1234 with 
ZASP were identified by a series of pair-wise titrations. Unlabelled ZASP-PDZ was first 
titrated against 15N-Act-EF34 and 15N-HSQC spectra were recorded for each addition of 
ZASP-PDZ (Figure 6.2). The observed chemical shift changes confirm that ZASP-PDZ 
interacts with a-actinin-2, with the changes mostly being in the intermediate exchange 
regime. Plotting the A5weighted against residue number (Figure 6.3) reveal changes 
localised to Act-EF34’s C-terminus section, ranging from the 0 to the -12 position. The 
same conclusion was made for the titration using the longer 15N-Act-EF1234 construct 
(Figure 6.1 and Figure 6.3) and unlabelled ZASP-PDZ. Although the NMR assignment 
of this section of Act-EF1234 is not available, a partial analysis was conducted by 
superimposing the assigned 15N-HSQC spectra of Act-EF34 against Act-EF1234’s 
(Section 4.4 and Figure 4.11). The peaks most affected are those corresponding to Act- 
EF34’s A61, S71, D72, and L73 (Figure 6.13B. The titration shows the direction and 
A8weighted changes for these residues are almost identical to the Act-EF34 and ZASP-PDZ 
titration. No appreciable effect could be observed from the peaks attributed to residues 
from Act-EF12. Both titrations were taken to an Act/ZASP ratio of 1:2. See Appendix 
10.8 for the experimental conditions for the titrations.
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Figure 6.1: 15N-HSQC titration of 15N-Act-EF1234 with (red) and without (black) 
ZASP-PDZ (2:1 ZASP-PDZ excess, final titration point). Run at 600 MHz, 300 K, with
0.46 mM (initial) ,5N-Act-EF1234.
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Figure 6.2: 15N-HSQC of 15N-Act-EF34 with (red) and without (black) ZASP-PDZ (2:1 
ZASP-PDZ excess, final titration point). Run at 500 MHz, 300K, 0.60 mM (initial) 15N- 
Act-EF34.
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Figure 6.3: A5weighted changes in 15N-Act-EF34 upon binding ZASP-PDZ. The changes 
appear to be localised to Act-EF34’s C-terminus.
6.1.2 ,5N-ZASP-PDZ with Act-EF1234 and Act-EF34
The back-titration between unlabelled Act-EF1234 against 15N-ZASP-PDZ was 
performed (Figure 6.4) to a ratio of 2:1. Plotting A5weighted against residue number 
(Figure 6.6) localises the changes to a defined area of ZASP-PDZ. Residues W13, G14, 
and F I5 from the ‘GLGF’ motif (PWGF in ZASP) are in intermediate exchange, 
indicating a significant effect on these residues in the titration. Using a 0.3 A5weighted 
threshold highlights further changes in the second (3-strand: residues LI7 and Q18 have 
large chemical shift changes of ~6 ppm in the 15N dimension for both residues (Figure 
6.13A). A6weighted threshold of 0 .2  highlights that residues 16, 2 0 , 28 and 31 are also 
affected upon complex formation. The titration between 15N-ZASP-PDZ and Act-EF34 
(Figure 6.5) gave an almost identical change in chemical shift (Figure 6.6).
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Figure 6.4: lsN-HSQC of ,sN-ZASP-PDZ with (red) and without (black) Act-EF1234 
(2:1 Act-EF1234 excess, final titration point). Run at 600 MHz, 300K, 0.30 mM (initial) 
i5N-ZASP-PDZ.
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Figure 6.5: 15N-HSQC of 15N-ZASP-PDZ with (red) and without (black) Act-EF34 (2:1 
Act-EF34 excess, final titration point). Run at 600 MHz, 300K, 0.37 mM (initial) 15N- 
ZASP-PDZ.
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Figure 6.6: A 8weighted changes of 15N-ZASP-PDZ with Act-EF1234 (white) and Act- 
EF34 (black).
6.1.3 l5 N-Act-EF34 in complex with Minimal Titin ZR7 and ZASP-PDZ
The titration of the trimeric complex involves components of ZASP, a-actinin-2, 
and titin. The 15N-HSQC from the Act-EF34/ZR7 and Act-EF34/tZR7 final titration 
points were superimposed (Figure 6.7), revealing no significant difference between the 
two titin-ZR7 constructs on binding Act-EF34. The trimeric complex titration was 
carried out between Act-EF34, tZR7, and ZASP-PDZ; this strategy reduced the size of 
the resulting complex, and the assignment is available for Act-EF34 and ZASP-PDZ - 
allowing straightforward analysis. Act-EF34 was produced as a l5N-labelled protein, as 
it is the common binding partner of ZASP-PDZ and tZR7. A 2:1 ratio of tZR7 was 
added to 15N-Act-EF34, followed by titrating ZASP-PDZ to a final Act-EF34/ZASP- 
PDZ ratio of 2:3 (Figure 6.8). ZASP-PDZ appears to interact with the C-terminal of Act- 
EF34 between the 0 and -6  residue positions (above 0.2 A 8weighted) with the biggest 
changes observed occur for residues G69, S71, D72, and L73 (A 8weighted changes above 
0.4) (Figure 6.9).
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Figure 6.7: 15N-HSQC of 15N-Act-EF34 with tZR7 (black) and ZR7 (red). Both spectra 
were run at 600 MHz, 300K, and with an excess of 2:1 ZR7 or tZR7.
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Figure 6 .8 : 15N-HSQC of 15N-Act-EF34/tZR7 with (red -  final titration point) and 
without (black) ZASP-PDZ. Run at 500 MHz, 300K, 0.53 mM (initial) 15N-Act-EF34 
with a 2:1 excess of tZR7 and 1.5:1 excess of ZASP-PDZ
116
A
Sw
ei
gh
te
d 
A
Sw
ei
gh
te
d
Chapter 6: Interaction o f a-Actinin-2 with ZASP and Titin
1.4
1.2 
1.0 
0.8 
0.6 
0.4 
0.2 
0.0
Figure 6.9: A8weighted changes for 15N-Act-EF34/tZR7, after binding ZASP-PDZ.
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Figure 6.10: Comparison of the changes in A 8weighted against residue number for the 15N- 
Act-EF34/titin-ZR7 complex, after binding ZASP-PDZ.
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6.1.4 NMR Kd calculations between ZASP, a-actinin-2, and Titin
Titrations experiments were carried out on 15N-ZASP-PDZ’s with both 
unlabelled Act-EF1234 and Act-EF34, 15N-Act-EF1234 and 15N-Act-EF34 with 
unlabelled ZASP-PDZ, and the trimeric complex (15N-Act-EF34 saturated with tZR7, 
titrating in unlabelled ZASP-PDZ). Kd calculations could not be performed between 
15N-Act-EF1234 and unlabelled ZASP-PDZ as all peaks were in intermediate exchange, 
so did not produce data suitable for the calculation. In all NMR experiments, a 
stoicheometric binding regime was observed -  this is indicated by a linear start of the 
binding curve, followed by sharp a plateau (Figure 6.11). In stoicheometric binding there 
is no free ligand, as all added ligand forms a complex with the enzyme. Kd 
measurements from peaks displaying stoicheometric binding is inappropriate, as this will 
lead to an overestimation of the Kd by at least a factor of ten (personal communication 
from Dr. Berry Birdsall): only a limiting value can be determined. Kd calculations for 
the experiments ranged between ~200-500 pM, hence the Kd is expected to be tighter 
than ~20-50pM as an estimate; any comparison between Kd’s from different titrations 
will be erroneous, as the overestimation is not accurately known. Reducing enzyme 
concentration (i.e. the labelled component) to the Kd observed in the fluorometric 
titration (~30 pM) may move the reaction to a non-stoicheometric binding regime, 
however, this will reduce the signal observed in the NMR experiment.
Many limitations in the NMR titrations make it difficult to rely on the accuracy of 
these Kd calculations. The large amount of protein required for NMR protein/protein 
titrations mean that ligand concentrations can not be taken to a high excess of the 
concentration of the fixed protein, required for accurate Kd measurement. Also, the large 
amount of material required makes it impractical to make repeat titrations. A significant 
cause of experimental error can derive from the inaccuracy of protein concentration 
determination and from sample manipulation during the ligand additions. Due to these 
limitations, the Kd calculations from the fluorometric titration were favoured over the 
NMR derived values.
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Figure 6.11: Binding graphs of A) 15N-ZASP-PDZ against Act-EF1234 (from N67), B) 
l5N-ZASP-PDZ against Act-EF34 (from N67), C) 15N-Act-EF34 against ZASP-PDZ 
(from S64), and D) 15N-Act-EF34/tZR7 against ZASP-PDZ (from S64). All graphs 
display stoicheometric binding, leading to an overestimation of the Kd calculated by non­
linear regression analysis.
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6.2 Fluorometric Titration
Dr. Steve Martin at the NIMR carried out the fluorometric titration. Both Act- 
EF34 and the Act-EF34/titin-ZR7 complex were titrated against ZASP-PDZ, producing a 
titration curve from which the Kd was calculated (Figure 6.12). The only tryptophan 
residue from which the change in fluorescence was monitored (W13) is serendipitously 
located in the binding pocket (Figure 6.13A). The titration between Act-EF34 against 
ZASP-PDZ yielded a Kd of 35.8 ± 5.3 pM, whilst the titration between the Act- 
EF34/tZR7 complex and ZASP-PDZ gave a Kd of 31.6 ± 3.8 pM. From these results, a 
Student’s T test reveals that there is no significant difference between these two results, 
meaning that the Kd between ZASP-PDZ and Act-EF34 does not appear to be affected in 
the presence of tZR7.
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Figure 6.12: Fluorescence titration of ZASP-PDZ against Act-EF34 (black diamonds), 
and the Act-EF34/tZR7 complex (white open circles).
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6.3 Modelling of a-Actinin. Titin and ZASP Tertiary Complex
The relatively low affinity between ZASP and a-actinin-2 prevented the direct 
elucidation of the complex; the interacting residues were in intermediate exchange, 
meaning NOE restraints between the complex could not be observed. Therefore we 
resorted to comparative modelling. From the titration data, the affected peaks were 
highlighted on the lowest energy structure of ZASP-PDZ from RXCANDID (Section 5.3 
and Figure 6.13 A) -  this was compatible with a class I PDZ to ligand interaction as they 
include the ‘GLGF’ motif residues within the groove between the P2 and the a2. The 
residues that were affected on Act-EF34 were highlighted on the Act-EF34/ZR7 structure 
(Figure 6.13B), which was previously solved in our group (Atkinson et al., 2001). This 
was also consistent with the class I PDZ target proteins, as they were at the C-terminus. 
The Act-EF34/tZR7/ZASP-PDZ complex was modelled on the third PDZ domain from 
PSD-95 in complex with a C-terminal peptide derived from Cript (1BE9) (Doyle et al., 
1996) -  i.e. a class I PDZ domain bound to its target peptide. First, the last four residues 
on Act-EF34 were rebuilt in an extended conformation compatible with class I PDZ 
recognition. Secondly, ZASP-PDZ was superimposed onto the structure of 1BE9, using 
the regions of maximal superposition as indicated by DALI (Holm and Sander, 1996b). 
Finally, the last four residues of Act-EF34 were aligned with the interacting peptide in 
1BE9 - aligning L73 of Act-EF34 to position 0 of the peptide (position 0 is the C- 
terminal residue, and subsequent residues are -1, -2, etc). The resulting structure 
appeared to have no apparent clashes, so a GROMOS energy minimization 
(http://www.igc.ethz.ch/gromos/) was applied on the model to correct any distorted 
geometries arising from the manipulation of the structures (Figure 6.14).
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A
B
Figure 6.13: A) ZASP-PDZ with highlighted A 8weighted changes from binding Act-EF34 
with residues in intermediate exchange in purple (13, 14, 15), A5Weighted changes of over 
0.3 in red (17, 18), and over 0.2 in yellow (16, 20, 28, 31). W13 is shown in stick 
representation. B) Act-EF34 (blue) in complex with titin-ZR7 (green) showing changes 
in its changes in the C-terminus with the same colour scheme as above: in purple - L73; 
red - G69, S71 and D72, and yellow -  L67.
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Figure 6.14: Ribbon representation of the Act-EF34/tZR7/ZASP-PDZ trimeric
complex, rotated to highlight the ZASP-PDZ/Act-EF34 interaction (A) and the Act- 
EF34/ZR7 interaction (B).
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We took a modular approach to study the interaction of ZASP and a-actinin-2 by 
NMR; the domains of interest were analysed as opposed to the full protein. The 
limitations become apparent looking at the size of full ZASP and a-actinin-2 in complex 
(134 Kda) -  a size currently beyond the scope of NMR. In combination with titin for the 
study of the trimeric complex adds a further 3 MDa.
The titration indicates major chemical shift changes of a-actinin-2’s last three C- 
terminal residues (S71, D72, L73) changing upon binding ZASP-PDZ. These changes 
are observed for both Act-EF1234 and Act-EF34, signifying that the binding between 
ZASP-PDZ and Act-EF1234/EF34 is essentially the same. Other significant changes in 
A8Weighted upon complex formation include A61, F62, S64, Y68, and G69 of Act-EF34: 
the structure of Act-EF34 in complex with ZR7 (Atkinson et al., 2001) place these 
residues on one face of the last helix of Act-EF34, suggesting possible secondary 
interaction with ZASP-PDZ. In total, the interaction with ZASP-PDZ affects the 0 to the 
-12 residue position of a-actinin-2 with no affect observed on Act-EF12 (the 0 position 
is the last C-terminal residue, counting back to negative positions to the N-terminus). 
The changes observed on the interaction of Act-EF34 and ZASP-PDZ appear to be 
altered in the presence tZR7: changes above a A5weighted of 0.2 in the trimeric complex 
only has significant changes from 0 to the -6  position. This may derive from the a- 
helical structural stabilisation caused by the presence of ZR7 observed in a previous 
study (Atkinson et al., 2000a), however the fluorometric titration result suggests that this 
is only a minor modification to the interaction between Act-EF34 and ZASP-PDZ as 
there is no significant difference in affinity between the two components.
The titration between 15N-ZASP-PDZ and Act-EF1234 showed the biggest 
changes between residues 13-18, which encompasses the ‘GLGF m otif (PWGF in 
ZASP) that is known to co-ordinate the C-terminal carboxylate group of the target 
protein in class I PDZ domains (Doyle et al., 1996). Residues 13-18 and 20 correspond 
to the second P-strand (P2), which is modelled to form an intermolecular P-sheet with the 
target protein. The changes in residues 28 and 31, residues within P3, were probably 
caused by the effect of a-actinin-2 on p2 to which P3 pairs with.
The fluorometric titration gives a Kd of 35.8 ± 5.3 pM between Act-EF34 and 
ZASP-PDZ, and a Kd of 31.6 ± 3.8 pM between Act-EF34/tZR7 and ZASP-PDZ. The 
lack of significance between these Kd values suggests no effect to the affinity between 
Act-EF34 and ZASP-PDZ with the presence of tZR7, which indicates that titin and
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ZASP bind to a-actinin-2 in a non-competitive fashion -  i.e. they occupy different 
binding sites.
The tertiary complex demonstrates a conventional PDZ to target interaction, with 
Act-EF34’s C-terminus forming an intermolecular p-sheet with ZASP-PDZ’s second P- 
strand and the carboxyl-group of Act-EF34 is co-ordinated within the ‘GLGF m otif. An 
inspection of the model of the tertiary complex reveals six hydrogen bonds forming 
between Act-EF34 and ZASP-PDZ (Figure 6.15): W13, G14, and F15 backbone amides 
form a hydrogen bond network with the C-terminal carboxylate group, F15’s backbone 
carboxy group pairs with the 0 position (L73) backbone amide, while L17’s carboxy and 
amide backbone groups pair with -2  (S71) backbone amide and carboxy group 
respectively. The electrostatic potential at pH 7 of ZASP-PDZ and Act-EF34 was 
mapped onto the Connolly surface (Figure 6.16). This shows a complementarity between 
the surface of interaction, with ZASP-PDZ displaying a positive charged surface 
accommodating the negative charged Act-EF34 C-terminus. An analysis by residue 
property (Figure 6.17), again highlighting a direct complementarily between the residues 
at the interacting surface: ZASP W13, G14 and F I5 forms a hydrophobic contact with 
the 0 position (L73) Act-EF34, ZASP R16 forms a electrostatic interaction with the -1 
position (D72), Q66 forms a polar interaction with the -2  position (S71), and finally, 
H62 forms another electrostatic interaction with the -3  position (E70).
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Figure 6.15: Hydrogen bond network between ZASP-PDZ (yellow ribbons) and Act- 
EF34 (stick to red ribbon representation) in the complex, forming six possible hydrogen 
bonds.
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Titin-Zr7
Figure 6.16: Connolly surface representation (solvent accessibility; probe radius of 1.4 
A) of the trimeric complex. This shows electrostatic and surface complimentarily 
between ZASP-PDZ and Act-EF34.
Figure 6.17: Interacting surface between ZASP-PDZ and Act-EF34 coloured by residue 
property at pH 7: Grey indicates non-polar hydrophobic, yellow - polar, red - negative 
charge, and blue indicates a positively charged residue.
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Chapter 7
Homology Modelling of the Enigma 
______________Family PDZ Domains
In general, structure determination is a difficult and laborious process; therefore 
one of the ways to use available structures to predict information from proteins with 
unknown structure is ‘homology modelling’, also known as comparative modelling. 
Homology modelling is implemented on protein sequences that are homologs of the 
known protein structure, and one of the main uses of homology modelling is to infer 
whether related proteins share similar structural features, which may imply comparable 
functional characteristics. Paradoxically, they can also be used to aid structure 
determination, as has been utilised in the structure determination of ZASP-PDZ.
Homology modelling of the structure of an undetermined target protein requires a 
known molecular structure of second protein known as the ‘template’, with which it 
shares greater than 30% sequence identity. The procedure involves an alignment of the 
protein sequences, followed by the direct substitution of the homologous protein onto the 
template, after which an energy minimisation is performed to correct anomalies in the 
generated model, such as clashes, etc.
The solution structure of ZASP-PDZ presented in this thesis is the first available 
structure of an enigma family PDZ domain, so homology models of the other enigma 
family PDZ domains were produced and used to identify the significance of the 
conserved residues across the enigma family. This may have implications as to the 
function of this family of proteins, in particular, their ability to bind a-actinin-2.
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7.1 Homology modelling of the enigma family of PDZ
A BLAST search (Altschul et al., 1997) using the ZASP’s PDZ sequence 
recovered fifty sequences. This search revealed that the PDZ domains in all variants of 
ZASP, cypher, and oracle (see Introduction 1.4) are 100% identical (residues 1-82). Non­
mammalian and hypothetical protein sequences were discarded from further analysis to 
concentrate on the known mammalian proteins. The remaining 36 sequences were then 
aligned using CLUSTALX (Thompson et al., 1997), which grouped the sequences into 
their respective sub-groups within the enigma family: enigma, ENH, RIL, ALP, and elfin 
(Figure 7.1). There was no available structural information regarding any of these 
sequences at time of writing.
The enigma family PDZ domains have high sequence identity with ZASP-PDZ, 
with pair-wise sequence identity varying between 54 and 61%, and pair-wise sequence 
similarity between 71 and 81% (Table 7.1). There was little or no difference in sequence 
identity within each sub-group, so one representative sequence per group was used for 
homology modelling. These representative sequences were chosen on criteria such as 
species and tissue type of origin, and highest sequence identity to ZASP: the PDZ 
domain sequences in the enigma sub-group family are identical, while ENH1 was chosen 
as it was the main functioning protein, and each of the human forms of elfin, ALP and 
RIL were selected. All selected proteins are expressed in mammalian heart and/or 
striated muscle with the exception of RIL, which has only been reported in epithelial 
tissue (Cuppen et al., 1998). The SWISS-MODEL server was used to construct the 
homology models by using the structure of the ZASP-PDZ, accompanied with the 
alignment of the homologous sequence (Figure 7.2).
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Name Species (# isoforms)* Tissue
**
a-Actinin-2
Binding
Loci on 
a-actinin
Locus ID (%) Sim. (%)
ZASP H(4), M(4) H, S Yes C-term Z-disk 100 100
Enigma H(S), M(2), R(l) S NR NR Z & I band 56.5 78.8
ENH H(2), M(3), R(l) H, S Yes NR Z-disk 60.0 81.2
ALP H(3), M(l), R(l), S(l), G(2) H, S Yes Spectrin Z-disk 54.1 76.5
RIL H(2), R(l), G(l) E NR NR Epithelial 56.5 71.8
Elfin H(1),R(1) H Yes C-term Z-disk 61.2 78.8
Table 7.1: Details of the enigma family members including species, tissue type, ability to 
bind a-actinin-2, location of a-actinin-2 binding, and sequence identity and similarity 
with respect to ZASP-PDZ. * H  = Homo Sapiens, M  = Mus Musculus, R = Rattus 
Norvegicus, S = Salmo Salar, G = Galus Galus, ** H = Heart, S = Skeletal, Epithelial. 
NR = Not Reported
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Figure 7.1: ClustalX sequence alignment of the results from the BLAST search from 
ZASP’s PDZ domain. The subgroups in the enigma family (enigma, ENH, ZASP, Elfin, 
RIL and ALP) group together, and are indicated on the alignment. There is almost no 
variation in sequence in the PDZ domains of each subgroup.
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Figure 7.2: Homology models of the PDZ domains of ENH, enigma, elfin, ALP and 
RIL, generated using SWISS-PDB Viewer and SWISS-MODEL -  ‘ALL’ refers to the 
sequence conservation across the whole enigma family. Highlighted red and yellow 
residues represent identical and similar residues respectively. The green arrow on ‘ALL’ 
indicates the binding pocket in class I PDZ target recognition.
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The BLASTP search revealed that the PDZ domains of enigma, ENH, ALP, RIL, 
and elfin protein sequences are homologous to that of ZASP-PDZ, therefore, homology 
modelling may help identify structural or functionally relevant residues across the 
enigma family. The sequence alignment of the enigma family revealed 27 identical and 
44 similar residues (31% and 51% respectively, over the aligned 86 residues), and all 
generated structures appear to be feasible folds, as there are no large sections of 
unconserved residues that might disrupt the fold (Figure 7.2). Comparing these 
homology models with the known structure of the PSD-95/Cript complex (Doyle et al., 
1996), show that residues 13-15 of the PDZ form hydrogen bonds with the target’s C- 
terminal carboxylate group, and residues 16 and 19 form additional hydrogen bonds with 
the target; these residues are well conserved in the enigma family. Histidine 62, which is 
thought to be important for target specificity in PSD-95 PDZ, is also conserved across 
the enigma family. Other conserved residues along the PDZ domain’s sequence may 
serve a more structural purpose. For example, K37 and A38 appear to stabilise the 
orientation of the ‘GLGF’ loop. Other similar residues appear to be involved in 
maintaining the PDZ fold, as they appear to ‘pair-up’ along stretches of P-strands, and 
also residues in a2 have similarity preserved.
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This project’s main aims were to gain new insights into the muscle ultrastructure 
by solving the structure of ZASP-PDZ and investigating how it interacts with other 
proteins that localise in the Z-disk. The last two and four EF-hands of the calmodulin­
like domain of a-actinin-2 and ZASP-PDZ were successfully purified in rich and 
minimal media -  resulting in the near-to-complete NMR assignment of ZASP-PDZ, Act- 
EF34 backbone assignment, partial assignment of the 15N-ZASP-PDZ/Act-EF1234 
complex, and partial assignment of Act-EF1234. Assignment of ZASP-PDZ allowed its 
NMR structure calculation by employing a number of protocols, which were 
subsequently assessed for accuracy, precision, and quality. The high-resolution structure 
of ZASP-PDZ was then used to model the a-actinin-2/titin/ZASP-PDZ ternary complex, 
and also for modelling the PDZ domains in the enigma family of proteins.
The NMR assignments allowed a set of 15N-HSQC titrations to be completed, 
characterising the specific interactions between a-actinin-2, ZASP, and titin. Coupling 
the NMR and fluorescence titrations with the structures of the components demonstrated 
that ZASP-PDZ binds to a-actinin-2 in a class I PDZ interaction, with no significant 
effect from the presence of tZR7. Subsequent modelling of the a-actinin-2, titin, and 
ZASP ternary complex may help us understand how multiple protein interactions 
contribute towards correct Z-disk function, and it may be useful for further modelling of 
the Z-disk.
The surface of interaction mapped on ZASP upon complex formation is in 
excellent agreement with the mutational analysis conducted on cypher, the mouse 
orthologue of ZASP (Zhou et al., 2001). In this study, residues G14, F15, H62, L76, 
L78, and L80 of cypher’s PDZ were mutated to alanine to test their role in a-actinin-2 
binding (Figure 8.1). The G14A and F15A mutations (within the GLGF motif) abolished 
binding to a-actinin-2, consistent with our observation on complex formation. However, 
the L76K, L78K, and L80K mutants that displayed a reduction in binding affinity to a- 
actinin-2 do not appear be directly involved in the interaction, as they are located on the 
opposite side of the binding groove. These mutations may only disrupt the PDZ fold, as 
they are involved in |3-sheet formation with pi. Zhou, et. al. predicted that a H62A
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mutation would cause a reduction in affinity for a-actinin-2 (Zhou et al., 2001) as PSD- 
95’s PDZ domain forms a hydrogen bond; however, the mutation only caused a minor 
change in affinity to the ligand. It is interesting to note the NMR titration show that L63, 
directly next to H62, has a large change in chemical shift. The mutational analysis Zhou, 
et. al. made on a-actinin-2’s C-terminal concurs with the NMR titrations -  deletion of 
these residues lead to abolition of ZASP-PDZ binding. The only human mutation of 
ZASP linked to DCM (at time of writing) present in the PDZ domain, is the silent 
mutation V55I -  this is a mild mutation as valine and isoleucine are chemically similar.
G14A,
F15A
Figure 8.1: Mapping of point mutations described in (Zhou et al., 2001) onto the 
structure of ZASP-PDZ.
As mentioned above, the structure of ZASP-PDZ allowed the homology 
modelling of the PDZ domains of the other members of the enigma family. As these 
proteins had high sequence homology and identity with ZASP-PDZ, it is reasonable to 
suggest functional similarities for these homologs. The large chemical shift variations 
observed in the 15N-HSQC of ZASP-PDZ titration with Act-E1234 and Act-EF34 
(Section 6.1.2) compare well with the conserved residues in the sequence alignment of 
the enigma family. The chemical shift changes in 13-17 in the titration parallel the 
conservation of 13-17. Q18 experiences large A5weighted upon complex formation, but is
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not well conserved. However, the structure of the PSD-95/Cript complex shows only a 
minor Van der Waals contact between Q18 and the Cript target peptide. Another 
difference between the titration and the sequence alignment is the absence of large 
chemical shift change observed in a2, with the exception of L63. Again, referring to 
PSD-95/Cript, the contacts between a2 and the target are side-chain mediated, therefore 
reducing the effect on the a2 amide protons.
Highlighting the conserved residues from the homology models onto the structure 
of ZASP-PDZ reveal that many of them are in the binding groove (Figure 8.2). These 
residues, that include W13-L17, G19, G20, D22, F23, H62, A65, Q66, and 169, are also 
involved in the corresponding residues for PSD-95/Cript recognition (Doyle et al., 1996), 
suggesting that the PDZ domain of the enigma family may also be able to bind a-actinin- 
2’s C-terminus. The literature regarding the enigma family proteins contains 
contradictions regarding their potential binding partners. All of these proteins, with the 
exception of RIL (epithelial), have been localised to the sarcomeric Z-disk. ZASP, ENH 
and ALP have been reported to bind a-actinin-2 via their PDZ domains (Faulkner et al., 
1999; Nakagawa et al., 2000; Xia et al., 1997), except for ALP that was reported to bind 
to a-actinin-2’s spectrin like domains, not the C-terminus. However, the homology 
model of ALP suggests a PDZ to C-terminal interaction. Enigma has been reported to 
bind P-tropomyosin, but not a-actinin-2 (Guy et al., 1999). However, ENH’s PDZ 
domain, sharing a 69% sequence identity to enigma, does not have the ability to bind P- 
tropomyosin (Nakagawa et al., 2000). The information across elfin/hCLIMl/CLP- 
36/hCLP-36 is even more confusing. It was reported that /zCLIMl binds to a-actinin-2 
via its LIM domains (Kotaka et al., 2000), ACLP36 binds to a-actinin-1 via the 
intervening sequence between the PDZ and LIM domain (Bauer et al., 2000), while CLP- 
36 was reported to bind to a-actinin-1 and a-actinin-4 via its PDZ domain (Vallenius et 
al., 2000). Based on our results and the pattern of sequence conservation, we predict that 
all currently known members of the family are able to bind a-actinin-2 in vitro. It is 
possible that in vivo other regions of the proteins intervene in a family member specific 
fashion to modify the signalling properties of the Z-disk through the interaction with 
other components such as calsarcins and other Z-disk proteins (Frey and Olson, 2002). 
Further studies will be necessary to test these hypotheses and to assess further the reasons 
for redundancy of the enigma protein family.
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Figure 8.2: Ribbon representation of Z A S P -P D Z  showing A : the conserved residues 
from the sequence alignment (identical and similar residues in red and orange 
respectively), and B: the residues most affected upon binding a-actinin-2 (coloured from 
red, orange and yellow in order of A8weighted change -  red being the highest). This shows 
that the many of the residues directly involved in binding a-actinin-2 are conserved 
within the enigma family.
Chapter 8: Discussion
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_______________________Appendix
10.1 Protein Sequences
10.1.1 ZASP [1-85] (ZASP-PDZ)
87 residues, MW = 9267.5 Da, pi = 9.78, e = 8250 M-l cm-1
GA M SY SV T L T G P GPW GFRLQGG K D F N M P L T IS  R IT P G S K A A Q  S Q L S Q G D L W  A ID G V N TD TM  
T H L E A Q N K IK  S A S Y N L S L T L  QKSKR
10.1.2 a-Actinin-2 [745-894] (Act-EF1234)
154 residues, MW = 17163.2 Da, pi = 4.64, e = 7800 M-l cm-1
G AM GRDA KGIT QEQM NEFRAS FN HFD RRKN G LM DHEDFRAC L ISM G Y D L G E  A E F A R IM T L V  
D PN G Q G TV TF Q S F ID F M T R E  TAD TD TA EQ V  I A S F R I L A S D  K P Y IL A E E L R  R E LPPD Q A Q Y  
C IK R M PA Y SG  PG SV PG A LD Y  A A FSS A L Y G E  SD L
10.1.3 a-Actinin-2 [823-894] (Act-EF34)
75 residues, MW = 8071.0 Da, pi = 4.34, e = 6400 M-l cm-1
GA M ADTDTAEQV IA S F R IL A S D  K P Y IL A E E L R  R E LPPD Q A Q Y  C IK R M PA Y SG  PG SV PG A LD Y  
A A FSS A L Y G E  SD L
10.1.4 Titin ZR7
53 residues, MW = 5659.3 Da, pi = 5.71, e = 3840 M-l cm-1
GA MGKVGVGKKA E A V A T W A A V  D Q A R V R EPR E PG L P E D SY A Q  Q TTLEY G Y K E H
10.1.5 Titin ZR7 minimum sequence
23 residues, MW = 2421.7 Da, pi = 9.98 
GKKAEAVATV VAAVDQARVR EPR
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10.2 Media and Buffers
10.2.1 Luria-Bertani Media (LB)
1 % w/v bacto-tryptone, 0.5 % w/v bacto-yeast extract, 1 % w/v NaCl, 1 mM 
Tris.HCl
10.2.2 Preparation of M9 Minimal Media
Autoclave, and leave to cool before the addition of the following solutions, (* if 
appropriate):
Compound Concentration Volume (ml) Final Concentration
MgS04 1 M 1 . 0 1 mM
CaCl2 1 M 0.3 0.3 mM
M9 salts 1 0  x 1 0 0 . 0 1 X
Trace elements 1 0 0 0  x 1 . 0 1 X
Biotin 1 mg/ml 1 . 0 1 mg/L
Thiamine 1 mg/ml 1 . 0 1 mg/L
13C-glucose* 1 0 .0 0 % 2 0 . 0 0 .2 0 %
Kanamycin* 30 mg/ml 1 ml 30 mg/L
Ampicillin* 1 0 0  mg/ml 1 ml 100 mg/L
10.2.2.110 x M9 Salts with 15N as a Source of Nitrogen
Compound Formula Weight (Da) Final Molarity (M) Amount (g)/100 ml
Na2HP04 141.96 0.423 6 . 0 0
k h 2po 4 136.09 0 . 2 2 0 3.00
NaCl 58.44 0.086 0.50
,5NH4C1 53.49 0.187 1 . 0 0
10.2.2.2 Trace Elements x 1000
Compound Formula Weight (Da) Final Molarity (mM) Amount (mg)/100 ml
EDTA 397.7 25.00 5ml 0.5M, pH 8  in 80
ml H20
FeCl3 162.2 30.83 500
ZnCl3 136.3 3.67 50
CuCl2 134.5 0.74 1 0
CoC13 H20 237.9 0.42 1 0
h 3b o 3 61.83 1.62 1 0
Na2Mo04 *2H20 205.9 0 . 1 0 2
MnCl2 '6H20 125.8 127.19 1600
Adjust to pH 7.5 - 8  in 100 ml 
Filter 0.22 pm, Store at 4 °C
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10.2.2.3 Biotin 1 mg/ml 
For 50 ml:
Dissolve 50 mg biotin in 1:1 ethanol/water solution.
Filter 0.22 pm, Store at 4 °C
10.2.2.4 Thiamine 1 mg/ml 
For 50 ml:
Dissolve 50 mg of thiamine into 50 ml water.
Filter 0.22 pm, Store at 4 °C
10.2.2.5 IPTG 0.5 M
For 50 ml:
Dissolve 5.96g of IPTG into 50 ml water.
Filter 0.22 |im, Store at -20 °C in 1 ml aliquots.
10.2.3 Nickel-NTA Column Buffers
All buffers are 0.2 pm filtered.
10.2.3.1 Lysis Buffer
20 mM Tris.HCl pH 8.0, 200 mM NaCl, 5 mM Imidazole, 0.2% v/v IPEGAL 
CA-630
10.2.3.2 Wash Buffer
20 mM Tris.HCl pH 8.0, 200 mM NaCl, 5 mM Imidazole
10.2.3.3 1MNaCl Wash Buffer
20 mM Tris.HCl pH 8.0,1000 mM NaCl, 5 mM Imidazole
10.2.3.4 30 mM Imidazole Wash Buffer
20 mM Tris.HCl pH 8.0,1000 mM NaCl, 30 mM Imidazole
10.2.3.5 300 mM Imidazole Wash Buffer
20 mM Tris.HCl pH 8.0,1000 mM NaCl, 300 mM Imidazole
10.2.4 FPLC Column Buffer
20 mM Tris.HCl pH 8.0, 200 mM NaCl, 0.02 mM NaN3, 0.2 pM filtered and 
degassed with Nitrogen.
10.2.5 NMR Sample Buffer
20 mM Sodium Phosphate Buffer pH 6 .6 , 0.02 mM NaN3 , 10% D2 O.
152
Chapter 10: Appendix
10.2.6 Broad Molecular Weight Marker
Amersham Biosciences: Cat # RPN5800
Protein Mr Source
Myosin 205000 Rabbit muscle
P-Galactosidase 116000 Escherichia coli
Phosphorylase b 97000 Rabbit muscle
Transferrin 80000 Human serum
Albumin 66000 Bovine serum albumin
Glutamate dehydrogenase 55000 Bovine liver
Ovalbumin 45000 Chicken egg white
Carbonic anhydrase 30000 Bovine erythrocyte
Trypsin inhibitor 2 1 0 0 0 Soybean
Lysozyme 14000 Chicken egg white
Aprotinin 6500 Bovine lung
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10.3.1 ZASP-PDZ Spectra
10.3.1.1 GM-COSY
-x N 2 0 4 8 -y N 7 6 8 \
-XT 1 0 2 4 -y T 3 8 4 \
-xMODE C o m p lex -yMODE C o m p lex \
-xSW 8 0 0 0 . 0 0 0 -ySW 8 0 0 0 . 0 0 0 \
-xO BS 5 9 9 . 9 2 4 -yO BS 5 9 9 . 9 2 4 \
-xCAR 4 . 7 3 0 -yCAR 4 . 7 3 0 \
-xLAB HI -yLAB H2 \
-n d im 2 -a q 2 D S t a t e s \
11.2 ‘H-H-TOCSY
-XN 2 0 4 8 - y N 7 6 8
-XT 1 0 2 4 - y T 3 8 4
-xMODE C o m p lex -yMODE C o m p lex
-xSW 6 4 9 9 . 8 3 8 -ySW 6 4 9 9 . 8 3 8
-xO BS 5 0 0 . 0 9 0 -yO BS 5 0 0 . 0 9 0
-xCAR 4 . 7 3 0 -yCAR 4 . 7 3 0
-xLAB HI -yLAB H2
-n d im 2 -a q 2 D S t a t e s
2D-TOCSY spectra were acquired with the above parameters and with these 
combinations of mixing times and temperatures:
Mixing Time (ms) Temperature (Celsius)
40 27
50 27
70 10 ,27
80 27
________100________________ 1 0 , 1 4 , 1 9 , 2 3 , 2 7
10.3.1.3 ‘H-1H-NOESY
- x N 2 0 4 8 - y N 7 6 8 \
- x T 1 0 2 4 - y T 3 8 4 \
-xMODE C o m p lex -yMODE C o m p lex \
-xSW 6 4 9 9 . 8 3 8 -ySW 6 4 9 9 . 8 3 8 \
-xO BS 5 0 0 . 0 9 0 -yO BS 5 0 0 . 0 9 0 \
-xCAR 4 . 7 3 0 -yCAR 4 . 7 3 0 \
-xLAB HI -yLAB H2 \
-n d im 2 -a q 2 D S t a t e s \
2D-NOESY spectra were acquired with the above parameters and with these 
combinations of mixing times and temperatures:
Mixing Time (ms) Temperature (Celsius)
50 27
75 27
100 10,19,  27
150 10, 27
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10.3.1.4 lsN-HSQC
- x N 2 4 3 2 - y N 5 6 0
- x T 1 2 1 6 - y T 2 8 0
-xMODE C o m p lex -yMODE C o m p lex
-nSW 8 0 0 0 . 0 0 0 -ySW 2 5 0 0 . 0 0 0
-xO BS 5 9 9 . 8 9 3 -yO BS 6 0 . 7 9 4
-xCAR 4 . 7 3 0 -yCAR 1 1 8 . 0 8 8
-xLAB HN -yLAB N
-n d im 2 -a q 2 D S t a t e s
10.3.1.513C-HSQC
-x N 2 4 0 0 - y N 4 0 0
- x T 1 2 0 0 - y T 2 0 0
-xMODE C o m p lex -yMODE C o m p lex
-xSW 8 0 0 0 . 0 0 0 -ySW 1 0 0 6 0 . 3 6
-xO BS 5 0 0 . 0 8 7 -yO BS 1 2 5 . 7 5 2
-xCAR 4 . 7 3 0 -yCAR 4 0 . 8 1 1
-xLAB HC -yLAB C
-n d im 2 -a q 2 D S t a t e s
10.3.1.6 HCCH-TOCSY
-x N 1 0 2 4 - y N 12 8 - z N 2 8 4
- x T 5 1 2 - y T 64 - z T 14 2
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex
-xSW 8 0 0 0 . 0 0 0 -ySW 1 0 5 5 9 . 6 6 2 -zSW 8 0 0 0 . 0 0 0
-xO BS 5 9 9 . 8 9 1 -yO BS 1 5 0 . 8 4 8 -zO B S 5 9 9 . 8 9 1
-xCAR 4 . 7 3 -yCAR 4 0 . 9 3 1 -zCAR 4 . 7 3
-xLAB HC -yLAB C -zLA B HH
-n d im 3 -a q 2 D S t a t e s
10.3.1.7 H- N-HSQC-TOCSY: 100 ms Mixing Time
-x N 1 0 2 4 - y N
- x T 5 1 2 - y T
-xMODE C o m p lex -yMODE
-xSW 8 0 0 0 . 0 0 0 -ySW
-xO BS 5 0 0 . 0 9 0 -yO BS
-xCAR 4 . 7 3 -yCAR
-xLAB HN -yLAB
-n d im 3 -a q 2 D
16 0 -z N 12 8
80 -z T 64
C o m p lex - zMODE C o m p lex
8 0 0 0 . 0 0 0 -zSW 2 0 2 7 . 1 6 4
5 0 0 . 0 9 0 -zO B S 5 0 . 6 7 9
4 . 7 3 -zCAR 1 1 8 . 0 8 9
HH -zLA B N15
S t a t e s
10.3.1.81H-15N-HSQC-NOESY: 100 ms Mixing Time
-x N 1 0 2 4 - y N 16 8 - z N 1 2 8 \
- x T 51 2 - y T 84 - z T 64 \
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex \
-xSW 8 0 0 0 . 0 0 0 -ySW 8 0 0 0 . 0 0 0 -zSW 2 0 2 7 . 1 6 4 \
-xO BS 5 0 0 . 0 9 0 -yO BS 5 0 0 . 0 9 0 -zO B S 5 0 . 6 7 9 \
-xCAR 4 . 7 3 -yCAR 4 . 7 3 -zCAR 1 1 8 . 0 8 9 \
-xLAB HN -yLAB HH -zLA B N \
-n d im 3 -a q 2 D S t a t e s \
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10.3.1.91H-,sN-HSQC-NOESY: SO ms Mixing Time
-x N 1 0 2 4 - y N 2 0 0 - z N 1 2 8
- x T 512 - y T 10 0 - z T 64
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex
-xSW 8 0 0 0 . 0 0 0 -ySW 8 0 0 0 . 0 0 0 -zSW 2 4 3 1 . 7 5 9
-xO BS 5 9 9 . 8 9 3 -yO BS 5 9 9 . 8 9 3 -zO B S 6 0 . 7 9 4
-xCAR 4 . 7 3 -yCAR 4 . 7 3 -zCAR 1 1 7 . 9 4 1
-xLAB HN -yLAB HH -zLA B N
-n d im 3 -a q 2 D S t a t e s
10.3.1.1013 C-NOESY
-x N 1 0 2 4 - y N 12 8 - z N 152 \
- x T 512 - y T 64 - z T 76 \
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex \
-xSW 8 0 0 0 . 0 0 0 -ySW 1 0 0 6 0 . 3 6 2 -zSW 8 0 0 0 . 0 0 0 \
-xO BS 5 0 0 . 0 8 7 -yO BS 1 2 5 . 7 5 2 -zO B S 5 0 0 . 0 9 0 \
-xCAR 4 . 7 3 -yCAR 4 0 . 8 1 1 -zCAR 4 . 7 3 \
-xLAB HC -yLAB C -zLA B HH \
-n d im 3 -a q 2 D S t a t e s \
.3.1.11 HNCA
-x N 1 0 2 4 - y N 16 4 - z N 1 2 8 \
- x T 512 - y T 82 - z T 64 \
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex \
-xSW 8 0 0 0 . 0 0 0 -ySW 4 5 2 5 . 4 0 0 -zSW 2 4 3 1 . 8 3 2 \
-xO BS 5 9 9 . 8 9 0 -yO BS 1 5 0 . 8 5 1 -zO B S 6 0 . 7 9 4 \
-xCAR 4 . 7 3 0 -yCAR 5 5 . 9 3 9 -zCAR 1 1 7 . 9 3 9 \
-xLAB H -yLAB C -zLA B N \
-n d im 3 -a q 2 D S t a t e s \
.3.1.12 HNCOCA
-x N 1 0 2 4 - y N 2 2 0 -ZN 64 \
- x T 51 2 - y T 1 1 0 - z T 32 \
-xMODE C o m p lex -yMODE C o m p lex -zMODE C o m p lex \
-xSW 8 0 0 0 . 0 0 0 -ySW 4 5 2 6 . 1 6 7 -zSW 1 9 4 5 . 3 8 3 \
-xO BS 5 9 9 . 8 9 0 -yO BS 1 5 0 . 8 5 1 -zO B S 6 0 . 7 9 4 \
-xCAR 4 . 7 3 0 -yCAR 5 5 . 9 3 9 -zCAR 1 1 7 . 9 3 9 \
-xLAB H -yLAB C -zLA B N \
-n d im 3 -a q 2 D S t a t e s \
10.3.1.13 CBCANH
-x N 1 0 2 4 - y N 80 - z N 1 2 0 \
- x T 512 - y T 40 - z T 60 \
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex \
-xSW 8 0 0 0 . 0 0 0 -ySW 1 9 4 5 . 5 2 5 -zSW 9 9 5 7 . 6 8 0 \
-xO BS 5 9 9 . 9 2 4 -yO BS 6 0 . 7 9 7 -ZOBS 1 5 0 . 8 5 6 \
-xCAR 4 . 7 3 0 -yCAR 1 1 8 . 0 6 7 -zCAR 4 5 . 8 7 4 \
-xLAB H -yLAB N -zLA B C \
-n d im 3 -a q 2 D S t a t e s \
156
Chapter 10: Appendix
10.3.1.14 CBCACONH
-x N 1 0 2 4 - y N 80 - z N 1 2 0
- x T 5 1 2 - y T 40 - z T 60
-xMODE C o m p lex -yMODE C o m p lex -zMODE C o m p lex
-xSW 8 0 0 0 . 0 0 0 -ySW 1 9 4 5 . 5 2 5 -zSW 9 9 5 7 . 6 8 0
-xO BS 5 9 9 . 9 2 4 -yO BS 6 0 . 7 9 7 -zO B S 1 5 0 . 8 5 6
-xCAR 4 . 7 3 0 -yCAR 1 1 8 . 0 6 7 -zCAR 4 5 . 8 7 4
-xLAB H -yLAB N -zLA B C
-n d im 3 -a q 2 D S t a t e s
10.3.1.15 HNCO
-x N 1 0 2 4 - y N 1 6 8 - z N 96
- x T 512 - y T 84 - z T 48
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex
-xSW 8 0 0 0 . 0 0 0 -ySW 2 1 1 2 . 2 6 7 -zSW 1 9 4 5 . 5 2 5
-xO BS 5 9 9 . 9 2 1 -yO BS 1 5 0 . 8 5 0 -zO B S 6 0 . 7 8 9
-xCAR 4 . 7 3 0 -yCAR 1 7 6 . 9 0 4 -zCAR 1 1 6 . 0 7 3
-xLAB HN -yLAB CO -zLA B N
-n d im 3 -a q 2 D S t a t e s
10.3.1.16 HNHA
-x N 1 0 2 4 - y N 2 4 4 - z N 84
- x T 5 1 2 - y T 122 - z T 42
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex
-xSW 8 0 0 0 . 0 0 0 -ySW 8 0 0 0 . 0 0 0 -zSW 2 4 3 1 . 6 8 5
-xO BS 5 9 9 . 8 9 3 -yO BS 5 9 9 . 8 9 3 -zO B S 6 0 . 7 9 4
-xCAR 4 . 7 3 0 -yCAR 4 . 7 3 0 -zCAR 1 1 8 . 0 8 9
-xLAB HN -yLAB HI -zL A B N15
-n d im 3 -a q 2 D S t a t e s
10.3.1.17 Hbond (Modified HNCO)
-x N 2 1 3 4 - y N 19 2 \
- x T 1 0 6 7 - y T 96 \
-xMODE C o m p lex -yMODE C o m p lex \
-xSW 1 0 6 6 6 . 6 7 -ySW 2 8 1 7 . 0 0 1 \
-xO BS 8 0 0 . 3 2 1 -yO BS 2 0 1 . 2 7 5 \
-xCAR 4 . 7 1 6 -yCAR 1 7 6 . 9 9 6 \
-xLAB HI -yLAB C13 \
-n d im 2 -a q 2 D S t a t e s \
10.3.1.18 Jmod 'H-lsN-HSQC (aligned in PEG)
-x N 3 6 0 0 - y N 12 - z N 2 2 0 \
- x T 1 8 0 0 - y T 12 - z T 1 1 0 \
-xMODE C o m p lex -yMODE R e a l - zMODE C o m p lex \
-xSW 1 1 9 9 9 . 4 0 0 -ySW 1 2 . 0 0 0 -zSW 3 2 4 4 . 1 2 0 \
-xO BS 8 0 0 . 3 0 4 -yO BS 1 . 0 0 0 -zO B S 8 1 . 1 0 3 \
-xCAR 4 . 7 5 4 -yCAR 0 . 0 0 0 -zCAR 1 1 8 . 0 3 0 \
-xLAB HN -yLAB t l -zL A B N \
-n d im 3 -a q 2 D S t a t e s \
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10.3.1.19 Jmod 'H-,sN-HSQC (no alignment)
-x N 3 3 6 0 - y N 12 - z N 2 0 0  \
- x T 1 6 8 0 - y T 12 - z T 1 0 0  \
-xMODE C o m p lex -yMODE R e a l - zMODE C o m p lex  \
-xSW 1 1 9 9 9 . 4 0 0 -ySW 1 2 . 0 0 0 -zSW 3 2 4 4 . 1 2 0  \
-xO BS 8 0 0 . 3 0 4 -yO BS 1 . 0 0 0 -zO B S 8 1 . 1 0 3  \
-xCAR 4 . 7 5 4 -yCAR 0 . 0 0 0 -zCAR 1 1 8 . 0 3 0  \
-xLAB HN -yLAB t l -zL A B N \
-n d im 3 -a q 2 D S t a t e s
10.3.1.1.20 T1/T2/NOE Relaxation
-x N 2 0 4 8 - y N 14 - z N 2 5 6  \
- x T 1 0 2 4 - y T 14 - z T 1 2 8  \
-xMODE C o m p lex -yMODE R e a l - zMODE C o m p lex  \
-xSW 8 0 0 0 . 0 0 0 -ySW 1 4 . 0 0 0 -zSW 2 0 0 0 . 0 0 0  \
-xO BS 5 9 9 . 8 9 3 -yO BS 1 . 0 0 0 -zO B S 6 0 . 7 9 3  \
-xCAR 4 . 7 5 4 -yCAR 0 . 0 0 0 -zCAR 1 1 8 . 2 8 2  \
-xLAB HI -yLAB t l -zL A B N 15 \
-n d im 3 -a q 2 D S t a t e s
T1 (ms)________________________ T2 (ms)
8.62 8.59
48.74 17.18
96.87 25.78
145.01 34.37
193.15 42.96
249.31 51.55
297.44 60.14
393.72 68.74
498.01 85.92
746.72 103.10
995.43 120.29
1244.13 146.06
1492.84 42.96
249.31
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The following graphs show ZASP-PDZ Tl (A), T2 (B), and NOE (C) relaxation 
results at 27 °C, 600 MHz. Residues with a backbone amide NOE relaxation of less than 
0.7 were excluded from ‘ordered’ RMSD calculations, as they were deemed too flexible.
A
T1 Relaxation: ZASP-PDZ @ 600 MHz
5a  600  
<
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85
Residue Number
B
T2 R elaxation: ZASP-PDZ @ 600  MHz
15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85
Residue Number
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c
ZASP-PDZ NOE @ 600
0.8
0.6
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0.2
0.0
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10.3.2 Act-EF34 Spectra
10.3.2.1 ISN-HSQC
-x N 1 6 0 0 - y N 2 5 6
- x T 8 0 0 - y T 1 2 8
-xMODE C o m p lex -yMODE C o m p lex
-xSW 8 0 0 0 . 0 0 0 -ySW 2 0 4 8 . 0 2 6
-xO BS 5 9 9 . 9 2 4 -yO BS 6 0 . 7 9 7
-xCAR 4 . 7 5 4 -yCAR 1 1 8 . 0 8 9
-xLAB HI -yLAB N15
-n d im 2 -a q 2 D S t a t e s
.3.2.2 UC-HSQC
-x N 2 4 3 2 - y N 1 0 2 4
- x T 1 2 1 6 - y T 5 1 2
-xMODE C o m p lex -yMODE C o m p lex
-xSW 8 0 0 0 . 0 0 0 -ySW 2 1 1 1 9 . 3 2 4
-xO BS 5 9 9 . 9 2 4 -yO BS 1 5 0 . 8 6 0
-xCAR 4 . 7 5 4 -yCAR 6 8 . 8 1 8
-xLAB HI -yLAB C13
-n d im 2 -a q 2 D S t a t e s
10.3.2.31H-'sN-NOES¥-HSQC: 80 ms Mixing Time
-x N 1 9 2 0 - y N 2 5 6 - z N 48
- x T 9 6 0 - y T 1 2 8 - z T 24
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex
-xSW 6 4 9 9 . 8 3 8 -ySW 6 4 9 9 . 8 3 8 -zSW 1 2 5 0
-xO BS 5 9 9 . 9 2 4 -yO BS 5 9 9 . 9 2 4 -zO B S 6 0 . 7 9 7
-xCAR 4 . 7 3 0 -yCAR 4 . 7 3 0 -zCAR 1 1 8 . 9 0 9
-xLAB HN -yLAB HI -zLA B N
-n d im 3 -a q 2 D S t a t e s
10.3.2.4 'H-'5N-TOCSY-HSQC: SO ms Mixing Time
-x N 1 9 2 0 - y N 2 4 0 - z N 56 \
- x T 96 0 - y T 12 0 - z T 28 \
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex \
-xSW 6 4 9 9 . 8 3 8 -ySW 6 4 9 9 . 8 3 8 -zSW 1 4 0 0 \
-xO BS 5 9 9 . 9 2 4 -yO BS 5 9 9 . 9 2 4 -zO B S 6 0 . 7 9 7 \
-xCAR 4 . 7 3 0 -yCAR 4 . 7 3 0 -zCAR 1 1 8 . 2 4 3 \
-xLAB HN -yLAB HH -zLA B N \
-n d im 3 -a q 2 D S t a t e s \
10.3.2.5 CBCANH
-x N 1 0 2 4 - y N 48 - z N 1 2 0 \
- x T 51 2 - y T 24 - z T 60 \
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex \
-xSW 6 8 0 0 . 4 0 8 -ySW 1 4 0 0 . 0 2 1 -zSW 1 0 0 0 0 . 0 0 \
-xO BS 5 9 9 . 9 2 4 -yO BS 1 5 0 . 8 5 6 -zO B S 6 0 . 7 9 7 \
-xCAR 4 . 7 5 4 -yCAR 4 1 . 2 6 1 -zCAR 1 1 8 . 4 3 9 \
-xLAB HI -yLAB C13 -zLA B N15 \
-n d im 3 -a q 2 D S t a t e s \
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10.3.2.6 CBCACONH
-x N 1 0 2 4 - y N 50 - z N 1 2 0
- x T 5 1 2 - y T 25 - z T 60
-xMODE C o m p lex -yMODE C o m p lex -zMODE C o m p lex
-xSW 6 8 0 0 . 4 0 8 -ySW 1 4 0 0 . 0 2 1 -zSW 1 0 0 0 0 . 0 0
-xO BS 5 9 9 . 9 2 4 -yO BS 1 5 0 . 8 5 6 -zO B S 6 0 . 7 9 7
-xCAR 4 . 7 5 4 -yCAR 4 1 . 2 6 1 -zCAR 1 1 8 . 4 3 9
-xLAB HI -yLAB C13 -zLA B N15
-n d im 3 -a q 2 D S t a t e s
10.3.2.7 HNHA
-x N 1 6 0 0 - y N 192 - z N 48 \
- x T 8 0 0 0 - y T 96 - z T 24 \
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex \
-xSW 5 4 9 9 . 7 9 4 -ySW 2 7 4 9 . 8 9 7 -zSW 1 2 0 0 . 0 1 2 \
-xO BS 5 0 0 . 1 0 3 -yO BS 5 0 0 . 1 0 3 -zO B S 5 0 . 6 8 1 \
-xCAR 4 . 7 5 4 -yCAR 4 . 7 5 4 -zCAR 1 1 8 . 4 1 7 \
-xLAB HN -yLAB HI -zLA B N15 \
-n d im 3 -a q 2 D S t a t e s \
.3.2.8 HNHB
-x N 1 6 0 0 - y N 192 - z N 48
- x T 8 0 0 0 - y T 96 - z T 24
-xMODE C o m p lex -yMODE C o m p lex - zMODE C o m p lex
-xSW 5 4 9 9 . 7 9 4 -ySW 2 7 4 9 . 8 9 7 -zSW 1 2 0 0 . 0 1 2
-xO BS 5 0 0 . 1 0 3 -yO BS 5 0 0 . 1 0 3 -zO B S 5 0 . 6 8 1
-xCAR 4 . 7 5 4 -yCAR 4 . 7 5 4 -zCAR 1 1 8 . 4 1 7
-xLAB HN -yLAB HI -zLA B N15
-n d im 3 -a q 2 D S t a t e s
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10.3.2.9 T1/T2/NOE Relaxation
-x N 1 9 2 0 - y N 13 - z N  2 5 6  \
- X T 96 0 - y T 13 - z T  1 2 8  \
-xMODE C o m p lex -yMODE R e a l - zMODE C o m p lex  \
-xSW 6 4 9 9 . 8 9 3 -ySW 1 3 . 0 0 0 -zSW 1 4 0 0 . 0 2 1  Y
-xO BS 5 9 9 . 9 2 4 -yO BS 1 . 0 0 0 -zO B S  6 0 . 7 9 7  \
-xCAR 4 . 7 5 4 -yCAR 0 . 0 0 0 -zCAR 1 1 8 . 9 5 3  \
-xLAB HI -yLAB t l -zL A B  N 15 \
-n d im 3 -a q 2 D S t a t e s \
T l (ms) T2 (ms)
1.50 0.00
49.66 8.69
97.82 17.38
145.98 26.06
194.14 34.75
250.33 43.44
298.49 52.13
394.81 60.82
499.16 78.19
747.98 95.57
996.81 121.63
1245.64 147.70
194.14 17.38
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10.4 NMR Spectral Assignment
10.4.1 Assignment of ZASP-PDZ
Chapter 10: Appendix
Res HA HA2 HB HB2 HB3 HG HG1 HG2 HG3 HD1 HD 2 HD3 HN N
M l 4 . 4 5 8 . 5 0 1 2 0 . 1 0
A2 5 . 1 9 1 . 2 6 8 . 0 6 1 2 5 . 5 0
Y3 4 . 8 6 2 . 9 4 2 . 9 4 6 . 7 4 6 . 7 4 8 . 8 3 1 1 9 . 2 0
S 4 5 . 3 5 3 . 6 0 3 . 6 0 8 . 5 0 1 1 5 . 5 0
V5 4 . 4 5 1 . 7 6 0 . 8 4 0 . 8 3 8 . 6 0 1 2 0 . 6 0
T 6 5 . 0 4 3 . 7 9 0 . 8 7 8 . 5 7 1 2 1 . 9 0
L 7 4 . 6 5 1 . 4 3 1 . 4 3 1 . 2 9 0 . 8 0 0 . 7 3 9 . 2 3 1 2 8 . 5 0
T 8 4 . 4 8 4 . 1 0 1 . 3 4 8 . 7 5 1 1 9 . 0 0
G9 3 . 8 2  3 . 5 8 8 . 5 4 1 1 3 . 8 0
P 1 0 4 . 3 4 2 . 2 3 2 . 1 2 1 . 8 4 1 . 7 1 3 . 4 7 3 . 4 3
G i l 2 . 3 2  2 . 2 7 7 . 8 8 1 0 7 . 3 0
P 1 2
W13 4 . 2 0 1 . 9 7 1 . 6 5 7 . 0 2 8 . 0 9 1 1 9 . 4 0
G 1 4 3 . 7 1  3 . 7 1 8 . 2 3 1 0 2 . 7 0
F 1 5 5 . 7 1 3 . 1 5 2 . 6 0 6 . 8 2 6 . 8 2 6 . 9 6 1 1 2 . 3 0
R 1 6 4 . 6 9 1 . 8 6 1 . 6 0 1 . 5 7 1 . 5 7 3 . 1 5 3 . 0 9 8 . 3 2 1 2 0 . 0 0
L 1 7 5 . 4 0 1 . 6 0 1 . 3 2 1 . 6 6 0 . 7 6 0 . 7 6 8 . 7 9 1 2 1 . 5 0
Q 1 8 4 . 6 0 1 . 8 2 1 . 8 2 2 . 1 5 2 . 1 5 9 . 0 2 1 1 9 . 5 0
G 1 9 4 . 5 9  3 . 3 1 8 . 4 1 1 0 8 . 2 0
G 2 0 4 . 8 7  4 . 0 5 7 . 6 1 1 0 4 . 4 0
K 2 1 4 . 1 7 1 . 4 5 1 . 3 8 1 . 2 7 1 . 2 7 1 . 7 3 1 . 5 0 8 . 7 6 1 2 2 . 8 0
D 2 2 4 . 2 4 2 . 6 4 2 . 4 3 1 0 . 7 7 1 1 4 . 2 0
F 2 3 4 . 5 0 3 . 3 7 2 . 6 2 7 . 0 9 7 . 0 9 7 . 8 2 1 1 8 . 1 0
N 2 4 4 . 3 9 3 . 0 6 2 . 7 1 1 4 . 2 4 8 . 0 2 1 1 6 . 3 0
M2 5 5 . 0 0 2 . 0 9 1 . 7 5 2 . 6 3 2 . 6 3 7 . 3 3 1 1 4 . 6 0
P 2 6 4 . 3 6 2 . 2 3 1 . 6 9 1 . 9 3 1 . 8 8 3 . 7 2 3 . 6 2
L 2 7 4 . 8 9 1 . 7 6 1 . 5 6 1 . 4 6 0 . 7 7 0 . 7 6 8 . 3 7 1 2 4 . 5 0
T 2 8 5 . 2 6 3 . 6 8 0 . 9 7 9 . 0 8 1 1 8 . 2 0
1 2 9 4 . 3 3 2 . 1 2 2 . 1 5 0 . 7 6 0 . 2 4 8 . 2 9 1 1 9 . 8 0
S 3 0 4 . 5 0 3 . 7 9 3 . 3 7 9 . 1 9 1 2 6 . 4 0
R 3 1 4 . 3 8 1 . 7 0 1 . 7 0 1 . 4 9 1 . 4 9 3 . 1 1 3 . 1 1 7 . 2 7 1 1 9 . 5 0
1 3 2 4 . 6 7 1 . 6 5 2 . 1 7 0 . 6 9 0 . 5 8 8 . 6 7 1 2 4 . 7 0
T 3 3 4 . 4 0 3 . 9 3 1 . 3 0 9 . 2 6 1 2 8 . 0 0
P 3 4 4 . 3 1 2 . 3 1 1 . 8 7 2 . 1 1 2 . 0 0 4 . 1 9 3 . 7 4
G 3 5 4 . 0 8  3 . 7 2 8 . 8 5 1 1 1 . 4 0
S 3 6 4 . 4 4 3 . 7 8 3 . 7 8 7 . 4 0 1 1 4 . 4 0
K 3 7 4 . 1 2 2 . 1 5 2 . 0 7 1 . 5 9 1 . 5 9 2 . 0 0 2 . 0 0 9 . 0 6 1 2 0 . 5 0
A3  8 3 . 9 8 1 . 4 9 8 . 4 5 1 1 9 . 8 0
A3  9 4 . 1 4 1 . 5 9 7 . 6 4 1 2 1 . 2 0
Q 4 0 4 . 3 4 2 . 2 9 2 . 0 5 2 . 4 5 2 . 3 8 7 . 6 4 1 1 7 . 3 0
S 4 1 4 . 6 9 3 . 9 4 3 . 9 4 7 . 5 5 1 1 5 . 6 0
Q 4 2 4 . 0 3 1 . 9 6 1 . 8 9 2 . 2 0 2 . 1 5 8 . 1 6 1 1 4 . 1 0
L 4 3 4 . 2 8 1 . 3 9 1 . 0 3 1 . 6 8 0 . 5 0 0 . 4 8 7 . 7 4 1 1 9 . 8 0
S 4 4 4 . 6 4 3 . 5 8 3 . 5 8 7 . 1 0 1 1 3 . 4 0
Q 4 5 3 . 5 8 1 . 8 9 1 . 8 9 2 . 2 1 2 . 1 5 8 . 6 7 1 2 4 . 7 0
G 4 6 4 . 3 8  3 . 5 2 9 . 3 0 1 1 5 . 3 0
D 4 7 4 . 6 0 2 . 6 4 2 . 4 5 7 . 5 3 1 2 1 . 5 0
L 4 8 4 . 5 6 1 . 5 6 1 . 5 1 1 . 5 5 0 . 8 2 0 . 8 1 8 . 3 8 1 2 1 . 3 0
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Res HA HA2 HB HB2 HB3 HG HG1 HG2 HG3 HD1 HD2 HD3 HN N
V 4 9 4 . 0 7 1 . 8 0 0 . 6 0 0 . 5 9 8 . 3 8 1 2 3 . 1 0
V 5 0 4 . 0 6 1 . 8 9 0 . 7 5 0 . 6 3 8 . 7 2 1 2 6 . 8 0
A 5 1 5 . 1 2 1 . 0 2 7 . 9 0 1 2 1 . 5 0
1 5 2 4 . 2 6 1 . 2 3 1 . 0 8 0 . 6 5 0 . 6 5 8 . 1 9 1 1 9 . 1 0
D 5 3 4 . 2 1 2 . 9 4 2 . 3 8 9 . 7 1 1 2 9 . 7 0
G 5 4 3 . 9 8 3 . 4 1 8 . 3 4 1 0 1 . 8 0
V 5 5 4 . 0 3 1 . 9 7 0 . 8 7 0 . 8 5 7 . 8 9 1 2 3 . 7 0
N 5 6 4 . 9 4 2 . 9 2 2 . 8 1 1 4 . 4 1 8 . 6 6 1 2 6 . 9 0
T 5 7 4 . 2 2 4 . 5 3 5 . 3 8 1 . 0 3 8 . 1 2 1 1 3 . 0 0
D 5 8 4 . 3 1 2 . 7 3 2 . 7 3 8 . 7 0 1 2 3 . 5 0
T 5 9 4 . 3 3 4 . 3 0 1 . 1 4 7 . 5 9 1 0 6 . 4 0
M6 0 4 . 6 8 2 . 0 7 2 . 0 7 2 . 5 4 2 . 5 4 7 . 7 9 1 2 1 . 9 0
T 6 1 4 . 4 6 4 . 6 7 1 . 2 9 8 . 6 2 1 1 3 . 6 0
H 6 2 4 . 0 5 3 . 6 3 3 . 4 4 1 0 . 3 2 1 2 3 . 3 0
L 6 3 3 . 9 9 1 . 6 4 1 . 6 4  1 . 5 8 0 . 9 2 0 . 9 1 8 . 9 7 1 1 8 . 0 0
E 6 4 3 . 8 9 2 . 2 2 1 . 8 6 2 . 3 0 2 . 3 0 7 . 7 0 1 1 9 . 0 0
A 6 5 4 . 0 3 1 . 2 4 8 . 1 4 1 2 2 . 7 0
Q 6 6 3 . 8 9 2 . 0 3 2 . 0 3 2 . 2 7 2 . 2 7 8 . 2 8 1 1 6 . 5 0
N 6 7 4 . 4 8 2 . 8 8 2 . 7 5 1 4 . 3 2 8 . 7 5 1 1 8 . 8 0
K 6 8 4 . 1 0 1 . 9 6 1 . 9 6 1 . 3 9 1 . 3 9 1 . 6 4 1 . 6 4 8 . 0 8 1 2 3 . 1 0
1 6 9 3 . 7 5 2 . 0 0 2 . 9 2 0 . 9 2 0 . 7 2 7 . 7 4 1 1 8 . 3 0
K 7 0 4 . 1 9 1 . 9 4 1 . 9 4 1 . 5 8 1 . 4 9 1 . 6 7 1 . 6 7 8 . 1 3 1 1 9 . 9 0
S 7 1 4 . 3 4 4 . 0 7 3 . 9 4 7 . 6 8 1 1 2 . 8 0
A 7 2 4 . 4 2 1 . 5 9 7 . 3 4 1 2 6 . 2 0
S 7 3 4 . 4 6 3 . 7 5 3 . 7 5 8 . 6 5 1 1 7 . 8 0
Y 7 4 4 . 3 8 3 . 0 6 3 . 0 6 7 . 1 3 7 . 1 3 8 . 2 9 1 2 0 . 4 0
N 7 5 5 . 1 3 2 . 6 7 2 . 6 4 1 4 . 2 4 8 . 1 6 1 1 6 . 3 0
L 7 6 4 . 5 0 0 . 4 8 0 . 3 4  0 . 9 2 0 . 6 5 0 . 0 6 8 . 2 2 1 2 2 . 3 0
S 7 7 5 . 3 4 3 . 7 3 3 . 7 3 8 . 9 1 1 2 3 . 4 0
L 7 8 4 . 9 6 1 . 4 3 1 . 0 5  1 . 2 3 0 . 6 8 0 . 3 2 8 . 8 7 1 2 5 . 0 0
T 7 9 4 . 6 8 3 . 6 4 1 . 0 0 8 . 3 8 1 1 9 . 0 0
L 8 0 5 . 5 3 1 . 1 9 1 . 1 9  1 . 3 4 0 . 5 1 0 . 5 0 9 . 1 2 1 2 9 . 0 0
Q 8 1 4 . 8 7 1 . 8 2 1 .  8 2 2 . 1 9 2 . 1 9 8 . 6 3 1 1 7 . 1 0
K 8 2 4 . 3 7 1 . 7 8 1 . 7 8 1 . 4 3 1 . 4 3 1 . 5 6 1 . 5 6 8 . 6 6 1 2 3 . 5 0
S 8 3 4 . 3 1 3 . 8 2 3 . 8 2 8 . 4 9 1 1 8 . 1 0
K 8 4 4 . 3 0 1 . 6 9 1 . 6 1 1 . 3 5 1 . 3 5 1 . 7 8 1 . 7 8 8 . 2 3 1 2 3 . 7 0
R 8 5 4 . 1 1 1 . 7 7 1 . 6 3 1 . 5 5 1 . 5 5 3 . 1 4 3 . 1 4 7 . 9 7 1 2 8 . 4 0
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Assignment of ZASP-PDZ continued: Additional Sidechain Chemical Shifts
Res HE HEl HE2 HE3 HH2 HZ HZ2 HZ 3 ND2 NEl NE2
Ml
A2
Y3
S 4
V5
T 6
L 7
T 8
G9
P 1 0
G i l
P 1 2
W13
G 1 4
F 1 5
R 1 6
L 1 7
Q 1 8
G 1 9
G 2 0
K 2 1
D 2 2
F 2 3
N 2 4
M2 5
P 2 6
L 2 7
T 2 8
1 2 9
S 3 0
R 3 1
1 3 2
T 3 3
P 3 4
G 3 5
S 3 6
K 3 7
A3 8
A3 9
Q 4 0
S 4 1
Q4 2
L 4 3
S 4 4
Q 4 5
G 4 6
D 4 7
L 4 8
V 4 9
V 5 0
A 5 1
6 . 2 9  6 . 2 9
1 0 . 0 1 7 . 2 4  6 . 7 1 7 . 2 5  6 . 5 1 1 2 9 . 0 0
6 . 8 0
1 3 . 9 0
2 . 8 9  2 . 8 9
1 1 1 . 7 0
6 . 7 8  6 . 7 8 6 . 8 7
1 1 2 . 6 0
3 . 0 7  3 . 0 0
1 3 . 8 8
1 4 . 0 8
1 4 . 2 6
1 1 1 . 4 0  
1 1 2 . 3 0
1 1 1 . 4 0
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Res HE
~ I5 2
D 5 3
G 5 4
V 5 5
N 5 6
T 5 7
D 5 8
T 5 9
M 60
T 6 1
H 6 2
L 6 3
E 6 4
A 6 5
Q 6 6
N 6 7
K 6 8
1 6 9
K 7 0
S 7 1
A 7 2
S 7 3
Y 7 4
N 7 5
L76
S 7 7
L 7 8
T 7 9
L 8 0
Q 8 1
K 8 2
S 8 3
K 8 4
R 8 5
HE1 HE2 HE3 HH2 HZ HZ2 HZ3 ND2 NE1 NE2
6 . 7 9  6 . 7 9
1 1 2 . 2 0
1 4 . 0 8  
2 . 8 4  2 . 8 4  
2 . 9 2  2 . 9 2
1 1 1 . 4 0
1 1 1 . 1 0
1 1 2 . 7 0
1 4 . 0 2  
3 . 0 7  3 . 0 7
2 . 9 2  2 . 9 2
1 1 0 . 9 0
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Assignment of ZASP-PDZ Continued: l3C Chemical Shifts
Res C CA CB CD CD1 CD2 CE CE1 CG CGI CG2
M l  1 7 4 . 8 0  5 5 . 2 0  3 2 . 7 0
A2 1 7 6 . 9 0  5 0 . 9 0  2 0 . 6 0
Y3 1 7 2 . 2 0  5 6 . 2 0  4 0 . 0 0  3 8 . 1 0
S 4  1 7 3 . 5 0  5 6 . 7 0  6 5 . 5 0
V 5  1 7 4 . 2 0  6 0 . 1 0  3 6 . 2 0  2 1 . 1 0  2 1 . 0 0
T 6  1 7 3 . 8 0  6 1 . 1 0  7 0 . 3 0  2 1 . 3 0
L 7  1 7 5 . 7 0  5 2 . 9 0  4 3 . 1 0
T 8  1 7 5 . 5 0  6 2 . 0 0  6 9 . 3 0  2 1 . 7 0
G9 4 5 . 1 0
P 1 0  1 7 6 . 4 0  6 1 . 9 0  3 4 . 6 0  4 9 . 8 0  2 4 . 3 0
G i l  4 2 . 4 0
P 1 2  1 7 8 . 2 0  6 4 . 3 0  3 7 . 3 0
W13 1 7 6 . 5 0  5 8 . 4 0  3 2 . 5 0
G 1 4  1 7 3 . 2 0  4 5 . 3 0
F 1 5  1 7 3 . 1 0  5 4 . 5 0  4 2 . 1 0
R 1 6  1 7 5 . 2 0  5 3 . 8 0  3 3 . 8 0  4 3 . 0 0  2 7 . 0 0
L 1 7  1 7 6 . 6 0  5 3 . 0 0  4 5 . 5 0  2 4 . 4 0  2 5 . 6 0  2 6 . 4 0
Q 1 8  1 7 3 . 9 0  5 4 . 1 0  3 2 . 4 0  3 3 . 1 0
G 1 9  1 7 2 . 5 0  4 4 . 5 0
G 2 0  1 7 6 . 4 0  4 3 . 2 0
K 2 1  1 7 8 . 7 0  5 9 . 7 0  3 2 . 6 0  2 9 . 2 0  4 1 . 9 0  2 4 . 0 0
D 2 2  1 7 6 . 1 0  5 4 . 0 0  3 6 . 4 0
F 2 3  1 7 4 . 7 0  5 7 . 5 0  4 0 . 4 0
N 2 4  1 7 3 . 6 0  5 4 . 0 0  3 7 . 3 0
M2 5 5 2 . 9 0  3 6 . 6 0  3 1 . 1 0
P 2 6  1 7 5 . 5 0  6 2 . 0 0  3 2 . 1 0  5 0 . 5 0  2 6 . 9 0
L 2 7  1 7 7 . 0 0  5 4 . 8 0  4 2 . 5 0  2 5 . 5 0  2 5 . 5 0  2 7 . 4 0
T 2 8  1 7 4 . 1 0  5 9 . 4 0  7 3 . 2 0  2 1 . 2 0
1 2 9  1 7 6 . 5 0  5 9 . 6 0  3 6 . 0 0  1 1 . 3 0  2 6 . 1 0  1 7 . 9 0
S 3 0  1 7 4 . 6 0  5 8 . 1 0  6 4 . 3 0
R 3 1  1 7 4 . 2 0  5 5 . 7 0  3 3 . 5 0  4 3 . 1 0  2 6 . 8 0
1 3 2  1 7 6 . 1 0  5 9 . 2 0  4 0 . 0 0  1 3 . 7 0  2 8 . 0 0  1 7 . 0 0
T 3 3  6 1 . 0 0  6 9 . 8 0  2 1 . 0 0
P 3 4  1 7 7 . 5 0  6 3 . 8 0  3 1 . 6 0  5 1 . 6 0  2 7 . 6 0
G 3 5  1 7 3 . 4 0  4 5 . 4 0
S 3 6  1 7 5 . 2 0  5 7 . 4 0  6 6 . 8 0
K 3 7  1 8 0 . 1 0  6 0 . 0 0  3 2 . 5 0  2 9 . 1 0  4 2 . 4 0  2 6 . 5 0
A3 8 1 7 9 . 3 0  5 4 . 8 0  1 9 . 2 0
A3 9 1 7 9 . 3 0  5 4 . 0 0  1 8 . 1 0
Q 4 0  1 7 5 . 9 0  5 5 . 9 0  2 8 . 5 0  3 3 . 8 0
S 4 1  1 7 2 . 8 0  5 8 . 1 0  6 5 . 9 0
Q 4 2  1 7 5 . 1 0  5 6 . 0 0  2 7 . 9 0  3 4 . 2 0
L 4 3  1 7 5 . 9 0  5 6 . 1 0  4 3 . 1 0  2 5 . 0 0  2 5 . 0 0  2 7 . 2 0
S 4 4  1 7 3 . 3 0  5 6 . 4 0  6 4 . 9 0
Q 4 5  1 7 6 . 3 0  5 7 . 8 0  2 7 . 9 0  3 3 . 8 0
G 4 6  1 7 3 . 9 0  4 4 . 3 0
D 4 7  1 7 4 . 8 0  5 5 . 4 0  4 0 . 4 0
L 4 8  1 7 6 . 6 0  5 4 . 6 0  4 2 . 5 0  2 4 . 9 0  2 4 . 6 0  2 8 . 0 0
V 4 9  1 7 5 . 4 0  6 1 . 5 0  3 0 . 6 0  2 2 . 4 0  2 0 . 9 0
V 5 0  1 7 6 . 5 0  6 2 . 8 0  3 2 . 3 0  2 1 . 1 0  2 0 . 1 0
A 5 1  1 7 5 . 3 0  5 2 . 2 0  2 1 . 4 0
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Res C CA CB CD CD1 CD2 CE CE1 CG CGI CG2
1 5 2 1 7 5 . 2 0 6 0 . 0 0 4 1 . 2 0 1 4 . 0 0 2 6 . 6 0 1 8 . 0 0
D 5 3 1 7 6 . 2 0 5 5 . 4 0 3 9 . 7 0
G 5 4 1 7 3 . 9 0 4 4 . 8 0
V 5 5 1 7 5 . 2 0 6 1 . 6 0 3 2 . 1 0 2 1 . 1 0 2 1 . 1 0
N 5 6 1 7 7 . 3 0 5 3  . 8 0 3 8 . 5 0
T 5 7 1 7 6 . 9 0 6 1 . 5 0 6 9 . 3 0 2 1 . 9 0
D 5 8 1 7 7 . 1 0 5 7 . 0 0 3 9 . 6 0
T 5 9 1 7 4 . 7 0 6 0 . 8 0 6 9 . 0 0 2 1 . 2 0
M60 1 7 7 . 8 0 5 6 . 3 0 3 4 . 0 0 3 3 . 4 0
T 6 1 1 7 4 . 5 0 6 1 . 1 0 7 1 . 0 0 2 2 . 3 0
H 6 2 1 7 7 . 5 0 6 1 . 5 0 2 9 . 3 0
L 6 3 1 7 8 . 9 0 5 7 . 5 0 4 1 . 9 0 2 3 . 7 0 2 4 . 8 0 2 6 . 8 0
E 6 4 1 7 9 . 8 0 5 9 . 2 0 2 9 . 5 0 3 7 . 1 0
A 6 5 1 7 9 . 2 0 5 5 . 2 0 1 8 . 9 0
Q 6 6 1 7 9 . 7 0 5 8 . 5 0 2 8 . 4 0 3 3  . 1 0
N 6 7 1 7 8 . 2 0 5 5 . 1 0 3 7 . 2 0
K 6 8 1 7 9 . 3 0 5 8 . 1 0 3 1 . 3 0 2 8 . 2 0 4 1 . 9 0 2 4 . 6 0
1 6 9 1 7 8 . 2 0 6 4 . 1 0 3 7 . 4 0 1 3 . 6 0 2 9 . 0 0 1 7 . 8 0
K 7 0 1 7 7 . 7 0 5 8 . 6 0 3 2 . 4 0 2 9 . 3 0 4 1 . 9 0 2 5 . 2 0
S 7 1 1 7 3 . 7 0 5 9 . 0 0 6 3  . 7 0
A 7 2 1 7 7  . 3 0 5 2 . 7 0 1 9 . 3 0
S 7 3 1 7 4 . 5 0 5 9 . 5 0 6 3  . 7 0
Y 7 4 1 7 5 . 7 0 6 0 . 3 0 3 9 . 1 0 3 8 . 1 0
N 7 5 1 7 2 . 7 0 5 2 . 1 0 4 0 . 6 0
L 7 6 1 7 4 . 3 0 5 4 . 0 0 4 4 . 3 0 2 3 . 2 0 2 5 . 9 0 2 6 . 9 0
S 7 7 1 7 3 . 3 0 5 6 . 8 0 6 3 . 9 0
L 7 8 1 7 5 . 8 0 5 2 . 9 0 4 6 . 6 0 2 4 . 3 0 2 5 . 9 0 2 6 . 6 0
T 7 9 1 7 3 . 1 0 6 2 . 0 0 6 9 . 0 0 2 1 . 6 0
L 8 0 1 7 5 . 5 0 5 3  . 5 0 4 5 . 1 0 2 6 . 6 0 2 6 . 1 0 2 7 . 7 0
Q 8 1 1 7 5 . 3 0 5 4 . 1 0 3 2 . 7 0 3 7 . 1 0
K 8 2 1 7 7 . 0 0 5 5 . 7 0 3 2 . 7 0 3 3 . 5 0 4 3  . 1 0 2 6 . 8 0
S 8 3 1 7 4 . 3 0 5 8 . 2 0 6 3  . 7 0
K 8 4 1 7 5 . 3 0 5 6 . 2 0 3 2  . 9 0 3 3  . 0 0 4 1 . 9 0 2 4 . 4 0
R 8 5 5 7 . 3 0 3 1 . 3 0 4 3 . 3 0 2 6 . 9 0
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10.4.2 Assignment of ZASP-PDZ bound to Act-EF1234
R e s  HA HA2 HB HB2 HB3 H 6 HG1 HG2 HG3 HD1 HD 2 HD 3 HE1 HN N
M l 8 . 5 3  1 1 9 . 8 0
A2 5 . 2 0 1 . 2 4 8 . 0 6  1 2 5 . 1 0
Y3 4 . 8 2 2 . 9 2 2 . 9 2 6 . 7 2 6 . 7 2 8 . 8 4  1 1 8 . 9 0
S4 5 . 3 6 3 . 5 9 3 . 5 9 8 . 5 1  1 1 5 . 2 0
V5 4 . 4 6 1 . 7 7 0 . 8 5 0 . 7 8 8 . 6 5  1 2 0 . 0 0
T6 5 . 0 5 3 . 8 0 0 . 8 5 8 . 5 5  1 2 1 . 3 0
L7 4 . 6 5 1 . 4 1 1 . 4 1 1 . 2 7 0 . 9 1 0 . 6 9 9 . 2 4  1 2 8 . 2 0
T8 4 . 4 9 1 . 3 3 8 . 7 8  1 1 8 . 7 0
G9 3 . 7 8 3 . 6 4 8 . 5 8  1 1 4 . 2 0
P10 4 . 3 4
G i l 2 . 2 0 2 . 0 9 7 . 9 7  1 0 7 . 5 0
W13 9 . 7 6 8 . 1 0  1 1 9 . 3 0
G14 8 . 2 3  1 0 2 . 5 0
F15 6 . 8 7  1 1 2 . 2 0
R16 8 . 4 3  1 1 9 . 9 0
L17 5 . 2 3 8 . 9 6  1 2 5 . 0 0
Q18 1 . 8 4 1 . 8 4 2 . 1 7 2 . 1 7 9 . 2 6  1 2 3 . 2 0
G19 4 . 5 7 3 . 4 0 8 . 4 2  1 0 8 . 3 0
G20 4 . 8 5 4 . 0 0 7 . 7 7  1 0 4 . 5 0
K21 4 . 1 8 1 . 3 6 1 . 3 4 1 . 3 0 1 . 3 0 1 . 6 9 1 . 4 3 8 . 7 9  1 2 2 . 9 0
D22 4 . 1 8 2 . 6 2 2 . 4 1 1 0 . 7 7  1 1 3 . 8 0
F23 4 . 4 3 3 . 4 0 2 . 5 2 7 . 8 4  1 1 7 . 7 0
N24 4 . 3 9 3 . 0 4 2 . 6 9 7 . 9 9  1 1 5 . 9 0
M2 5 4 . 9 6 2 . 1 0 1 . 7 9 2 . 6 1 2 . 6 1 7 . 3 5  1 1 4 . 2 0
P26 4 . 3 8 2 . 22
L27 4 . 8 5 1 . 7 3 1 . 6 7 1 . 5 2 0 . 7 2 0 . 7 0 8 . 3 6  1 2 3 . 5 0
T28 5 . 1 5 3 . 7 0 0 . 8 9 9 . 2 2  1 1 8 . 9 0
129 0 . 7 2 8 . 3 2  1 1 9 . 8 0
S30 4 . 5 4 3 . 8 2 3 . 4 3 9 . 1 5  1 2 5 . 5 0
R31 4 . 4 1 1 . 7 1 1 . 7 1 1 . 5 7 1 . 5 7 7 . 4 2  1 1 9 . 8 0
132 4 . 6 5 0 . 7 0 8 . 6 8  1 2 4 . 6 0
T33 4 . 3 4 3 . 9 1 1 . 2 6 9 . 1 9  1 2 7 . 9 0
G35 4 . 0 4 3 . 7 1 8 . 8 6  1 1 1 . 0 0
S36 4 . 4 4 3 . 7 5 3 . 7 5 7 . 4 1  1 1 4 . 4 0
K37 4 . 1 0 2 . 2 4 2 . 1 8 1 . 6 2 1 . 6 2 2 . 0 3 2 . 0 3 9 . 0 2  1 2 0 . 4 0
A3 8 8 . 4 8  1 1 9 . 8 0
A3 9 4 . 1 4 1 . 5 9 7 . 7 8  1 2 1 . 0 0
Q40 4 . 2 9 2 . 3 3 2 . 0 2 2 . 4 4 2 . 3 6 7 . 6 3  1 1 7 . 0 0
S41 4 . 6 9 3 . 9 1 3 . 9 1 7 . 5 9  1 1 5 . 4 0
Q42 3 . 9 8 1 . 9 6 1 . 8 9 2 . 1 7 2 . 1 3 8 . 1 8  1 1 3 . 8 0
L43 4 . 2 3 1 . 3 8 1 . 0 6 1 . 6 4 0 . 4 9 0 . 4 7 7 . 7 9  1 1 9 . 8 0
S44 4 . 6 5 3 . 5 8 3 . 5 8 7 . 1 6  1 1 3 . 6 0
Q45 1 . 9 0 1 . 9 0 2 . 2 3 2 . 1 0 8 . 6 9  1 2 4 . 5 0
G46 4 . 3 4 3 . 5 3 9 . 4 3  1 1 5 . 4 0
D47 4 . 6 0 2 . 6 3 2 . 4 3 7 . 5 3  1 2 1 . 4 0
L48 4 . 6 2 1 . 5 8 1 . 4 8 1 . 5 4 0 . 8 0 0 . 7 4 8 . 4 3  1 2 0 . 5 0
V49 4 . 0 5 1 . 8 1 0 . 5 5 0 . 5 1 8 . 3 2  1 2 2 . 3 0
V50 4 . 0 6 1 . 9 5 0 . 6 5 0 . 6 0 8 . 7 1  1 2 6 . 0 0
A51 5 . 1 1 1 . 0 0 7 . 9 3  1 2 1 . 4 0
152 4 . 2 3 1 . 2 0 1 . 0 6 0 . 6 6 0 . 6 9 8 . 2 1  1 1 8 . 9 0
D53 4 . 2 1 2 . 9 4 9 . 6 9  1 2 9 . 5 0
G54 3 . 9 8 3 . 3 9 8 . 3 5  1 0 1 . 5 0
V55 4 . 0 0 1 . 9 6 0 . 8 7 0 . 8 4 7 . 9 1  1 2 3 . 5 0
N56 4 . 9 1 2 . 9 1 2 . 7 9 8 . 6 7  1 2 6 . 6 0
T57 4 . 5 6 4 . 5 2 1 . 0 0 8 . 0 5  1 1 2 . 3 0
D58 4 . 2 8 2 . 7 2 2 . 7 2 8 . 6 9  1 2 3 . 1 0
T59 4 . 3 1 4 . 2 6 1 . 1 4 7 . 6 7  1 0 6 . 1 0
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R e s HA HA2 HB HB2 HB3 HG HG1 HG2 HG3 HD1 HD2 HD3 H E l HN N
M60 4 . 6 7 2 . 0 6 2 . 0 6 2 . 5 4 2 . 5 4 7 . 8 0 1 2 1 . 5 0
T61 4 . 4 5 4 . 6 9 1 . 2 9 8 . 6 2 1 1 3 . 5 0
H62 3 . 9 9 3 . 5 8 3 . 4 4 1 0 . 3 2 1 2 2 . 8 0
L63 3 . 9 5 1 . 6 1 1 . 6 1 1 . 5 6 0 . 8 7 0 . 8 4 9 . 0 3 1 1 7 . 3 0
E64 3 . 9 2 2 . 2 0 1 . 8 7 2 . 3 2 2 . 3 2 7 . 6 9 1 1 8 . 6 0
A65 4 . 0 5 1 . 2 4 8 . 0 6 1 2 2 . 3 0
Q66 3 . 9 4 2 . 0 0 2 . 0 0 8 . 4 9 1 1 7 . 0 0
N67 4 . 3 9 2 . 8 5 2 . 7 1 8 . 6 8  1 1 7 . 4 0
K68 4 . 0 0 1 . 9 4 1 . 9 4 1 . 2 6 1 . 2 6 1 . 4 0 1 . 4 0 8 . 0 8  1 2 2 . 3 0
169 3 . 6 8 1 . 9 2 1 . 0 1 0 . 7 8 7 . 8 3 1 1 8 . 9 0
K70 1 . 8 8 1 . 8 8 1 . 6 3 8 . 1 4 1 1 9 . 8 0
S71 4 . 7 0 4 . 0 3 3 . 9 8 7 . 6 8 1 1 2 . 0 0
A72 4 . 3 8 1 . 6 4 7 . 3 2 1 2 6 . 4 0
S73 4 . 4 0 3 . 7 1 3 . 7 1 8 . 5 9  1 1 7 . 7 0
Y74 3 . 0 3 3 . 0 3 8 . 3 0 1 2 0 . 2 0
N75 5 . 1 4 2 . 6 2 2 . 5 6 8 . 1 7 1 1 6 . 5 0
L76 4 . 5 0 0 . 5 5 0 . 4 9 0 . 8 4 0 . 6 5 8 . 3 4 1 2 1 . 8 0
S77 5 . 3 5 3 . 7 0 3 . 7 0 8 . 8 9 1 2 2 . 9 0
L78 4 . 9 4 1 . 4 3 1 . 0 5 1 . 2 0 0 . 8 0 8 . 8 1 1 2 4 . 8 0
T79 4 . 6 9 3 . 6 3 1 . 0 0 8 . 4 1 1 1 8 . 7 0
L80 5 . 5 4 1 . 1 7 1 . 1 7 1 . 3 5 0 . 5 2 0 . 4 6 9 . 1 4 1 2 8 . 8 0
Q81 4 . 8 6 1 . 8 2 1 . 8 2 8 . 6 6 1 1 7 . 0 0
K82 4 . 3 9 1 . 8 3 1 . 8 3 1 . 5 6 1 . 5 6 1 . 6 9 1 . 6 9 8 . 6 5 1 2 3 . 3 0
S83 4 . 3 6 3 . 8 1 3 . 8 1 8 . 5 2 1 1 7 . 8 0
K84 4 . 2 8 1 . 7 0 1 . 7 0 8 . 2 4 1 2 3 . 4 0
R85 4 . 1 2 1 . 6 5 1 . 6 5 7 . 9 9 1 2 8 . 2 0
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Res CA CB HA HA2 HB HB2 HB3 HB# HG HG# HG1# H G 2# HN N
G - l 4 5 . 0 0
AO 5 2 . 3 9 1 9 . 1 8 4 . 2 8 1 . 3 2 7 . 9 7  1 2 3 . 3 5
Ml 5 5 . 2 6 3 2 . 8 2 4 . 3 7 1 . 9 5 2 . 4 5 8 . 4 4  1 1 9 . 3 3
A2 5 2 . 1 6 1 9 . 2 8 4 . 2 9 1 . 3 3 8 . 3 0  1 2 4 . 7 9
D3 5 4 . 6 1 4 0 . 7 6 4 . 5 4 2 . 6 8 2 . 6 3 8 . 3 2  1 1 9 . 6 1
T4 6 1 . 7 1 6 9 . 3 7 4 . 2 6 3 . 7 5 7 . 8 6  1 1 1 . 7 8
D5 5 4 . 7 5 4 1 . 1 7 4 . 6 3 2 . 6 3 8 . 1 8  1 2 2 . 7 9
T6 6 2 . 1 5 6 9 . 7 3 4 . 2 4 4 . 0 9 8 . 0 6  1 1 3 . 9 1
A7 5 4 . 8 4 1 7 . 9 6 4 . 0 0 1 . 4 0 8 . 4 4  1 2 4 . 3 7
E8 5 9 . 1 3 2 9 . 1 3 3 . 9 9 2 . 0 0 2 . 3 0 8 . 3 3  1 1 6 . 5 3
Q9 5 7 . 9 7 2 8 . 6 3 4 . 0 7 2 . 0 8 2 . 3 4 7 . 8 3  1 1 9 . 4 9
V I 0 6 5 . 5 4 3 0 . 4 4 3 . 5 7 2 . 0 6 0 . 8 7 0 . 8 1  7 . 9 9  1 2 2 . 0 7
111 6 5 . 3 2 3 7 . 5 5 3 . 6 7 1 . 8 9 8 . 2 4  1 2 1 . 0 6
A12 5 4 . 4 9 1 7 . 8 6 4 . 0 4 1 . 4 0 7 . 8 2  1 2 1 . 2 3
S13 6 1 . 0 0 6 2 . 4 2 4 . 1 4 3 . 8 1 3 . 6 9 7 . 7 7  1 1 4 . 0 9
F14 6 0 . 3 7 3 8 . 7 7 4 . 0 4 2 . 6 9 2 . 1 7 7 . 8 7  1 2 2 . 0 5
R15 5 9 . 6 4 2 9 . 7 6 3 . 5 7 8 . 1 7  1 1 9 . 9 9
116 6 3 . 9 1 3 7 . 9 0 3 . 7 9 1 . 8 5 7 . 2 7  1 1 8 . 0 8
L17 57 . 17 4 1 . 7 7 4 . 0 0 1 . 7 8 7 . 6 0  1 2 2 . 6 4
A18 5 1 . 5 5 1 8 . 8 8 4 . 2 2 1 . 3 3 8 . 0 1  1 1 9 . 2 2
S19 5 8 . 8 9 6 1 . 1 1 4 . 0 6 3 . 9 1 8 . 1 1  1 1 6 . 4 1
D20 5 5 . 7 2 4 0 . 0 8 4 . 0 7 2 . 8 4 2 . 7 0 8 . 6 3  1 1 2 . 3 2
K21 3 1 . 6 6 4 . 3 8 2 . 0 5 7 . 3 3  1 1 9 . 0 5
P22 6 3 . 1 2 3 1 . 3 3
Y23 5 4 . 2 5 4 0 . 6 8 4 . 7 9 2 . 8 1 6 . 4 2  1 1 2 . 9 6
124 5 8 . 6 4 43 . 3 4 4 . 9 0 9 . 1 0  1 1 6 . 7 8
L25 5 3 . 1 7 4 3 . 0 4 5 . 0 4 1 . 9 0 1 . 6 3 8 . 9 2  1 2 5 . 0 9
A26 5 6 . 0 7 17 . 45 4 . 3 5 9 . 5 2  1 2 6 . 8 9
E27 5 9 . 1 5 2 9 . 1 1 9 . 2 0  1 1 3 . 9 9
E28 5 8 . 7 6 2 8 . 9 9 3 . 9 7 1 . 8 6 7 . 1 7  1 1 8 . 4 7
L29 5 8 . 1 9 4 2 . 3 0 3 . 9 0 2 . 0 7 7 . 3 4  1 1 8 . 4 9
R30 5 8 . 3 6 3 0 . 8 9 3 . 8 9 1 . 7 0 8 . 1 0  1 1 3 . 9 1
R31 5 8 . 1 8 3 0 . 8 4 4 . 1 5 1 . 9 6 1 . 7 5 1 . 6 0 7 . 4 4  1 1 6 . 9 2
E32 5 6 . 2 5 3 2 . 1 8 4 . 4 6 1 . 6 6 2 . 1 9 7 . 2 4  1 1 4 . 0 9
L33 5 2 . 1 0 42 . 7 1 4 . 9 2 1 . 6 7 1 . 3 3 7 . 7 6  1 1 8 . 8 0
P35 6 5 . 9 8 3 2 . 0 5
D36 5 6 . 8 4 3 9 . 1 9 4 . 3 6 2 . 69 2 . 6 0 8 . 8 9  1 1 6 . 0 0
Q37 5 8 . 2 7 2 9 . 3 1 4 . 2 1 2 . 0 9 7 . 4 4  1 2 1 . 7 5
A3 8 5 6 . 0 1 1 7 . 5 6 1 . 2 8 8 . 8 1  1 2 2 . 2 4
Q39 5 8 . 5 8 2 8 . 3 9 3 . 9 8 2 . 1 7 2 . 0 8 2 . 4 5 8 . 1 0  1 1 5 . 0 9
Y40 6 1 . 0 9 3 8 . 5 9 4 . 0 2 3 . 3 2 7 . 6 3  1 1 9 . 7 1
C41 6 3 . 9 3 2 7 . 6 2 3 . 8 8 3 . 0 5 2 . 4 5 7 . 9 6  1 1 5 . 2 7
142 6 5 . 4 2 3 8 . 2 6 8 . 4 1  1 1 9 . 7 6
K43 5 7 . 6 7 3 2 . 5 0 4 . 0 4 1 . 7 5 7 . 5 2  1 1 5 . 2 2
R44 5 5 . 6 4 3 1 . 4 5 4 . 2 5 1 . 3 1 7 . 1 8  1 1 6 . 0 4
M45 4 . 5 7 1 . 7 9 2 . 5 3 7 . 6 0  1 2 0 . 2 3
P46 6 1 . 1 4 3 2 . 0 7
A47 5 2 . 4 8 1 8 . 3 7 4 . 3 6 1 . 3 2 8 . 4 1  1 2 1 . 3 9
Y48 5 7 . 4 3 3 8 . 8 7 4 . 5 9 2 . 4 2 8 . 3 1  1 2 2 . 1 9
S49 5 6 . 3 5 6 3 . 4 4 8 . 7 1  1 2 4 . 2 9
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Res CA CB HA HA2 HB HB2 HB3 HB# HG HG# HG1# HG 2# HN N
G50 4 . 0 2 3 . 53 5 . 1 9 1 0 7 . 1 0
G52 4 5 . 5 2
S53 5 9 . 3 3 6 2 . 8 4 3 . 7 0 3 . 5 2 7 . 6 1  1 1 1 . 7 1
V54 5 7 . 5 7 3 3 . 1 1 4 . 6 7 2 . 2 2 6 . 3 0  1 1 4 . 5 6
P55 6 3 . 8 8 3 1 . 3 7
G56 4 4 . 6 9 4 . 2 6 3 . 6 7 8 . 6 0  1 1 1 . 9 0
A57 5 3 . 0 4 4 3 . 1 4 4 . 0 2 1 . 0 6 7 . 7 6 1 2 1 . 5 5
L58 5 4 . 1 7 4 3 . 8 3 4 . 3 5 1 . 4 5 9 . 5 2  1 2 6 . 5 3
D59 5 1 . 8 8 4 1 . 0 1 3 . 1 1 9 . 0 6  1 2 1 . 7 3
Y60 5 8 . 4 1 3 7 . 2 2 4 . 2 4 2 . 7 7 2 . 3 4 7 . 0 6  1 2 2 . 5 5
A61 5 4 . 3 7 1 7 . 1 5 4 . 2 0 1 . 3 2 7 . 9 9  1 2 7 . 6 4
A62 5 2 . 2 7 1 8 . 6 7 4 . 3 0 1 . 3 0 7 . 5 0  1 2 1 . 0 3
F63 5 9 . 2 3 4 0 . 6 4 4 . 4 6 3 . 2 3 3 . 1 1 7 . 4 6  1 1 8 . 8 2
S64 5 9 . 3 7 6 3 . 6 4 4 . 2 1 3 . 9 9 3 . 8 1 7 . 8 9  1 1 7 . 7 1
S65 5 9 . 8 6 6 3 . 2 0 4 . 2 1 3 . 9 0 8 . 1 3  1 1 6 . 5 7
A66 52 . 77 1 8 . 5 7 4 . 2 0 1 . 2 8 7 . 7 8 1 2 4 . 0 0
L67 5 5 . 5 9 4 2 . 2 6 4 . 0 6 1 . 2 1 7 . 7 3  1 1 9 . 6 3
Y68 5 7 . 7 9 3 8 . 7 9 4 . 4 9 3 . 0 7 2 . 7 8 7 . 8 6 1 1 8 . 4 7
G69 4 5 . 0 9 3 . 9 5 3 . 8 8 8 . 0 1  1 0 9 . 8 2
E70 5 6 . 3 0 3 0 . 2 4 4 . 2 8 2 . 0 4 1 . 9 0 2 . 2 3 8 . 1 8 1 2 0 . 2 9
S71 5 8 . 1 0 6 4 . 1 7 4 . 4 7 3 . 8 1 8 . 2 8  1 1 6 . 0 7
D72 5 4 . 1 4 4 0 . 8 4 4 . 6 1 2 . 6 9 2 . 5 5 8 . 3 6  1 2 2 . 8 3
L73 4 . 1 6 1 . 5 3 7 . 6 9  1 2 7 . 1 9
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10.5.1 Init.cya
This is read when CYANA starts, setting parameters for the structure calculation, 
such as the name of the protein, violation cut-off limits, restraints, stereo-assignments, 
and hydrogen bonds, etc.
# G e n e r a l  P a r a m e t e r s
n a m e : = z a s p  # p r o t e i n  n a m e
a n g _ c u t = 0 . 4  # A n g l e  c u t - o f f  (A)
c u t _ u p l = 0 . 5  # U p p e r - l i m i t  c u t - o f f  (A)
c u t _ l o l = 0 . 5  # L o w e r - l i m i t  c u t - o f f  (A)
c u t _ a c o = 5 . 0  # A n g l e  c u t - o f f  ( d e g r e e s )
c u t _ v d w = 0 . 5  # v a n  d e r  W a a l s  c u t - o f f  (A)
r m s d r a n g e : =  1 . . 8 5  # D e f a u l t  r e s i d u e  r a n g e  f o r  RMSD
r e a d  l i b  f i l e = l i b / d y a n a - l . 5 / l i b / d y a n a . l i b  # r e a d  l i b r a r y
r e a d  s e q  f i l e = R E S T R A I N T S / $ n a m e . s e q  # r e a d  s e q u e n c e  f i l e
r e a d  p r o t  f i l e = R E S T R A I N T S / $ n a m e . p r o t  # r e a d  p r o t  f i l e
# R e s t r a i n t s  ( NO E ,  d i h e d r a l s )
r e a d  u p l  f i l e = R E S T R A I N T S / z a s p _ 1 5 N n o e s y . u p l  # r e a d  NOE u p p e r  l i m i t s  
r e a d  u p l  f i l e = R E S T R A I N T S / z a s p _ 1 3 c n o e s y . u p l  a p p e n d  
r e a d  a c o  f i l e = R E S T R A I N T S / h n h a . a c o  # r e a d  HNHA a n g l e s
r e a d  a c o  f i l e = R E S T R A I N T S / t a l o s . a c o  # r e a d  T AL OS  a n g l e s
# S t e r e o  a s s i g n m e n t s  ( f r o m  GLOMSA)
2 3  3 0  3 7  6 7  7 6
a t o m s w a p  HA1 4 6 5 4
a t o m s w a p  HB2 1 0 1 7
a t o m s w a p  H G 1 2 3 2 6 9
a t o m s w a p  HD2 3 4 1 0
a t o m s w a p  H E 2 1 1 8 4 5
a t o m s t e r e o  H A l 4 6 5 4
a t o m s t e r e o  HB2 1 0 1 5
a t o m s t e r e o  HG2 4 2 4 5
a t o m s t e r e o  H G 1 2 3 2 6 9
a t o m s t e r e o  QG1 4 9 5 0
a t o m s t e r e o  HD2 3 4 1 0
a t o m s t e r e o  H E 2 1 1 8 4 5
1 6  1 7  2 1  2 3  3 0  3 7  4 8  5 6  6 4  6 7  7 6
d i s t a n c e  m o d i f y  # r e m o v e s  i r r e l e v a n t  c o n s t r a i n t s
# R e s t r a i n t s  f r o m  H - b o n d  e x p e r i m e n t  ( s p e c 8 0 0 )
# C o n f i r m e d  H - b o n d s
h b o n d  a t o m l = H N  r e s i d u e l = 8 0  a t o m 2 = 0  r e s i d u e 2 = 3  
h b o n d  a t o m l = H N  r e s i d u e l = 8 2  a t o m 2 = 0  r e s i d u e 2 = l  
h b o n d  a t o m l = H N  r e s i d u e l = 3  a t o m 2 = 0  r e s i d u e 2 = 8 0  
h b o n d  a t o m l = H N  r e s i d u e l = 5  a t o m 2 = 0  r e s i d u e 2 = 7 8  
h b o n d  a t o m l = H N  r e s i d u e l = 3 3  a t o m 2 = 0  r e s i d u e 2 = 1 4  
h b o n d  a t o m l = H N  r e s i d u e l = 1 8  a t o m 2 = 0  r e s i d u e 2 = 2 8  
h b o n d  a t o m l = H N  r e s i d u e l = 8 1  a t o m 2 = 0  r e s i d u e 2 = 4 8
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10.5.2 Calibration.cya
Command to calibrate volumes/intensities for distance restraints.
r e a d  p e a k s  R E S T R A I N T S / z a s p _ n h s q c _ f i f t y _ v o l u m e s . p e a k s  a s s i g n e d  
i n t e g r a t e d
c a l i b a  d m i n = 2 . 2  d m a x = 6 . 0  b b = 2 . 2 7 E + 0 7
r e a d  p e a k s  R E S T R A I N T S / z a s p _ l 3 c n o e _ v o l u m e s . p e a k s  a s s i g n e d  i n t e g r a t e d  
c a l i b a  d m i n = 2 . 2  d m a x = 6 . 0  b b = 2 . 6 5 E + 0 7
d i s t a n c e  u n i q u e  
w r i t e  u p l  z a s p . u p l
10.5.3 CYCLE.cya
Macro that initiates the ANNEAL_STR.cya RED AC structure calculation. This 
defines 5 rounds of 100 structure calculations.
ANNEAL_STR s t r u c t u r e s = 1 0 0  a n g = P D B / z a s p _ 0 0 1 _  o v w = O V W / z a s p _ 0 0 1  
a c o = O V W / z a s p _ 0 0 1  s t a r t = r a n d o m  s t e p s = 1 0 0 0 0  
r e a d  a c o  O V W / z a s p _ 0 0 1 . a c o
ANNEAL_STR s t r u c t u r e s = 1 0 0  a n g = P D B / z a s p _ 0 0 2 _  o v w = 0 V W / z a s p _ 0 0 2  
a c o = 0 V W / z a s p _ 0 0 2  s t a r t = m e m o r y  s t e p s = 1 0 0 0 0  
r e a d  a c o  O V W / z a s p _ 0 0 2 . a c o
ANNEAL_STR s t r u c t u r e s = 1 0 0  a n g = P D B / z a s p _ 0 0 3 _  o v w = 0 V W / z a s p _ 0 0 3  
a c o = 0 V W / z a s p _ 0 0 3  s t a r t = m e m o r y  s t e p s = 1 0 0 0 0  
r e a d  a c o  O V W / z a s p _ 0 0 3 . a c o
ANNEAL_STR s t r u c t u r e s = 1 0 0  a n g = P D B / z a s p _ 0 0 4 _  o v w = O V W / z a s p _ 0 0 4  
a c o = O V W / z a s p _ 0 0 4  s t a r t = m e m o r y  s t e p s = 1 0 0 0 0  
r e a d  a c o  O V W / z a s p _ 0 0 4 . a c o
ANNEAL_STR s t r u c t u r e s = 1 0 0  a n g = P D B / z a s p _ 0 0 5 _  o v w = O V W / z a s p _ 0 0 5  
a c o = O V W / z a s p _ 0 0 5  s t a r t = m e m o r y  s t e p s = 1 0 0 0 0
s t r u c t u r e  s o r t  
s t r u c t u r e  s e l e c t  1 . . 3 0
w r i t e  c o r  f i l e = z a s p _ 0 0 5 . c o r  a l l  a p p e n d
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10.5.4 RED AC Annealing Protocol (ANNEAL_STR.cya)
U s a g e :  a n n e a l _ s t r  [ s t r u c t u r e s = < n > ]  [ a n g = < f i l e > ]  [ c o r = < f i l e > ]
[ o v w = < f i l e > ]  [ a c o = < f i l e > ]
[ s t a r t = m e m o r y | r a n d o m ] < f i l e > ]  [ s t e p s = < N > ]  [ t h i g h = < T 0 > ]
Calculate n structures using the simulated annealing protocol. The start structures 
are read from disk in angle format [file], copied from the structure memory [memory], or 
randomly generated [random]. The structures are saved to the structure memory and 
optionally written to angle [ang] or coordinates [cor] files. An overview file is written if 
[ovw] is specified. An angle constraint file is written if [aco] is specified:
v a r  i  1 2  j  i s e e d  n s e e d  i n f o  t  d t  
t  = w a l l t i m e
s y n t a x  s t r u c t u r e s = 0 < @ i  a n g = * =  c o r = * =  o v w = * =  a c o = * =  \
s t a r t = * = r a n d o m  s t e p s = @ i = 1 0 0 0 0  t h i g h = @ r = 8 . 0  a p p e n d
a n g s t a t  c l e a r
e c h o  : =  o f f  
i n f o  : =  n o r m a l  
i s e e d = s e e d
d o  j  1  s t r u c t u r e s
i f  ( ' $ s t a r t ' . e q . ' r a n d o m 1 ) t h e n
n s e e d = n i n t ( 1 0 0 0 0 0 0 * r a n d ( i s e e d , j ) )  
r a n d o m  n s e e d
p r i n t  " R a n d o m  s t r u c t u r e  $ j  w i t h  s e e d  $ n s e e d  c r e a t e d . "  
e l s e  i f  ( 1 $ s t a r t 1 . e q . ' m e m o r y ' )  t h e n  
s t r u c t u r e  c o p y  j  0 
e l s e
r e a d  a n g  { $ s t a r t } $ j ( 1 3 . 3 ) . a n g  
e n d  i f
a n n e a l  s t e p s = s t e p s
p r i n t  " S t r u c t u r e  $ j  m i n i m i z e d ,  f  = { $ t f } "  
i f  ( ' $ a n g ' . n e . '  ' )  t h e n
i f  ( a p p e n d )  t h e n
w r i t e  a n g  $ a n g . a n g  a p p e n d  
e l s e
w r i t e  a n g  ( $ a n g } $ j ( 1 3 . 3 ) . a n g  
e n d  i f  
e n d  i f
i f  ( ^ c o r 1 . n e .  ' ' )  w r i t e  c o r  { $ c o r } $ j  ( 1 3  . 3 )  . c o r
a n g s t a t  m a k e  a n g _ c u t = 0 . 4
i f  ( ' $ a c o ' . n e . ' ' )  w r i t e  a c o  $ a c o . a c o  r e d a c
s t r u c t u r e  c o p y  0 j  n a m e = s t r $ j  
e n d  d o
o v e r v i e w  $ o v w . o v w  s t r u c t u r e = $ j  r a n g e = -  h b o n d  v d w  f u l l
i f  ( s t r u c t u r e s . g t . 0 )  t h e n
t = w a l l t i m e - t ;  d t = r e a l ( t ) / s t r u c t u r e s
p r i n t  " $ s t r u c t u r e s  s t r u c t u r e s  f i n i s h e d  i n  $ t  s  ( $ d t  
s / s t r u c t u r e ) . "  
e n d  i f
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10.6.1 Init.cya
This is read when CYANA starts, setting parameters for the structure calculation, 
such as the name of the protein, violation cut-off limits, restraints, stereo-assignments, 
and hydrogen bonds, etc.
n a m e : = z a s p  # p r o t e i n  n a m e ,  u s e d  f o r  o u t p u t  f i l e  n a m e s
r m s d r a n g e : = 1 . . 8 5  # r e s i d u e  r a n g e  f o r  RMSD c a l c u l a t i o n s
n p r o c : = l  #  N u m b e r  o f  C P U s
r e a d  l i b  f i l e = R E S T R A I N T S / c y a n a . l i b  #  r e a d  l i b r a r y -
r e a d  s e q  R E S T R A I N T S / $ n a m e . s e q  # r e a d  p r o t e i n  s e q u e n c e
10.6.2 CANDID.CYA
Script to execute the CANDID automatic assignment.
p e a k s
p r o t
t o l e r a n c e
= z a s p  
= z a s p
= 0 . 0 2 ,  0 . 0 2 ,  0 . 0 5
# n a m e s  o f  p e a k  l i s t s
# n a m e s  o f  p r o t o n  l i s t s
#  c h e m i c a l  s h i f t  t o l e r a n c e s  ( p p m )  ;
#  1 H ( a ) , 1 H ( b ) , 1 3 C / 1 5 N ( a ) , 1 3 C / 1 5 N ( b )
s u b r o u t i n e  ANNEAL 
v a r  n  
. / i n i t
#  s t r u c t u r e  c a l c u l a t i o n
# r e - i n i t i a l i z e
r e a d  u p l  c y c l e $ c y c l e . u p l
# r e a d  u p l  z a s p . u p l  a p p e n d
r e a d  u p l  h b o n d s . u p l  a p p e n d
# r e a d  l o l  h b o n d s . l o l  a p p e n d
r e a d  a c o  t a l o s . a c o
s e e d = 5 6 7 1  
n = 1 0 0
i f  ( d e f ( 1n p r o c ' ) )  n = n i n t ( r e a l ( n ) / n p r o c ) * n p r o c  
c a l c _ a l l  s t r u c t u r e s = n  s t e p s = 1 0 0 0 0
# C A N D I D  N O E  U p p e r  D i s t a n c e  L i m i t s
# DYANA N OE  U p p e r  D i s t a n c e  L i m i t s
# a d d i t i o n a l  u p p e r  d i s t a n c e  l i m i t s
# a d d i t i o n a l  l o w e r  d i s t a n c e  l i m i t s
#  a n g l e  c o n s t r a i n t s
#  r a n d o m  n u m b e r  g e n e r a t o r  s e e d
# n u m b e r  o f  s t a r t  c o n f o r m e r s
# n u m b e r  o f  C P U s
#
o v e r v i e w  c y c l e $ c y c l e  s t r u c t u r e s = 2 0  c o r  
e n d
s t r u c t  c a l c u l a t i o n  
w r i t e  o v w  & c o r
c a n d i d  p e a k s = $ p e a k s  p r o t = $ p r o t  c a l c u l a t i o n = A N N E A L
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10.7 Homology Modelling
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10.8 Titration Data
Tables show the ligand to protein ratios used for the NMR titrations.
10.8.1 Titration of 15N-ZASP-PDZ with Unlabelled Act-EF1234
Data Point Total Vol. (ill) Fin [ZASP] (M) Fin [Actl4] (M) ZASP/ACT
0 520 2.76E-04 0.00E+00 N/A
1 545 2.64E-04 2.66E-05 9.92
2 570 2.52E-04 5.08E-05 4.96
3 620 2.32E-04 9.34E-05 2.48
4 645 2.23E-04 1.12E-04 1.98
5 670 2.14E-04 1.30E-04 1.65
6 695 2.07E-04 1.46E-04 1.42
7 720 2.00E-04 1.61E-04 1.24
8 770 1.87E-04 1.88E-04 0.99
9 820 1.75E-04 2.12E-04 0.83
1 0 870 1.65E-04 2.33E-04 0.71
1 1 920 1.56E-04 2.52E-04 0.62
1 2 1 0 2 0 1.41E-04 2.84E-04 0.50
10.8.2 Titration of ,sN-ZASP-PDZ with Unlabelled Act-EF34
Data Point Total Vol. (ul) Fin [ZASP] (M) Fin [Act34] (M) ZASP/ACT
0 600 3.70E-04 0.00E+00 N/A
1 610 3.64E-04 1.10E-05 33.09
2 625 3.55E-04 2.69E-05 13.24
3 635 3.50E-04 3.70E-05 9.45
4 665 3.34E-04 6.56E-05 5.09
5 700 3.17E-04 9.59E-05 3.31
6 735 3.02E-04 1.23E-04 2.45
7 765 2.90E-04 1.45E-04 2 . 0 1
8 800 2.78E-04 1.68E-04 1.65
9 830 2.68E-04 1.86E-04 1.44
1 0 860 2.58E-04 2.03E-04 1.27
1 1 930 2.39E-04 2.38E-04 1 . 0 0
1 2 990 2.24E-04 2.64E-04 0.85
13 1070 2.08E-04 2.95E-04 0.70
14 1150 1.93E-04 3.11E-04 0.62
15 1260 1.76E-04 3.40E-04 0.52
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10.8.3 Titration of 1SN-Act-EF1234 with Unlabelled ZASP-PDZ
Data Point Total Vol. (ul) Fin [ACT] (M) Fin [ZASP] (M) Act/ZASP
0 575 4.21E-04 0.00E+00 N/A
1 595 4.07E-04 4.47E-05 9.09
2 605 4.00E-04 6.60E-05 6.06
3 615 3.93E-04 8.65E-05 4.55
4 625 3.87E-04 1.06E-04 3.64
5 635 3.81E-04 1.26E-04 3.03
6 655 3.69E-04 1.62E-04 2.27
7 675 3.58E-04 1.97E-04 1.82
8 695 3.48E-04 2.30E-04 1.52
9 715 3.38E-04 2.60E-04 1.30
1 0 735 3.29E-04 2.90E-04 1.14
1 1 755 3.20E-04 3.17E-04 1 . 0 1
1 2 855 2.83E-04 4.36E-04 0.65
13 955 2.53E-04 5.29E-04 0.48
10.8.4 Titration of ,5N-Act-EF34 with Unlabelled ZASP-PDZ
Data Point Total Vol. (Ml) Fin [ACT] (M) Fin [ZASP] (M) Act/ZASP
0 580 6.08E-04 0.00E+00 N/A
1 585 6.03E-04 1.66E-05 36.22
2 590 5.97E-04 3.30E-05 18.11
3 595 5.92E-04 4.91E-05 12.07
4 600 5.88E-04 6.49E-05 9.05
5 605 5.83E-04 8.04E-05 7.24
6 615 5.73E-04 1.11E-04 5.17
7 625 5.64E-04 1.40E-04 4.02
8 635 5.55E-04 1.69E-04 3.29
9 650 5.42E-04 2.10E-04 2.59
1 0 670 5.26E-04 2.61 E-04 2 . 0 1
1 1 690 5.11E-04 3.10E-04 1.65
1 2 720 4.90E-04 3.79E-04 1.29
13 760 4.64E-04 4.61 E-04 1 . 0 1
14 820 4.30E-04 5.70E-04 0.75
15 880 4.01 E-04 6.64E-04 0.60
16 940 3.75E-04 7.46E-04 0.50
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10.8.5 Titration of 1 5N-Act-EF34 with Unlabelled tZR7, followed by ZASP-PDZ
Data Point Total Vol (fil) Fin [Act-EF34] 
(M)
Fin [Zr7] (M) Act/Zr7
0 600 5.25E-004 0.00E+000 N/A
1 847 3.72E-004 7.44E-004 0.50
Data Point Total Vol (|il) Fin [Act-EF34] Fin [ZASP] (M) Act/ZASP
m
0 600 3.72E-004 0.00E+000 N/A
1 610 3.66E-004 2.11E-005 17.30
2 620 3.60E-004 4.16E-005 8.65
3 640 3.49E-004 8.06E-005 4.33
4 655 3.41E-004 1.08E-004 3.15
5 675 3.31E-004 1.43E-004 2.31
6 695 3.21E-004 1.76E-004 1.82
7 710 3.14E-004 2.00E-004 1.57
8 730 3.06E-004 2.30E-004 1.33
9 750 2.98E-004 2.58E-004 1.15
1 0 775 2.88E-004 2.91E-004 0.99
1 1 815 2.74E-004 3.40E-004 0.80
1 2 860 2.60E-004 3.90E-004 0.67
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10.9 Perl Scripts
10.9.1 D2X.PL: DYANA To XPLOR Distance Restraint Conversion Script
10.9.1.1 Description
Converts DYANA NOE upper-limit constraints (.upl) files into XPLOR format. 
NOE constraints will be either used as the maximum distance (dmax) or separated into 
NOE classes. NOE distances above the maximum NOE class will be inputted as a very 
weak NOE with dmax corresponding to the distance. The conversion has three distinct 
stages:
• Option to remove of DYANA pseudo-atom correction (generated from ‘distance 
modify): as XPLOR adds its own correction.
• Substitution of DYANA with XPLOR atom nomenclature.
• Conversion of DYANA format into XPLOR format.
10.9.1.2 Usage
The script requires renaming of the input files, and the setting of the options 
referring to pseudoatom correction, and distance method, as described above.
10.9.1.3 Code
# ! / u s r / b i n / p e r l  - w  
# D e f i n e  f i l e s :
$ n a m e
$ d y a n a
$ t e m p
$ t e m p 2
$ x p l o r
= ' z a s p 1 ;
= ' z a s p . u p l '  
= ' z a s p . p s u '  
= ' z a s p . s u b ' 
= ' z a s p . t b l '
#  NAME o f  t h e  p r o t e i n
# DYANA I n p u t
#  P s e u d o a t o m  c o r r e c t i o n  r e m o v a l
# DYANA t o  X P L O R  n o m e n c l a t u r e  c h a n g e
# X P L O R  O u t p u t
#  S e t  m e t h o d ,  a n d  b o u n d r i e s  ( d  = d i s t a n c e ,  $ s t r / m e d / w e a / v w k  = b o u n d s ) :
#  1 .  U p p e r  b o u n d a r y  a l o n e  ( i . e . :  0  0  d  )
#  2 .  S a m e  a s  1 ,  1 . 8  l o w e r  b o u n d  ( i . e . :  d  ( d - 1 . 8 )  0  )
#  3 .  NO E c l a s s  b o u n d r i e s  ( e . g . :  $ s t r l  ( $ s t r - 1 . 8 )  $ s t r 2 - $ s t r l )
#  S e t  D i s t a n c e  m e t h o d  a n d  p s e u d o a t o m  c o r r e c t i o n :
$ m e t h o d  = 
$ p s e u d o  =
’ 2 ' ; 
- y  ;
# S e t  N OE  c l a s s  b o u n d r i e s  i f  m e t h o d  3 i s  s e t :
$ s t r l = ' 2 . 5 ' # S t r o n g
$ s t r 2 = ' 2 . 7 '
$ m e d l = ' 3 . 0 ' # M e d i u m
$ m e d 2 = ' 3 . 3 '
$ w e a l - ' 4 . 0 ' # W e a k
$ w e a 2 - ' 5 . 0 '
$ v w k l - ' 4 . 0 ' # V e r y  W e a k
$ v w k 2 = ' 6 . 0 '
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# A)  DYANA P s e u d o a t o m  C o r r e c t i o n  r e m o v a l
o p e n  ( I N ,  $ d y a n a )  o r  d i e  " c a n n o t  o p e n  $ d y a n a  f o r  r e a d  : $ ! " ;
o p e n  ( T E M P ,  " >  $ t e m p " )  o r  d i e  " C a n n o t  o p e n  $ t e m p  f o r  w r i t e
i f  ( $ p s e u d o  e q  ' y ' )  {
# P s e u d o a t o m  c o r r e c t i o n  e x e c u t e d
w h i l e  ( $ l i n e  = < I N > )  {
( $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ d i s t )  = $ l i n e = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? \  
. \ d + ? ) \ s / ;
# F i r s t  P s e u d o a t o m  C o r r e c t i o n :
i f
e l s i f
i f
e l s e
e l s i f
i f
e l s e
i f  ( $ a a  
$ d i s t  -  0 . 8 8 ;  }
e l s i f  ( $ a a l  n e  
$ d i s t  -  1 . 0 3 ;  } 
e l s e
$ d i s t  -  2 . 1 3 ;  }}
e l s i f  ( $ a t l  e q  ' Q R ' )  
e l s e
e q ' Q A '  ) { ii
T—1
P</> $ d i s t  - 0 . 8 0 ; > )
e q • Q B '  ) {
n e ' A L A ' ) ( $ d l  = $ d i s t  - 0 . 8 8 }
{ $ d l  = $ d i s t  - 1 . 0 3 }}
e q ' Q G '  ) { $ d l  = $ d i s t  - 0 . 8 8 }
e q ' Q G 1 ' ) { $ d l  = $ d i s t  - 1 . 0 3 }
e q ’ QG2 ’ ) { $ d l  = $ d i s t  - 1 . 0 3 }
e q • Q QG' ) { $ d l  = $ d i s t  - 2 . 3 1 }
e q • Q D '  ) {
n e ' T Y R ' a n d  $ a a l n e  ’ P H E ' )  { $ d l  = $ d i s t  - 0 . 8 8 ;
{ $ d l  = $ d i s t  - 2 . 1 3 ;
e q ' Q D 1 ' ) ( $ d l  = $ d i s t  - 1 . 0 3 }
e q ' QD2 ' ) ( $ d l  = $ d i s t  - 1 . 0 3 }
e q ’ Q Q D ' )  { $ d l  = $ d i s t  - 2 . 3 1 }
e q ' Q E '  ) {
n e  ' M E T ’ a n d $ a a l  n e  ' T Y R ' a n d  $ a a l n e  ' P H E ' ) { $ d l
}}
T Y R ’ a n d  $ a a l  n e  ' P H E '
{ $ d l  = $ d i s t  -  2 . 4 8 ;
{ $ d l  = $ d i s t ;
{ $ d l  = 
{ $ d l  =
# S e c o n d  P s e u d o a t o m  C o r r e c t i o n :
i f  ( $ a t 2  e q  ' Q A ' )  
e l s i f  ( $ a t 2  e q  ' Q B ' )  
i f  ( $ a a 2  n e  ' A L A ' )  
e l s e
e l s i f  ( $ a t 2  e q  ' Q G ' )  
e l s i f  ( $ a t 2  e q  ' Q G 1 ' )  
e l s i f  ( $ a t 2  e q  ' Q G 2 ' )  
e l s i f  ( $ a t 2  e q  ' Q Q G ' )  
e l s i f  ( $ a t 2  e q  ' Q D ' )  
i f  ( $ a a 2  n e  
e l s e
e l s i f  ( $ a t 2  e q  1Q D 1 1 ) 
e l s i f  ( $ a t 2  e q  1Q D 2 ' )  
e l s i f  ( $ a t 2  e q  1Q Q D 1 ) 
e l s i f  ( $ a t 2  e q  ' Q E ' )  
i f  ( $ a a 2  n e  
$ d l  -  0 . 8 8 ;  }
e l s i f  ( $ a a 2  n e  
$ d l  -  1 . 0 3 ;  } 
e l s e  
$ d l  -  2 . 1 3 ;  }}
{ $ d 2  = $ d l  -  0 . 8 0 ;  
{
{ $ d 2  = $ d l  -  0 . 8 8
{ $ d 2  = $ d l  -  1 . 0 3
{ $ d 2  = $ d l  -  0 . 8 8
{ $ d 2  = $ d l  -  1 . 0 3
{ $ d 2  = $ d l  -  1 . 0 3
{ $ d 2  = $ d l  -  2 . 3 1
{
}
}}
}
}
}
}
T Y R ' a n d  $ a a 2  n e  ' P H E ' )  { $ d 2
{ $ d 2  
0 3 ;  } 
0 3 ;  }
= $ d l  -  0 . 8 8 ;  }
= $ d l  -  2 . 1 3 ;  }}
{ $ d 2  = $ d l  -  1 
{ $ d 2  = $ d l  -  1 
{ $ d 2  = $ d l -  2 . 3 1 ;  }
{
M E T '  a n d  $ a a 2  n e  ' T Y R '  a n d  $ a a 2  n e  ' P H E ' )  { $ d 2  = 
T Y R ' a n d  $ a a 2  n e  ' P H E ' )  { $ d 2  =
{ $d2 =
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e l s i f  ( $ a t 2  e q  * Q R ’ ) { $ d 2  = $ d l  -  2 . 4 8 ;  } 
e l s e  { $ d 2  = $ d l ;  }
p r i n t f  TEMP " % 3 d  % - 4 s  % - 5 s  % 3 d  % - 4 s  % - 5 s  
% . 2 f \ n " , $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ d 2 ;
}
} e l s e  {
# N o  P s e u d o a t o m  C o r r e c t i o n
w h i l e  ( $ l i n e  = < I N > )  {
( $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ d i s t ) = $ l i n e = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? \  
. \ d + ? ) \ s / ;
p r i n t f  TEMP " % 3 d  % - 4 s  % - 5 s  % 3 d  % - 4 s  % - 5 s  
% . 2 f \ n " , $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ d i s t ;
>
}
c l o s e  I N ;  
c l o s e  T E M P ;
# B)  DYANA t o  XP LO R  a t o m  n o m e n c l a t u r e  c o n v e r s i o n
o p e n  ( T E M P ,  $ t e m p )  o r  d i e  " c a n n o t  o p e n  $ t e m p  f o r  r e a d  : $ ! " ;
o p e n  ( T E M P 2 ,  " >  $ t e m p 2 " )  o r  d i e  " C a n n o t  o p e n  $ t e m p 2  f o r  w r i t e
# S u b s t i t u t i o n  M a t r i x  
m y  % s u b  = (
# S u b s t i t u t e
H A l ' = > ' HA2 '
HA2 ' = > ' H A l '
HB3 ’ => ' H B l '
HD3 ' = > ' H D l 1
HE 3 ' = > ■ H E l '
H G 1 3  ' => ' H G 1 1
HG3 ' => 1 H G 1 '
# N o  S u b s t i t u t e
• C ' = > ' C '
• C A ' = > ' C A '
' C B ' = > ' C B '
' C D ' = > ' C D '
1 C D l 1 = > ' C D l '
' CD2  ' = > ' CD2 '
' C E ' = > ' C E '
' C E l ' = > ' C E l  ’
' C E 2  ' => ' C E 2  '
' C E 3  ' = > ' C E 3  '
' C G ' = > ' C G '
' C G I ' = > ' C G I '
1CG2 ' = > ' CG2 '
' CH2 ' = > ' CH2 '
' C Z ' = > ' C Z '
■CZ2 ' = > ' C Z 2  '
' C Z 3  ' = > ' C Z 3  '
' H A ' = > ' H A '
' H B ' = > ' H B '
' H B l ' = > ' H B l '
' HB2 ' = > ’ HB2 '
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' H D 1 ' = > 1 H D l 1
' H D 1 1 ' = > 1 H D l l
' H D 1 2 ' = > 1 HD 12
1H D 1 3 ' = > 1 HD 13
' HD2 ' = > 1 HD2 1
1H D 2 1 ' => 1 H D 2 1
1H D 2 2 ' = > 1 HD 22
1H D 2 3 ' = > 1 HD 23
• H E ’ = > ' H E '
1 H E l ' => ' H E l 1
' HE 2 ' = > 1 HE 2 1
1H E 2 1 ' => 1 H E 2 1
1H E 2 2 ' = > 1 H E 2 2
' H G ' => ' H G '
' H G 1 ' = > 1 H G 1 1
' H G 1 1 ' = > 1 H G 1 1
' H G 1 2 ' = > 1 H G 1 2
1HG2 ' = > 1HG2 1
1H G 2 1 ' = > 1H G 2 1
1H G 2 2 ' = > 1HG 22
' H G 2 3 ' => 1 HG 23
' H H ' = > ' H H '
1H H l l 1 => ■ H H l l
' H H 1 2 ' = > ■HH12
' HH2 ' = > 1 HH2 1
’ H H 2 1 ' = > ■HH21
' H H 2 2 ' = > 1 HH 22
' H N ' = > ' H N '
' H Z ' = > ' H Z '
1 H Z l ' = > ' H Z l 1
' H Z 2 ' = > 1 HZ 2 1
' H Z 3  ' = > 1 H Z 3 1
' N ' = > ■N1
' N D l ' = > ' N D l 1
1 ND2 ' = > 1ND2 1
' N E ' => ' N E '
1 N E l ' => ' N E l 1
' N E 2  ' = > 1N E 2  1
' N H l ' = > ' N H l  1
' NH2 * = > 1NH2 1
' N Z  ' = > ' N Z '
' O ' = > ' O '
1 O D l ' = > ' O D l 1
' OD2 ' = > 1OD2 1
1 O E l ' => ' O E l '
1 OE 2 ' => ' OE2 '
' O G ' = > ' O G '
1O G 1 ' = > ' O G 1 '
' O H ' = > ' O H '
' S D ' = > ' S D '
' S G ' = > ' S G '
. S u b s t i t u t i o n s
' Q A ' = > ' H A #  '
' Q B ' = > ' H B #  '
' Q G 1 = > ' H G #  '
1 Q G 1 1 = > ' H G 1 #
1 QG2 1 = > ' H G 2 #
' Q Q G ' = > ' H G #  '
' Q D 1 => ' H D #  '
1 Q D 1 1 => ' H D l #
1 QD2 1 = > ' H D 2 #
' Q Q D ' => ' H D #  '
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Q E ' = > ' H E #  '
QE 2 ’ = > ' H E 2 #
Q R ' = > ' H D #  '
Q Z ' = > ' H Z #  '
Q H 1 ' = > ' H H l #
QH2 ’ = > ' H H 2 #
) ;
w h i l e  ( $ l i n e  = < T E M P > )  {
( $ r e s l , $ a a l , $ a t l f $ r e s 2 , $ a a 2 , $ a t 2 , $ d i s t )  = $ l i n e = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ?  ( \ w + ? . ) \ s + ? ( \ d + ? \
. \ d + ? ) \ s / ;
# C o r r e c t  A t o m  1
i f  ( $ a t l  e q  ' H B 3 • )  {
i f  ( $ a a l  n e  ' A L A '  ) { $ s a l  = $ s u b { $ a t l } ; }  
e l s e  { $ s a l  = $ a t l ;  }}
e l s i f  ( $ a t l  e q  ' H E 3 ' )  {
i f  ( $ a a l  n e  ' T R P 1 a n d  $ a a l  n e  ' M E T ' )  { $ s a l  = $ s u b { $ a t l } ;  } 
e l s e  { $ s a l  = $ a t l ;  }}
e l s i f  ( $ a t l  e q  ' H G 1 3 ' )  {
i f  ( $ a a l  n e  ' V A L ' )  { $ s a l  = $ s u b { $ a t l } ;  }
e l s e  { $ s a l  = $ a t l ;  }}
e l s e  { $ s a l  = $ s u b { $ a t l } ;  }
# C o r r e c t  A t o m  2
i f  ( $ a t 2  e q  ' H B 3 1 ) {
i f  ( $ a a 2  n e  ' A L A ' )  { $ s a 2  = $ s u b { $ a t 2 } ; }
e l s e  { $ s a 2  = $ a t 2 ; }
} e l s i f  ( $ a t 2  e q  ' H E 3 ' )  {
i f  ( $ a a 2  n e  ' T R P '  a n d  $ a a 2  n e  ' M E T ' )  { $ s a 2  = $ s u b { $ a t 2 } ; }  
e l s e  { $ s a 2  = $ a t 2 ;  }}
e l s i f  ( $ a t 2  e q  ' H G 1 3 ' )  {
i f  ( $ a a 2  n e  ' V A L ' )  { $ s a 2  = $ s u b { $ a t 2 } ; }
e l s e  { $ s a 2  = $ a t 2 ;  }}
e l s e  { $ s a 2  = $ s u b { $ a t 2 } ;  }
# P r i n t  O u t p u t
p r i n t f  T E M P 2 " % 3 d  % - 4 s  % - 5 s  % 3 d  % - 4 s  % - 5 s  
% . 2 f \ n " , $ r e s l , $ a a l , $ s a l , $ r e s 2 , $ a a 2 , $ s a 2 , $ d i s t ;
}
c l o s e  T E M P ;  
c l o s e  T E M P 2 ;
# C)  DYANA t o  XP LO R F o r m a t  c h a n g e
# M e t h o d  1 :  U s e  u p p e r  b o u n d a r y  a l o n e
i f  ( $ m e t h o d  = =  1  ) {
o p e n  ( I N ,  $ t e m p 2 )  o r  d i e  " c a n n o t  o p e n  $ d y a n a  f o r  r e a d
o p e n  ( O U T,  " >  $ x p l o r " )  o r  d i e  " C a n n o t  o p e n  $ x p l o r  f o r  w r i t e
w h i l e  ( $ l i n e  = < I N > )  {
( $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ d i s t )  = $ l i n e = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? \  
. \ d + ? ) \ s / ;
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p r i n t f  OUT " a s s i g n  ( s e g i d  %s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  ( s e g i d  %s
a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  0 0 % . 2 f \ n " ,
$ n a m e , $ r e s l , $ a t l , $ n a m e , $ r e s 2 , $ a t 2 , $ d i s t ;
}
c l o s e  I N ;  
c l o s e  OUT;
}
# M e t h o d  2 :  U s e  u p p e r  b o u n d a r y  w i t h  1 . 8 - a n g s t r o m  l o w e r  b o u n d a r y
i f  ( $ m e t h o d  = =  2 ) {
o p e n  ( I N ,  $ t e m p 2 )  o r  d i e  " c a n n o t  o p e n  $ d y a n a  f o r  r e a d  : $ ! " ;
o p e n  ( OU T,  " >  $ x p l o r " )  o r  d i e  " C a n n o t  o p e n  $ x p l o r  f o r  w r i t e  : $ ! " ;
w h i l e  ( $ l i n e  = < I N > )  {
( $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ d i s t )  = $ l i n e = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? \
. \ d + ? ) \ s / ;
$ d m i n  = $ d i s t  -  1 . 8 ;
p r i n t f  OUT " a s s i g n  ( s e g i d  %s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  ( s e g i d  %s 
a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  % . 2 f  % . 2 f  0 \ n " ,
$ n a m e , $ r e s l , $ a t l , $ n a m e , $ r e s 2 , $ a t 2 , $ d i s t , $ d m i n ;
}
c l o s e  I N ;  
c l o s e  OUT;
}
# M e t h o d  3 :  U s e  NOE c l a s s  b o u n d r i e s  ( u p p e r - l i m i t s  r o u n d e d  u p )
i f  ( $ m e t h o d  = =  3 ) {
o p e n  ( I N ,  $ t e m p 2 )  o r  d i e  " c a n n o t  o p e n  $ d y a n a  f o r  r e a d  : $ ! " ;
o p e n  ( OU T,  " >  $ x p l o r " )  o r  d i e  " C a n n o t  o p e n  $ x p l o r  f o r  w r i t e  : $ ! " ;
w h i l e  ( $ l i n e  = < I N > )  {
( $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ d i s t ) = $ l i n e = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? \
. \ d + ? ) \ s / ;
i f  ( $ d i s t  < =  $ s t r 2 )  {
$ m i d  = $ s t r l ;
$ l o w e r  = $ s t r l - 1 . 8 ;
$ u p p e r  = $ s t r 2 - $ s t r l ;
p r i n t f  OUT " a s s i g n  ( s e g i d  %s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  ( s e g i d
%s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  % . 2 f  % . 2 f  % . 2 f \ n " ,
$ n a m e , $ r e s l , $ a t l , $ n a m e , $ r e s 2 , $ a t 2 , $ m i d , $ l o w e r , $ u p p e r ;
} e l s i f  ( $ d i s t  > $ s t r 2  a n d  $ d i s t  < =  $ m e d 2 )  {
$ m i d  = $ m e d l  ;
$ l o w e r  = $ m e d l - 1 . 8 ;
$ u p p e r  = $ m e d 2 - $ m e d l ;
p r i n t f  OUT " a s s i g n  ( s e g i d  %s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  ( s e g i d  
%s  a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  % . 2 f  % . 2 f  % . 2 f \ n " ,
$ n a m e , $ r e s l , $ a t l , $ n a m e , $ r e s 2 , $ a t 2 , $ m i d , $ l o w e r , $ u p p e r ;
} e l s i f  ( $ d i s t  > $ m e d 2  a n d  $ d i s t  < =  $ w e a 2 )  {
$ m i d  = $ w e a l ;
$ l o w e r  = $ w e a l - 1 . 8 ;
$ u p p e r  = $ w e a 2 - $ w e a l ;
p r i n t f  OUT " a s s i g n  ( s e g i d  %s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  ( s e g i d  
%s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  % . 2 f  % . 2 f  % . 2 f \ n " ,
$ n a m e , $ r e s l , $ a t l , $ n a m e , $ r e s 2 , $ a t 2 , $ m i d , $ l o w e r , $ u p p e r ;
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} e l s i f  ( $ d i s t  > $ w e a 2  a n d  $ d i s t  < =  $ v w k 2 )  {
$ m i d  = $ v w k l ;
$ l o w e r  = $ v w k l - l . 8 ;
$ u p p e r  = $ v w k 2 - $ v w k l ;
p r i n t f  OUT " a s s i g n  ( s e g i d  %s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  ( s e g i d  
%s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  % . 2 f  % . 2 f  % . 2 f \ n " ,
$ n a m e , $ r e s l , $ a t l , $ n a m e , $ r e s 2 , $ a t 2 , $ m i d , $ l o w e r , $ u p p e r ;
} e l s i f  ( $ d i s t  > $ v w k 2 )  {
$ m i d  = $ v w k l ;
$ l o w e r  = $ v w k l - 1 . 8 ;
$ u p p e r  = $ d i s t - $ v w k l ;
p r i n t f  OUT " a s s i g n  ( s e g i d  %s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  ( s e g i d  
%s a n d  r e s i d  % 3 d  a n d  n a m e  % - 4 s )  % . 2 f  % . 2 f  % . 2 f \ n " ,
$ n a m e , $ r e s l , $ a t l , $ n a m e , $ r e s 2 ; $ a t 2 , $ m i d , $ l o w e r , $ u p p e r ;
}
}
c l o s e  I N ;  
c l o s e  O U T;
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10.9.2 TALOS2DYANA.PL: TALOS To DYANA Dihedral Angle Converter
10.9.2.1 Description
This script converts TALOS dihedral angle output to be used in DYANA. All that 
is required the input and output files to be defined. The script only converts TALOS data 
that have a 'Good' rating. Be sure to modify the charge states of the residues if you are 
operating at a non-neutral pH.
10.9.2.2 Code
# ! / u s r / b i n / p e r l  - w
# D e f i n e  I n p u t  a n d  O u t p u t  f i l e s :
$ i n  = ' p r e d . t a b ' ;
$ o u t  = ' t a l o s . a c o 1 ;
o p e n  ( I N , $ i n )  o r  d i e  " C a n n o t  o p e n  $ i n l  f o r  r e a d
o p e n  ( OU T,  " >  $ o u t " )  o r  d i e  " C a n n o t  o p e n  $ o u t  f o r  w r i t e  : $ ! " ;
#  S i n g l e  t o  T h r e e  l e t t e r  r e s i d u e  c o n v e r s i o n :  
m y  % o n e t o t h r e e  = (
' A ' = > ' A L A ' ,
• c = > ' C Y S ' ,
' D ' = > ' A S P - ' ,
' E ’ = > ' G L U - ' ,
• F ' = > ' P H E ' ,
' G ' = > ' G L Y ' ,
' H ' = > ' H I S + ' ,
' I ' = > ' I L E * ,
' K ' = > ' LYS + * ,
' L ' = > ' L E U ' ,
•M' = > ' M E T ' ,
' N ' = > ' A S N ' ,
■ p . = > ' P R O ' ,
' Q ' = > ' G L N ' ,
' R ' = > ' A R G + ’ ,
’ S ' =  > ' S E R ' ,
, T , = > ' T H R ' ,
• V ' = > ' V A L ' ,
•w* = > ' T R P ' ,
' Y ' = > ' T Y R ' ,
) ;
# P r o c e s s i n g  o f  T a l o s  i n p u t :  
w h i l e  ( $ l i n e  = < I N > )  {
( $ i d ,  $ r e s ,  $ p h i ,  $ p s i ,  $ d p h i ,  $ d p s i ,  $ d i s t ,  $ n o ,  $ r a t e )  = $ l i n e  = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? ) \ s + ? ( . \ d + ? \ . \ d + ? ) \ s + ? ( . \ d + ? \ . \ d + ? ) \ s + ? ( \ d + ? \ . \ d + ? ) \ s + ?  
( \ d + ? \ . \ d + ? ) \ s + ? ( \ d + ? \ . \ d + ? ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? ) \ s / ;  
i f  ( $ r a t e  e q  ' G o o d ' )  {
= $ p h i  -  $ d p h i ;
= $ p h i  + $ d p h i ;
= $ p s i  -  $ d p s i ;
= $ p s i  + $ d p s i ;
OUT " $ i d  $ o n e t o t h r e e { $ r e s }  P H I  $ l p h i  $ u p h i \ n " ;
OUT " $ i d  $ o n e t o t h r e e { $ r e s }  P S I  $ l p s i  $ u p s i \ n " ;
$ l p h i
$ u p h i
$ l p s i
$ u p s i
p r i n t
p r i n t
}
}
c l o s e
c l o s e
I N ;
OU T ;
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10.9.3 AC02TBL: DYANA to XPLOR Dihedral Angle Conversion
10.9.3.1 Description
This script converts the dihedral angle constraints from DYANA to be used in 
XPLOR. All that is required is the input and output files to be defined.
10.9.3.2 Code
# ! / u s r / b i n / p e r l
# D e f i n e  I n p u t  a n d  O u t p u t  f i l e s :
$ s e g i d  = ' z a s p ' ;
$ i n  = ' h n h a . a c o ' ;
$ o u t  = ' z a s p _ h n h a . t b l ' ;
# P r o c e s s i n g  o f  T a l o s  i n p u t :
o p e n  ( I N , $ i n )  o r  d i e  " C a n n o t  o p e n  $ i n l  f o r  r e a d  : $ ! " ;
o p e n  ( OU T ,  " >  $ o u t " )  o r  d i e  " C a n n o t  o p e n  $ o u t  f o r  w r i t e  : $ ! " ;
w h i l e  ( $ l i n e  = < I N > )  {
( $ i d , $ r e s , $ t y p e , $ a m i n , $ a m a x )  = $ l i n e  = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( . \ d + ? \ . \ d + ? ) \ s + ? ( . \ d + ? \ . \ d + ? ) \ s / ; 
$ a n g l e  = ( $ a m a x  + $ a m i n ) / 2 ;
$ e r r o r  = ( $ a m a x  -  $ a m i n ) / 2 ;
i f  ( $ t y p e  e q  ' P H I ' )  {
$ i d l  = $ i d  -  1 ;
$ a t l  = ' C ' ;  $ a t 2  = ' N ' ;
$ a t 3  = ' C A ' ;  $ a t 4  = ' C ' ;
p r i n t f  OUT " a s s i g n  ( s e g i d  % 4 s  a n d  r e s i d  % 4 d  a n d  n a m e  % 2 s )  ( s e g i d  % 4 s  
a n d  r e s i d  % 4 d  a n d  n a m e  % 2 s )
( s e g i d  % 4 s  a n d  r e s i d  % 4 d  a n d  n a m e  % 2 s )  ( s e g i d  % 4 s  a n d  r e s i d  % 4 d  
a n d  n a m e  % 2 s )  1 % - 4 . 2 f  % 3 . 2 f  2 \ n \ n " ,
$ s e g i d , $ i d l , $ a t l , $ s e g i d , $ i d , $ a t 2 , $ s e g i d , $ i d , $ a t 3 , $ s e g i d , $ i d , $ a t 4 , 
$ a n g l e , $ e r r o r ;
} e l s i f  ( $ t y p e  e q  ' P S I ' )  {
$ i d l  = $ i d  + 1 ;
$ a t l  = ' N ' ;  $ a t 2  = ' C A ' ;
$ a t 3  = ' C ' ; $ a t 4  = ' N ' ;
p r i n t f  OUT " a s s i g n  ( s e g i d  % 4 s  a n d  r e s i d  % 4 d  a n d  n a m e  % 2 s )  ( s e g i d  % 4 s  
a n d  r e s i d  % 4 d  a n d  n a m e  % 2 s )
( s e g i d  % 4 s  a n d  r e s i d  % 4 d  a n d  n a m e  % 2 s )  ( s e g i d  % 4 s  a n d  r e s i d  % 4 d  
a n d  n a m e  % 2 s )  1 % - 4 . 2 f  % 3 . 2 f  2 \ n \ n " ,
$ s e g i d , $ i d , $ a t l , $ s e g i d , $ i d , $ a t 2 , $ s e g i d , $ i d , $ a t 3 , $ s e g i d , $ i d l , $ a t 4 , 
$ a n g l e , $ e r r o r ;
}
}
c l o s e  I N ;  
c l o s e  O UT;
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10.9.4 COMPARE.PL: Dyana Restraint Comparison Script
10.9.4.1 Description 
This script compares the DYANA different distance constraint files, outputting 
the variations in connectivity, ignoring distance length as a difference. 
10.9.4.2 Code
# ! / u s r / b i n / p e r l  - w
$ i n l  = ' z a s p 1 ; # 1 s t  R e s t r a i n t  F i l e
$ i n 2  = ' z a s p c o m p l e x ' ; # 2 n d  R e s t r a i n t  F i l e
$ o u t  = ' z a s p . u p l ' ;  # D i f f e r e n c e
o p e n  ( I N I ,  $ i n l )  o r  d i e  " C a n n o t  o p e n  $ i n l  f o r  r e a d
o p e n  ( I N 2 ,  $ i n 2 )  o r  d i e  " C a n n o t  o p e n  $ i n 2  f o r  r e a d
o p e n  ( OU T ,  " >  $ o u t " )  o r  d i e  " C a n n o t  o p e n  $ o u t  f o r  w r i t e  : $ ! " ;
w h i l e  ( $ t a b l  = < I N 1 > )  {
( $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ d i s t l )  = $ t a b l = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? \  
. \ d + ? ) \ s / ;
w h i l e  ( $ t a b 2  = < I N 2 > )  {
( $ r e s 3 , $ a a 3 , $ a t 3 , $ r e s 4 , $ a a 4 , $ a t 4 , $ d i s t 2 ) = $ t a b 2 = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? \  
. \ d + ? ) \ s / ;
i f  ( $ r e s l  = =  $ r e s 3  a n d  $ a t l  = =  $ a t 3  a n d  $ r e s 2  = =  $ r e s 4  a n d  $ a t 2  
= =  $ a t 4 )  { l a s t  }
e l s i f  ( $ r e s l  = =  $ r e s 4  a n d  $ a t l  = =  $ a t 4  a n d  $ r e s 2  = =  $ r e s 3  a n d  $ a t 2  
= =  $ a t 3 )  { l a s t  }
e l s e  p r i n t f  OUT " % 3 d  % - 4 s  % - 5 s  % 3 d  % - 4 s  % - 5 s  
% . 2 f \ n " , $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ d i s t ;
}
}
c l o s e I N I ;
c l o s e I N 2 ;
c l o s e OU T;
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10.9.5 DIST_SEARCH.PL: MOLMOL Distance To XEASY Possible Assignment 
Comparison
10.9.5.1 Description
This script searches the MOLMOL distance output deriving from a structure. 
This was intended to aid the ‘possible assignments’ command in XEASY for quick 
evaluation of the presence with connectivity: 
• Calculate possible distances from an NMR ensemble (< 7 Angstroms) from all 
protons in MOLMOL. Write out the output.
• Input the residue-to-residue connectivity as directed by the script. This will 
search the distance file, and give an output if it is present.
10.9.5.2 Code
# ! / u s r / b i n / p e r l
# C a l c D i s t  F i l e :  
w h i l e  ( 1 )  {
# U s e r  I n p u t :
p r i n t  " E n t e r  r e s i d u e  n u m b e r :
$ r e f l  = < S T D I N > ;  c h o p  $ r e f l ;  
p r i n t  " E n t e r  a t o m  t y p e :
$ a t o m  = < S T D I N > ;  c h o p  $ a t o m ;
$q = 'n ';
w h i l e  ( $ q  e q  ' n ' )  {
$ i n  = ' C a l c D i s t . t x t ' ;
o p e n  ( I N , $ i n )  o r  d i e  " C a n n o t  o p e n  $ i n  f o r  r e a d  : $ ! " ;  
p r i n t  " E n t e r  r e s i d u e  n u m b e r :  " ;
$ r e f 2  = < S T D I N > ;  c h o p  $ r e f 2 ;  
i f  ( $ r e f l  < $ r e f 2 )  { 
w h i l e  ( $ l i n e  = < I N > )  {
( $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ f r e q )  = $ l i n e  = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? )  
\ s / ;
i f  ( $ r e f l  = =  $ r e s l  a n d  $ a t o m  e q  $ a t l  a n d  $ r e f 2  = =  $ r e s 2 )  { 
p r i n t  " $ l i n e " ;
}
}
} e l s i f  ( $ r e f 1 > $ r e f 2 )  { 
w h i l e  ( $ l i n e  = < I N > )  {
( $ r e s l , $ a a l , $ a t l , $ r e s 2 , $ a a 2 , $ a t 2 , $ f r e q )  = $ l i n e  = ~
/ ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? ) \ s + ? ( \ w + ? . ) \ s + ? ( \ w + ? . ) \ s + ? ( \ d + ? )  
\ s / ;
i f  ( $ r e f l  = =  $ r e s 2  a n d  $ a t o m  e q  $ a t 2  a n d  $ r e f 2  = =  $ r e s l )  { 
p r i n t  " $ l i n e " ;
}
}
}
p r i n t  " A s s i g n m e n t  F o u n d ?  ( y / n ) :
$ q  = < S T D I N > ;  c h o p  $ q ;  
c l o s e  I N ;
}}
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10.9.6 COMBINE.PL: XEASY Atom List Combiner
10.9.6.1 Description
This script combines atom lists generated from XEASY (prot files). Data is 
combined when there is an assignment in ‘table 2’, which is not present in ‘table 1*. The 
output can then be used again with another XEASY atom list. All that is required is that 
the input and output files are defined. (Suggested order of input: 15N-HSQC, HNHA, 
CBCACONH, HNCO, HCCH-TOC, 15N-HSQC-NOESY, 13C-HSQC-NOESY).
10.9.6.2 Code
# ! / u s r / b i n / p e r l
$ i n l  = ' z a s p _ p d z _ h s q c _ 2 7 . p r o t ' ;
$ i n 2  = ' z a s p _ p d z _ 1 3 c n o e s y . p r o t ' ;
$ o u t  = ' j u n k ' ;
o p e n  ( I N l , $ i n l )  o r  d i e  " C a n n o t  o p e n  $ i n l  f o r  r e a d  : $ ! " ;
o p e n  ( I N 2 , $ i n 2 )  o r  d i e  " C a n n o t  o p e n  $ i n 2  f o r  r e a d  : $ ! " ;
o p e n  ( OU T ,  " >  $ o u t " )  o r  d i e  " C a n n o t  o p e n  $ o u t  f o r  w r i t e
w h i l e  ( $ t a b l  = < I N 1 >  a n d  $ t a b 2  = < I N 2 > )  {
( $ i d l ,  $ c s l ,  $ s d l ,  $ a n a m e l ,  $ r e s l )  = $ t a b l  = ~
/ ( \ d + ? ) \ s + ? ( \ d + ? \ . \ d + ? ) \ s + ? ( \ d + ? \ . \ d + ? ) \ s + ? ( \ w + ? ) \ s + ? ( 0 | \ d + ? | \ -  
\ d + ? ) \ s / ;
( $ i d 2 ,  $ c s 2 ,  $ s d 2 ,  $ a n a m e 2 , $ r e s 2 )  = $ t a b 2  = ~
/ ( \ d + ? ) \ s + ? ( \ d + ? \ . \ d + ? ) \ s + ? ( \ d + ? \ . \ d + ? ) \ s + ? ( \ w + ? ) \ s + ? ( 0 | \ d + ? | \ -  
\ d + ? ) \ s / ;
$ t o t a l  + + ;
i f  ( $ c s l  = =  9 9 9  a n d  $ c s 2  = =  9 9 9 )  {
p r i n t f  OUT " % 4 d  % 7 . 3 f  % 5 . 3 f  % - 4 s  % 3 d \ n " ,  $ i d l ,  $ c s l ,  $ s d l ,
$ a n a m e l ,  $ r e s l ;
$ b l a n k s  + + ;
} e l s i f  ( $ c s l  = =  9 9 9  a n d  $ c s 2  < 9 9 9 )  {
p r i n t f  OUT " % 4 d  % 7 . 3 f  % 5 . 3 f  % - 4 s  % 3 d \ n " , $ i d l ,  $ c s 2 ,  $ s d l ,
$ a n a i r i e l ,  $ r e s l ;
$ s u b s  + + ;
} e l s e  {
p r i n t f  OUT " % 4 d  % 7 . 3 f  % 5 . 3 f  % - 4 s  % 3 d \ n " , $ i d l ,  $ c s l ,  $ s d l ,
$ a n a m e l ,  $ r e s l ;
$ o r i g i n a l  + + ;
}
}
$ a s s  = ( $ s u b s  + $ o r i g i n a l ) ;
$ p e r  = 1 0 0  * ( $ a s s / $ t o t a l ) ;
p r i n t  " $ b l a n k s  u n a s s i g n e d  o u t  o f  $ t o t a l \ n " ;  
p r i n t  " $ s u b s  s u b s t i t u t i o n s  f r o m  l i s t  2 \ n " ;
p r i n t  " $ o r i g i n a l  f r o m  l i s t  1 ,  $ a s s  ( $ p e r \ % )  A t o m s  A s s i g n e d \ n " ;
c l o s e  I N I ;  
c l o s e  I N 2 ;  
c l o s e  O UT;
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10.9.7 CALIBRATE.PL: Volume/Intensity To Distance Calibration
10.9.7.1 Description
T h i s  i s  a  s i m p l e  d i s t a n c e  c a l i b r a t i o n  s c r i p t  w h i c h  t a k e s  u s e s  t h e  p r o t  f i l e  a n d  p e a k  
l i s t s  t o  g e n e r a t e  D Y A N A  d i s t a n c e  c o n s t r a i n t  f i l e s .  T h e  d i s t a n c e  c a l i b r a t i o n  i s  s i m p l y  
e s t i m a t e d  u s i n g  t h r e s h o l d  l e v e l s  o f  p e a k  i n t e n s i t y / v o l u m e  t o  c a l c u l a t e  d i s t a n c e s .  A l l  t h a t  
i s  r e q u i r e s  a r e  t h e  i n p u t  a n d  o u t p u t  f i l e s  a r e  d e f i n e d ,  a n d  t h e  i n t e n s i t y / v o l u m e  t h r e s h o l d  i s  
e s t i m a t e d  u s i n g  t h e  l e n g t h s  o f  k n o w n  d i s t a n c e s .
10.9.7.2 Code
# ! / u s r / b i n / p e r l
$ i n l  = ' z a s p _ n o e c l 0 0 _ 2 7 . p e a k s ' ;
$ o u t l  = ' s o r t . t x t ' ;
$ s o r t i t  = ' n ' ;
$ s u b i t  = ' y ' ;
$ s e q i t  = ' y 1 ;
$ d i s t c a l  = ' y ' ;
# S o r t  o f  t h e  p e a k  r e s t r a i n t s ,  d e l e t i o n  o f  u n a s s i g n e d  p e a k s .
i f  ( $ s o r t i t  e q  ' y ' )  {
o p e n  ( I N l , $ i n l )  o r  d i e  " C a n n o t  o p e n  $ i n l  f o r  r e a d  : $ ! " ;  
o p e n  ( S O R T ,  " >  $ o u t l " )  o r  d i e  " C a n n o t  o p e n  $ o u t l  f o r  w r i t e
w h i l e  ( $ l i n e  = < I N 1 > )  {
Q p e a k l i s t  = s p l i t ( "  " , $ l i n e ) ;
$ p e a k  = $ p e a k l i s t [ 0 ] ;
$ i n t  = $ p e a k l i s t [ 5 ] ;
$ a t l  = $ p e a k l i s t [ 9 ] ;
$ a t 2  = $ p e a k l i s t [ 1 0 ] ;
i f  ( $ a t l  > 0 a n d  $ a t 2  > 0  a n d  $ a t l  ! =  $ a t 2 )  { 
i f  ( $ a t 2  < $ a t l ) {
p r i n t  SORT " $ a t 2  $ a t l  $ i n t  $ p e a k \ n " ;
} e l s e  {
p r i n t  SORT " $ a t l  $ a t 2  $ i n t  $ p e a k \ n " ;
}
}
}
c l o s e  S O R T ;  
c l o s e  I N I ;
}
# S u b s t i t u t i o n  o f  a t o m  n u m b e r s  f r o m  t h e  ' p r o t  f i l e ' .
i f  ( $ s u b i t  e q  ' y ' )  {
$ i n 2  = ' s o r t . t x t ' ;
$ i n 3  = ' a l l l . p r o t 1 ;
$ o u t 2  = ' s u b s t i t u t i o n . t x t ' ;
o p e n  ( I N 2 , $ i n 2 )  o r  d i e  " C a n n o t  o p e n  $ i n 2  f o r  r e a d  : $ ! " ;
o p e n  ( S U B ,  " >  $ o u t 2 " )  o r  d i e  " C a n n o t  o p e n  $ o u t 2  f o r  w r i t e  : $ ! " ;
w h i l e  ( $ p e a k  = < I N 2 > )  {
@ p e a k l i s t  = s p l i t ( "  " , $ p e a k ) ;
$ a t o m l  = $ p e a k l i s t [ 0 ] ;
$ a t o m 2  = $ p e a k l i s t [ 1 ] ;
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$ d i s t  = $ p e a k l i s t [ 2 ] ;
$ p e a k n o  = $ p e a k l i s t [ 3 ] ;
o p e n  ( I N 3 , $ i n 3 )  o r  d i e  " C a n n o t  o p e n  $ i n 3  f o r  r e a d  : $ ! " ;  
w h i l e  ( $ p r o t  = < I N 3 > )  {
@ p r o t l i s t  = s p l i t ( "  " , $ p r o t ) ;
$ a t  = $ p r o t l i s t [ 0 ] ;
$ r e s  = $ p r o t l i s t [ 4 ] ;
$ a t o m  = $ p r o t l i s t  [ 3 ] ;  
i f  ( $ a t o m l  = =  $ a t )  {
$ v a r l  = $ r e s ;
$ v a r 2  = $ r e s ;
$ v a r 3  = $ a t o m ;
}
i f  ( $ a t o m 2  = =  $ a t )  {
$ v a r 4  = $ r e s ;
$ v a r 5  = $ r e s ;
$ v a r 6  = $ a t o m ;
p r i n t  SUB " $ v a r l  $ v a r 2  $ v a r 3  $ v a r 4  $ v a r 5  $ v a r 6  $ d i s t  $ p e a k n o \ n " ; 
c l o s e  I N 3 ;
}
}
}
c l o s e  S U B;  
c l o s e  I N 2 ;
# S u b s t i t u t e  r e s i d u e  n u m b e r s  f o r  r e s i d u e  t y p e s .
i f  ( $ s e q i t  e q  ' y ' ) {
$ i n 5  = ' s u b s t i t u t i o n . t x t ' ;
$ i n 6  = ' z a s p . t x t 1 ;
$ o u t 3  = ' f i n i s h e d . u p l ' ;
o p e n  ( I N 5 , $ i n 5 )  o r  d i e  " C a n n o t  o p e n  $ i n 5  f o r  r e a d
o p e n  ( F I N ,  " >  $ o u t 3 " )  o r  d i e  " C a n n o t  o p e n  $ o u t 3  f o r  w r i t e
w h i l e  ( $ u p l  = < I N 5 > )  {
@ u p l l i s t  = s p l i t ( "  ” , $ u p l ) ;
$ r e s l  = $ u p l l i s t [ 0 ]  ;
$ t y p e l  = $ u p l l i s t [ l ] ;
$ a t o m l  = $ u p l l i s t [ 2 ]  ;
$ r e s 2  = $ u p l l i s t [ 3 ] ;
$ t y p e 2  = $ u p l l i s t [ 4 ] ;
$ a t o m 2  = $ u p l l i s t [ 5 ] ;
$ d i s t  = $ u p l l i s t [ 6 ] ;
$ p e a k  = $ u p l l i s t [ 7 ] ;
o p e n  ( I N 6 , $ i n 6 )  o r  d i e  " C a n n o t  o p e n  $ i n 6  f o r  r e a d  : $ ! " ;  
w h i l e  ( $ s e q  = < I N 6 > )  {
@ s e q l i s t  = s p l i t ( "  " , $ s e q ) ;
$ r e s  = $ s e q l i s t [ 0 ] ;
$ r e s n o  = $ s e q l i s t [ l ] ;  
i f  ( $ t y p e l  = =  $ r e s n o )  {
$ a a l  = $ r e s ;
}
i f  ( $ t y p e 2  = =  $ r e s n o )  {
$ a a 2  = $ r e s ;  
i f  ( $ d i s t  > 0 )  {
p r i n t  F I N  " $ r e s l  $ a a l  $ a t o m l  $ r e s 2  $ a a 2  $ a t o m 2  $ d i s t  $ p e a k \ n " ;
}
c l o s e  I N 6 ;
}
}
}
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c l o s e  F I N ;  
c l o s e  I N 5 ;
}
# D i s t a n c e  C a l i b r a t i o n  
i f  ( $ d i s t c a l  e q  ' y ' )  {
# F i l e n a m e s
$ i n 7  = ' f i n i s h e d . u p l ' ;
$ o u t 4  = ' c a l i b r a t e d . u p l ' ;
# V o l u m e s
$ i s t r  = ' 1 2 0 0 ' ;  # S t r o n g
$ i m e d  = ' 8 0 0 ' ;  # M e d i u m
$ i w e a  = ' 4 0 0 ' ;  # W e a k
# D i s t a n c e s  
$ s t r  = ' 3 . 0 '
$ m e d  = ' 4 . 0 '
$ w e a  = ' 5 . 0 '
$ v w k  = ' 7 . 0 '
# S t r o n g
# M e d i u m
# W e a k
# V e r y  W e a k
o p e n  ( I N 7 , $ i n 7 )  o r  d i e  " C a n n o t  o p e n  $ i n 7  f o r  r e a d
o p e n  ( C A L ,  " >  $ o u t 4 " )  o r  d i e  " C a n n o t  o p e n  $ o u t 4  f o r  w r i t e  : $ ! " ;
w h i l e  ( $ v o l u m e  = < I N 7 > )  {
$ c o u n t  + + ;
Q v o l l i s t  = s p l i t ( "  " , $ v o l u m e ) ;
$ r e s l  = $ v o l l i s t [ 0 ] ;
$ t y p e l  = $ v o l l i s t [ 1 ] ;
$ a t o m l  = $ v o l l i s t [ 2 ] ;
$ r e s 2  = $ v o l l i s t [ 3 ] ;
$ t y p e 2  = $ v o l l i s t [ 4 ] ;
$ a t o m 2  = $ v o l l i s t [ 5 ] ;
$ v o l  = $ v o l l i s t [ 6 ] ;
$ p e a k  = $ v o l l i s t [ 7 ] ;  
i f  ( $ v o l  > =  $ i s t r )  {
p r i n t f  CAL " % 3 d  % - 4 s  % - 5 s  % 3 d  % - 4 s  % - 5 s  % . 2 f  # p e a k
% 5 d \ n " , $ r e s l , $ t y p e l , $ a t o m l , $ r e s 2 , $ t y p e 2 , $ a t o m 2 , $ s t r , $ p e a k ;
$ s t r o n g  + + ;
} e l s i f  ( $ v o l  < $ i s t r  a n d  $ v o l  > =  $ i m e d )  {
p r i n t f  CAL " % 3 d  % - 4 s  % - 5 s  % 3 d  % - 4 s  % - 5 s  % . 2 f  # p e a k
% 5 d \ n " , $ r e s l , $ t y p e l , $ a t o m l , $ r e s 2 , $ t y p e 2 , $ a t o m 2 , $ m e d , $ p e a k ;  
$ m e d i u m  + + ;
} e l s i f  ( $ v o l  <  $ i m e d  a n d  $ v o l  > =  $ i w e a )  {
p r i n t f  CAL " % 3 d  % - 4 s  % - 5 s  % 3 d  % - 4 s  % - 5 s  % . 2 f  # p e a k
% 5 d \ n " , $ r e s l , $ t y p e l , $ a t o m l , $ r e s 2 , $ t y p e 2 , $ a t o m 2 , $ w e a , $ p e a k ;
$ w e a k  + + ;
} e l s i f  ( $ v o l  < $ i w e a )  {
p r i n t f  CAL " % 3 d  % - 4 s  % - 5 s  % 3 d  % - 4 s  % - 5 s  % . 2 f  # p e a k
% 5 d \ n " , $ r e s l , $ t y p e l , $ a t o m l , $ r e s 2 , $ t y p e 2 , $ a t o m 2 , $ v w k , $ p e a k ;
$ v w e a k  + + ;
}
}
p r i n t  "
S t r o n g  = $ s t r o n g
M e d i u m  = $ m e d i u m
W e a k  = $ w e a k
V .  W e a k  = $ v w e a k
T o t a l  = $ c o u n t \ n " ;
c l o s e  C A L ;  
c l o s e  I N 7 ;
}
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